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Abstract 
Understanding the gene regulatory networks driving the differentiation of the distinct 
cell types in embryos is a key component of understanding development. Amongst the 
first types of cell to differentiate during vertebrate development are blood cells, and 
haematopoiesis is tightly regulated by proteins known as haematopoietic transcription 
factors (HTFs). Although the mRNA expression patterns of many HTFs are now well 
characterised, little is known about their protein expression patterns or how their 
transcription regulation activity is controlled during early development. Knowledge of 
their spatial and temporal expression patterns and their post-translational regulation 
would greatly enhance our understanding of the genetic regulatory networks that 
produce blood. 
 
Antibodies have been successfully raised and characterised that recognise Xenopus Hex, 
fli1 and Tal1. Western blot experiments have shown that Hex and fli1 are expressed in 
oocytes and expression continues throughout development. This maternal expression is 
unexpected but is reminiscent of another embryonic HTF, Gata2. At stage VI of 
oogenesis the majority of fli1 and all Hex protein was localised within the cytoplasm, 
suggesting an alternative second function for each of these proteins. An intensively 
sampled developmental time-course carried out for fli1 between stages 24 and 31, 
revealed striking post-transcriptional control over fli1 expression. Neither Hex or fli1 
proteins have been shown to be absent from the regions containing sites of 
haematopoiesis and both proteins were eluted in the same fractions following size 
exclusion chromatography using Xenopus extract, suggesting the possibility that they 
may be in complex together. Finally, either Tal1 protein is undetectable during early 
Xenopus embryogenesis, or is heavily modified. 
 
Since, at least for fli1, knockdown of the zygotic protein specifically affects blood 
development a number of questions are raised. What is different about the maternal and 
zygotic proteins, which means that the zygotic form is needed for haematopoiesis? 
What is the function of the maternal proteins – are they even capable of transcription 
regulation?  
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1.1 General Introduction  
Discovering the processes by which a single cell, the fertilised egg, develops into a 
complex multicellular organism remains a major goal for modern biologists. Almost all 
cells in an individual contain the same DNA, which is made up of genes that get 
transcribed into mRNA then translated into protein. It is protein that gives cells their 
different characteristics and functions. In order for a cell to differentiate, specific gene 
activity must be spatially and temporally regulated during development. Blood and 
endothelial cells are the first types of cell to differentiate in the developing vertebrate 
embryo (Baron, 2001) and the processes by which both types of cell are formed are 
thought to be closely connected. Blood cells are produced by a process called 
haematopoiesis and blood vessels are formed by vasculogenesis, however both 
processes are thought to originate in a common precursor cell known as the 
haemangioblast (Murray, 1932). The molecular steps involved in how gene activity is 
controlled during early haematopoiesis and vasculogenesis are yet to be fully 
determined. Discovering these molecular steps is essential to understanding the genetic 
regulatory network that produces blood and vasculature.  
 
1.2 Xenopus as a model organism 
A model organism is a species that is studied to enhance our understanding of a 
particular biological process or processes. The species from which much of our 
knowledge about haematopoiesis and vasculogenesis has come is Xenopus laevis or the 
South African clawed frog, as it is more commonly known. Xenopus laevis was first 
introduced and used as a laboratory animal in Britain in the 1930s when Hogben (1930) 
discovered that if female Xenopus laevis were injected with anterior pituitary hormone 
then ovulation and oviposition could be induced. Bellerby (1934) and Shapiro and 
Zwarenstein (1935) later suggested using this phenomenon as a pregnancy test for 
women. Xenopus laevis are no longer used as a pregnancy test, however the embryos 
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produced by this species have become arguably the ideal model for studying the earliest 
events during vertebrate development. 
 
The embryos produced by Xenopus laevis are large, robust and develop externally 
making them easier to access and manipulate than the embryos produced by some other 
model organisms. As Xenopus laevis can be stimulated to ovulate with a simple 
hormone injection it means a large number of embryos are available to work with all 
year round. Another advantage of using the Xenopus laevis embryo is their rapid 
development; within a few days after fertilisation the embryo will have developed a full 
set of differentiated tissues meaning that experimental results can be rapidly obtained.  
 
Xenopus laevis can be used for both gain of function and loss of function experiments, 
although the fact that Xenopus laevis are pseudotetraploid (Hughes and Hughes, 1993) 
can cause complications when carrying out loss of function experiments. One solution 
to this problem is to use Xenopus tropacalis, a close relative of Xenopus laevis with a 
diploid genome. Xenopus tropicalis have another advantage over Xenopus laevis in that 
their embryos develop into sexually mature adults more quickly (four months) than the 
embryos of Xenopus laevis (one-two years), which is useful when conducting genetic 
studies. However, the disadvantage of using Xenopus tropicalis is that their embryos are 
smaller than that of Xenopus laevis and more fragile. 
 
1.3 Early Xenopus development 
The unfertilised Xenopus egg consists of two halves, the pigmented animal pole and the 
yolk-filled vegetal pole. Fertilisation occurs in the animal half of the egg. Following 
fertilisation several processes occur including cleavage, gatstrulation, neurulation and 
organogenisis in order to produce a multicellular organism from a single-celled 
fertilised egg. The stages of Xenopus embryonic development are described by 




The first process to occur following fertilisation is referred to as cleavage. During 
cleavage a period of rapid cell division occurs, however during this time the 
cytoplasmic volume does not increase, instead the original volume of cytoplasm in the 
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fertilised egg gets divided among increasingly smaller cells known as blastomeres. This 
is achieved by missing out the growth phases during the cell cycle.  
 
In the case of Xenopus the first division during cleavage begins in the animal pole and 
extends down into the vegetal pole, however because of the yolk in the vegetal pole the 
second division starts in the animal pole before the first has finished in the vegetal pole. 
The third division is displaced towards the animal pole creating an embryo that is made 
up of a larger number of smaller cells in the animal pole and a lesser number of larger 
cells in the vegetal pole (Beams and Kessel, 1976). By the 128-cell stage the embryo is 
known as a blastula (stages 7-8) and the blastocoel has formed. The blastocoel is a fluid 
filled cavity, which allows cell migration during gastrulation and prevents premature 
cell interaction between cells above and below the blastocoel (Kalt, 1971). 
 
Fate mapping has shown that even as early on as the blastula stage embryo cells have 
different fates depending on their location. Figure 1.1 shows a Xenopus fate map at the 
blastula stage indicating the three germ layers and the tissues they will eventually form. 
 
1.3.2 The mid-blastula transition 
In Xenopus the mid-blastula transition (MBT) occurs between the 12th and 13th cell 
cycle during cleavage. This marks the point at which the cleavage of blastomeres 
changes from synchronous to asynchronous, G1 and G2 phases are added to the cell 
cycle as well as check points at the M and S phase, cell motility is acquired and the 
zygotic genome is activated (Davidson, 1986). 
 
Up until the point of MBT, early development is mainly controlled by maternal gene 
products stored in the egg and only a few zygotic genes appear to be transcribed (Yang, 
2002). Possible reasons for the repression of the zygotic genome until its activation 
include: the high rate of mitosis and lack of G1 and G2 phases during cleavage are 
incompatible with transcription (Edgar and Schubiger, 1986; Yasuda and Schubiger, 
1992); Maternal factors stored in the egg inhibit transcription of the zygotic genome but 
once all of the available factor is bound to DNA the zygotic genome is activated since 
there is no longer available factor to inhibit its transcription (Newport and Kishner, 
1982b; Prioleau et al., 1994; Prioleau et al., 1995). Ruzov et al., 2004 report that the 
methyl-CpG repressor protein, xkaiso is required for silencing of the zygotic genome 




























Figure 1.1: Fate maps of the Xenopus blastula.  
(A) exterior and (B) interior. Fate mapping by Løvtrup (1975); Landstrom and Løvtrup 
(1979) and by Keller (1975, 1976) has shown the fates of different cells from the 
blastula stage Xenopus embryo. Endoderm and ectoderm precursors arise from the 
superficial layer on the surface of the embryo. Mesodermal precursors arise mostly 
from the deep layer of cells (taken from Development seventh edition, Scott, F. Gilbert, 
2003). 
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noted that Kim et al., (2004) report that kaiso binds to non-methylated DNA. However, 
further work by Ruzov et al., (2009) suggests that kaisos ability to bind to non-
methylated DNA is not conserved between species and its main role during early 
Xenopus laevis development is linked with pre-MBT gene silencing; Another 
hypothesis for the silencing of the zygotic genome is that transcription factors might be 
deficient or absent from the pre-MBT egg. Veenstra et al., 1999 suggest that 
transcriptionally regulated TATA-binding protein (TBP) maternally stored in the egg 
along with a deficiency in transcriptional cofactors contributes to silencing of the 
zygotic genome. 
 
1.3.3 Gastrulation  
Following cleavage and activation of the zygotic genome, gastrulation proceeds (stages 
10-12). This is a period of highly coordinated cell migrations, during which time the 
cells of the blastula must be rearranged in order to form a three-layered body plan 
consisting of the following three germ layers: the outer ectoderm which forms skin, the 
brain and the nervous system; the middle mesoderm which forms muscle, the skeletal 
system, the kidneys and the heart, blood and circulatory system; and the inner endoderm 
which forms the lining of the gut and the internal organs. Cells that are destined to form 
either endodermal or mesodermal organs must be brought inside the embryo and cells 
that are destined to become ectoderm are spread over the surface of the embryo 
(Reviewed in Keller, 2005). Cell movements during Xenopus gastrulation are 
summarised in figure 1.2. 
 
1.3.4 Neurulation and later stages 
Neurulation (stages 14-20) is the next phase of development to occur. It begins with the 
formation of the neural plate on the dorsal side of the embryo, which then folds to form 
the neural tube eventually. During and after neurulation, elongation of the embryo body 
also occurs. By the tailbud stage (from stage 26) somites appear in pairs alongside the 
neural tube, these will give rise to cells that form vertebrae, ribs, muscle and skin. Also 
at this stage, the blood islands have formed in the ventral mesoderm of the embryo. 
Later, a second population of blood cells develop in the dorsolateral mesoderm. The 
development of these two populations of blood cells is discussed further in the 














Figure 1.2: Cell movements during Xenopus gastrulation.  
(A) Blastula stage embryo within which is the blastcoel, a fluid filled cavity. (B) At the 
start of gastrulation the blastopore forms at the margin on the dorsal side of the embryo. 
Subsequently the dorsal marginal zone begins to move inside the embryo through the 
dorsal lip of the blastopore. (C, D) Mid-gastrulation. The mesoderm gets sandwiched 
between the endoderm and ectoderm. The blastocoel becomes displaced as the 
archenteron forms which will eventually form the gut. Cells migrate from the lateral and 
ventral lips of the blastopore into the embryo and cells of the animal region move down 
towards the vegetal region pushing the blastopore towards the vegetal region. (E, F) 
Late gastrulation. The blastocoel has been removed, the ectoderm has been spread over 
the surface of the embryo, the endoderm has been internalised and the mesoderm has 
been sandwiched between the endoderm and ectoderm (taken from Development 
seventh edition, Scott, F. Gilbert, 2003). 
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final stages of development can take place: organogenesis and lastly, metamorphosis. 
Figure 1.3 summarises the major steps during Xenopus development. 
 
1.4 Haematopoiesis 
Haematopoiesis is the process by which all lineages of blood cells are formed. This, as 
previously mentioned, is closely connected to vasculogenesis during early vertebrate 
development (figure 1.4). Blood cell formation is a continuous process throughout the 
life-time of an individual. In contrast vasculogenisis occurs predominantly during 
embryonic and fetal phases. Although it is not proven, blood and endothelial cells are 
thought to derive from a common precursor cell known as the hemangioblast (Murray, 
1932). Evidence for the haemagioblast comes from the co-expression of blood and 
endothelial genes in the early stages of haematopoiesis and vasculogenesis and from 
targeted mouse mutants affecting both blood and vascular development (Shalaby et al., 
1995; Dickson et al., 1995 and Stanier et al., 1995). More recently, Vogeli et al., (2006) 
have shown through the construction of zebrafish late blastula and gastrula fate maps 
that single cells give rise to both endothelial and haematopoietic cells.  
 
In vertebrates, haematopoiesis occurs in two successive phases. Firstly an embryonic 
“primitive” phase which is a transient phase that provides the embryo with its initial 
blood cells, these are primarily erythroid and myeloid cells, and the capillary network to 
the yolk. The second phase of haematopoiesis is the definitive “adult” phase that 
provides the embryo with the haematopoietic stem cells (HSC) that will last the lifetime 
of the individual and gives rise to all the cell lineages that constitute adult blood (Kau 
and Turpen, 1983). These two phases of haematopoiesis occur at two distinct sites. In 
Xenopus the site of primitive haematopoiesis is the ventral blood islands (VBI), 
equivalent to the mammalian yolk sac mesoderm and the site of definitive 
haematopoiesis is the dorsal lateral plate mesoderm (DLP), equivalent to the aorta, 
gonads, and mesonephros (AGM) in mammals (Dzierzak and Medvinsky, 1995). 
 
1.5 The origins of haematopoiesis in Xenopus 
Although it is now well established that haematopoiesis occurs at two distinct sites of 
the developing vertebrate embryo, the origins of these two haematopoietic sites remain 
controversial. Two models have been proposed, the single origin model suggests that 












Figure 1.3: Major steps in Xenopus development. 












































Figure 1.4: The different steps of haematopoiesis and vasculogenesis.  
Both haematopoiesis and vasculogenesis are thought to originate from a common 
precursor cell called the haemangioblast. Haematopoietic stem cells differentiate to 
form all cells found in circulating blood and angioblasts develop to form the vascular 
endothelial system (taken from Soufi and Jayaraman, 2008). 
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haematopoiesis where they receive instruction to differentiate (Dale and Slack, 1987; 
Turpen et al., 1997 and Lane and Sheets, 2002). The other model, the dual origins 
model, suggesting primitive and definitive HSCs derive from distinct origins (Ciau-Uitz 
et al., 2000). 
 
The origin of both primitive and definitive haemangioblasts has been traced back to 
single cells of the 32-cell stage embryo, using lineage tracing experiments. Previously it 
was thought that cells of the VBI derived entirely from the ventral marginal zone 
(VMZ), which originates from blastomere C4 of the 32-cell stage embryo (Dale and 
Slack, 1987 and Turpen et al., 1997). However, Tracey et al. (1998) demonstrated that 
isolated dorsal marginal zone (DMZ) extracts are capable of expressing Runx1, a gene 
known to be expressed in the VBI at the tadpole stage, furthermore when expression of 
Runx1 is suppressed in the DMZ of whole embryos expression of α-globin is lost in the 
anterior VBI. This suggested that cells of the DMZ do in fact contribute to primitive 
blood. 
 
Moreover, a study by Ciau-Uitz et al. (2000) challenged the results produced by Dale 
and Slack (1978) and Turpen et al. (1997) suggesting, that “the apparent common origin 
in earlier Xenopus experiments was a consequence of transplanting spatially distinct 
precursors for the VBI and the DLP contained within the same piece of tissue.” The 
recent lineage tracing experiments by Ciau-Uitz et al. (2000) have shown that the cells 
of the VBI not only derive from the VMZ but also the DMZ. Cells of the VMZ make up 
the posterior region of the VBI  (pVBI) and cells of the DMZ make up the anterior 
region of the VBI (aVBI). Precursors of the pVBI were found to originate from D4 and 
precursors of the aVBI were found to originate from C1 and D1 of the 32-cell stage 
embryo. During gastrulation, derivatives of these single blastomeres migrate until 
eventually at late neurula and tailbud stages presumptive blood can be found in the most 
ventral mesoderm, the VBIs. Lineage tracing experiments have shown that the DLP 
mesoderm, the source of adult blood is made up of cells entirely from the VMZ, which 
derived originally from C3 of the 32-cell stage embryo, supporting the dual origins 
model (figure 1.5).  
 
More recently Lane and Sheets (2002) who support the single origins model have 
produced results suggesting that Lac Z mRNA as used by Ciau-Uitz et al. (2000) does 





























Figure 1.5: 32-cell stage fate map of the Xenopus embryo.  
Indicates where the cells of the aVBI, pVBI and DLP mesoderm originate (taken from 
Ciau-Uitz et al., 2000). 
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the same result as Ciau-Uitz et al. (2000) was achieved using flourescent dextran 
(Matthew Guille, personal communication) and Lane and Sheets (2002) were thought to 
be using irregularly cleaving embryos in their experiments. Also the ability to label the 
primitive and definitive blood compartments separately suggests that their origins are 
distinct. The balance of evidence would suggest that there are two distinct origins of 
haematopoiesis. 
 
1.6 BMP-4 and FGF cell signalling in haematopoiesis 
In order to understand haematopoiesis fully it is important to understand the cell 
signalling received by blood precursors. Bone morphogenetic protein (BMP)-4 has been 
shown to be an essential factor required for inducing cells to become blood progenitors. 
Treating Xenopus VMZ explants with BMP-4 induces expression of α-globin, a blood 
specific marker, while expression of a dominant-negative form of BMP-4 suppresses α-
globin expression (Maéno et al., 1994b). A later study by Iraha et al., 2002 shows that 
BMP-4 signalling is also capable of inducing expression of Xtie-2 a specific marker for 
differentiating endothelial cells in DMZ explants and animal caps, suggesting that 
BMP-4 promotes both blood and vascular lineages. These results coincide with results 
from another study (Walmsley et al., 2002), which shows that BMP-4 signalling is 
required for Tal1 and Gata2 (blood precursor markers) expression in the primitive 
blood population in Xenopus embryos. However, in the primitive blood population fli1 
(an endothelial marker) was not dependent on BMP-4 signalling. In the definitive 
population fli1 was BMP-4 dependent suggesting that the primitive and definitive blood 
populations are programmed differently by BMP-4. 
 
The role of Fibroblast Growth Factor (FGF) in blood development has also been 
investigated (Kumano and Smith, 2000; Iraha et al., 2002; Nakazawa et al., 2006 and 
Yamauchi et al., 2006). Walmsley et al., (2008) investigated the role of FGF signalling 
in primitive haematopoiesis by conducting FGF over-expression experiments and by 
blocking FGF signalling in Xenopus embryos. Blocking FGF signalling during 
gastrulation leads to expanded expression of the haematopoietic markers Tal1, Lmo2 
and Runx1 from anterior into posterior regions. Over-expression of FGF caused 
suppression of the anterior haemangioblast program. A model is proposed from the 
results of this study (figure 1.6) in which the pVBI precursors receive prolonged FGF 



































Figure 1.6. A model for programming the anterior and posterior VBI.  
aVBI precursors (stage 10) quickly move away from FGF signaling by migrating over 
the roof of the blastocoel towards the animal pole where they receive BMP signaling 
and commit to a hemangioblast fate (stage 12). By stage 14 the aVBI precursors have 
continued to move in an anterior ventral direction until they reach the anterior ventral 
mesoderm just below the cement gland. Here they meet the pVBI precursors, which 
have migrated at a much slower rate and have been exposed to prolonged BMP and 
FGF signaling. pVBI precursors do not co-express erythroid and endothelial genes. 
BMP blocks endothelial gene expression and FGF blocks erythroid gene expression. At 
stage 16, FGF signaling becomes reduced in the ventral posterior region with higher 
BMP signaling favouring expression of erythroid genes. Since FGF signaling is higher 
and BMP signaling lower in the more lateral posterior region promoting endothelial 
gene expression (taken from Walmsley et al., 2008). 
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until such time that the cells are committed to either a blood or endothelial lineage. 
However, aVBI precursors quickly escape FGF signalling by migrating over the 
blastocoel roof where they encounter BMP signalling. This low level of FGF signalling 
for a short period of time and the subsequent experience of BMP signalling allows the 
aVBI precursors to take on a haemangioblast fate as characterised by the co-expression 
of blood and endothelial genes. Knowing that BMP is required for at least Tal1 
expression the authors managed to recapitulate the anterior hemangioblast program in 
animal cap cells. This was achieved by inducing the cells to become anterior mesoderm 
using activin, blocking FGF signalling and subsequent exposure to BMP. 
 
The results described show the importance of spatial and temporal control of both 
BMP-4 and FGF signalling in inducing cells to drive differentiation of blood or 
endothelial precursors. 
 
1.7 Haematopoietic transcription factors 
In order for a cell to differentiate, different genes must be expressed in specific spatial 
and temporal patterns during development. Proteins acting as transcription factors (TFs) 
have the ability to either suppress or activate transcription of a gene, one mechanism of 
regulating gene expression. TFs contain DNA-binding domains that recognise and bind 
to specific DNA sequences allowing them to target the genes they control. Knowing 
which TFs are involved in haematopoiesis is essential to understanding the molecular 
steps in haematopoiesis. The following sections discuss seven different TFs that have 
been shown to play essential roles in haematopoiesis, these are referred to as 
haematopoietic transcription factors (HTF).  
 
Although these HTFs are discussed using mouse and Xenopus as model organisms these 
proteins have homologues in humans, which are known to be involved in serious 
diseases, therefore a further understanding of these proteins, their role and regulation is 
of great interest with potential impact for human health. 
 
1.7.1 Fli1 
Fli1 (Friend leukemia integration 1) is a member of the ETS-domain family of 
eukaryotic transcription factors.  All ETS-family members contain a highly conserved 
DNA binding domain (the ETS-domain), which consists of a winged-helix-turn-helix 
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structure that binds to sites containing a central purine-rich GGA(A/T) trinucleotide 
motif (reviewed in Sharrocks et al, 1997 and Sharrocks, 2001). 
 
Fli1 was initially identified as a proto-oncogene in Friend virus induced 
erythroleukemia in mice (Ben-David et al, 1990). Mutational damage to a proto-
oncogene frequently causes over-expression or inappropriate expression of that gene. 
The damaged copy of the gene is referred to as an oncogene. Pro-viral integration of the 
replication competent component of the friend viral complex, Friend murine leukemia 
virus (F-MuLV) into the fli1 locus was found in 75% of erythroleukemias in mice that 
had been infected with the virus (Ben-David et al., 1991) and in humans transcriptional 
activation of the fli1 gene by chromosomal translocation occurs in over 90% of Ewing’s 
sarcomas (Ida et al., 1995).  
 
Melet et al, 1996 used in situ hybridization to show that Fli1 is preferentially expressed 
in haematopoietic cells, endothelial cells and in the mesenchyme during early 
embryogenesis in mouse embryos. In the adult mouse, fli1 is mainly expressed in 
haematopoietic tissues such as the thymus and spleen, however a lower level of 
expression is also observed in non-haematopoietic tissues such as the lungs, heart and 
ovaries (Ben-David et al., 1991; Watson et al., 1992). 
 
The effects of fli1 over-expression have been studied by Zhang et al., 1995. They 
generated lines of transgenic mice that over-expressed fli1 in various tissues. These 
mice showed increased lymphopoiesis and developed a high incidence of autoimmune 
disease in the kidneys, which eventually led to death through renal failure. Down 
regulation of fli1 expression in mice causes abnormal vascular development and 
megakaryopoiesis (Hart et al., 2002). A study by Spyropoulos et al., 2000 reported that 
mice carrying a targeted disruption of the fli1 gene were dead by E12.5. These mice 
suffered severe haemorrhaging into the fluid-filled spaces of the central nervous system 
and brain and abnormal hematopoiesis within the fetal liver was also observed. 
 
A homologue of fli1 has also been identified in Xenopus  (Meyer et al, 1993). From this 
study it was initially thought that fli1 transcripts were localised to the neural crest 
however, more recent studies using fli1 WISH have shown fli1 also to be expressed in 
angioblasts and endothelial cells (Meyer et al. 1995).  
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Another study (Walmsley et al., 2002) used WISH to look at the locations of cells co-
expressing blood and endothelial genes and to show that fli1 is one of the earliest 
markers to be expressed in both the primitive and definitive populations of 
hemangioblasts. Figure 1.7 shows the mRNA expression pattern of fli1 in the Xenopus 
laevis embryo between stage 17 and stage 28. From stage 20 strong staining in the DLP 
was observed and it also appeared that fli1 is expressed in the VBI, however results 
from whole-mount double in situ hybridization probing for both fli1 and Tal1 (another 
HTF described in section 1.7.3) showed that in the VBI region fli1 staining seems to 
surround Tal1 staining (figure 1.7), suggesting that fli1 is expressed in the developing 
vitelline veins surrounding the blood cells. A high level of fli1 expression was also 
detected in the anterior of the embryo from stage 17 to 28. In adult Xenopus, fli1 was 
expressed in the spleen, lungs, kidney, brain and heart (Remy and Baltzinger, 2000). 
 
A more recent study by Liu et al., 2008 has shown that fli1 acts at the top of the genetic 
cascade establishing the haematopoietic and endothelial programs within mesodermal 
cells of the early Xenopus laevis embryo. This study initially used antisense morpholino 
oligonucleotides (AMOs) to knockdown fli1 expression in the site of primitive blood 
formation by injecting AMOs against fli1 into the DMZ of four/eight cell stage 
embryos. WISH was used to analyse the expression of the following haematopoietic 
and endothelial genes; Scl, Lmo2 (described in sections 1.7.3 and 1.7.4), Fli1, Flk1, 
Mpo, SpiB and Runx1 and in each case expression was down regulated. This effect was 
found to be specific to the haemangioblasts. Further experiments also showed that 
Gata2 (an HTF known to act near the top of the haematopoietic GRN; section 1.7.5) 
expression is reduced but not as greatly as the genes previously mentioned. Injection of 
Gata2 AMOs does not down regulate fli1 expression, suggesting that fli1 is not only 
required for primitive hemangioblast formation but that it also acts upstream of all the 
genes previously mentioned. 
 
Moreover, results from this study suggest that fli1 is also required for and acts upstream 
of blood and endothelial genes in the formation of definitive hemangioblasts since 
injection of fli1 AMOs into the ventral marginal zone (VMZ) down regulated 
expression of; Scl, Gata2, Lmo2, Flk1, Msr and Tie2 and once again fli1 expression is 





































Figure 1.7: Whole mount in situ hybridisation showing fli1 and tal1 mRNA 
expression in the early Xenopus embryo.  
The numbers in the top right-hand corner indicate stage of development. 17 and 20a are 
anterior views; 20b is a dorsal view; 23, 24, 26 and 28 are lateral views of the embryo. 
The black arrow indicates the DLP, the green arrow indicates the vitelline veins and the 
red arrows indicate the VBI. (A) fli1 expression. (B) fli1 expression (purple staining) 
and tal1 expression (turquoise staining). Fli1is highly expressed in the DLP from stage 
20. In the VBI region fli1 staining appears to surround tal1 staining (taken from 
Walmsley et al., 2002). 
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Over-expression of the fli1 gene leads to abnormal anterio-posterior and dorso-ventral 
polarity formation and causes malformations in tissue differentiation in the early 
Xenopus laevis embryo. (Remy et al.,1996). The malformations in tissue differentiation 
include eye, head cartilage and gut development. A decrease in erythroid differentiation 
was also observed, which is consistent with findings that increased fli1 expression in 
mice causes erythroleukemia (Ben-David et al, 1990). 
 
1.7.2 Spi1 
Spi1 (SFFV proviral integration 1) was previously known as PU.1. It is also a member 
of the ETS-domain family of transcription factors, and like fli1, has been shown to be 
involved in the development of erythroleukemia in mice. Pro-viral integration of the 
replication-defective component of the Friend viral complex, spleen focus-forming virus 
(SFFV) into the Spi1 locus causes transcriptional activation of the adjacent gene coding 
for Spi1 (Moreau-Gachelin et al., 1989).  
 
Spi1 is specifically expressed in haematopoitic cells and as shown by Scott et al., 1994 
Spi1 is crucial for the generation of both some myeloid and lymphoid lineages. They 
showed that homozygous mouse embryos carrying a mutation in the Spi1 locus die at 
late gestation showing defects in the development of B and T lymphocytes, monocytes 
and granulocytes as well as variable degrees of abnormal erythroblast development. 
Over-expression of Spi1 is sufficient to immortalize erythroblasts in many cells 
(Schuetze et al., 1993). 
 
1.7.3 Tal1/Scl  
Scl (Stem cell leukaemia), also known as Tal1 was initially identified via a 
chromosomal translocation in T-cell acute lymphoblastic leukemia (T-ALL) from 
which the name Tal1 comes. Activation of the Tal1 gene occurs by chromosomal 
translocation, interstitial deletion, or mutation in over 60% of children and adults with 
T-ALL (Bash et al., 1995). 
 
Tal1 is a member of the basic helix-loop-helix (bHLH) group of transcription factors. 
The RNA expression patterns produced by Tal1, and its sequence, suggest that this 
protein plays an important role in haematopoiesis. Many members of the bHLH group, 
including Myo-D are expressed during development and have shown to be involved 
with cell differentiation (Kingston, 1989). Moreover, many have the ability to switch on 
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previously silent genes and to impose a specific cell fate when introduced to various 
cells types suggesting that Tal1 may act as a master regulator of haematopoiesis 
(Weintraub et al., 1989 and Weintraub et al., 1991). 
 
Studies have been carried out using mice to investigate the role of Tal1 in 
haematopoiesis. Robb et al, 1995 created mice with a null mutation of the tal1 gene 
using embryonic stem (ES) cell technology and demonstrated that Tal1 plays a crucial 
role in primitive haematopoiesis. Briefly, the tal1 gene in ES cells was mutated by 
introduction of a targeting vector. Two types of targeting vector were used, both of 
which worked by deleting the part of the tal1 gene that encodes the Tal1 bHLH DNA 
binding domain. Mice heterozygous for the tal1 null mutation were mated and the 
offspring genotyped. At embryonic day 7.5 (E7.5) and E8.5 no difference in the 
phenotype of wild-type (tal1+/+), heterozygous (tal1+/-) or homozygous (tal1-/-) 
embryos was detected. However, a change in phenotype could be seen by E8.75-E9.0, 
the yolk sac (the site of primitive haematopoiesis) of null mutants was paler than that of 
tal1+/+ and tal1+/- embryos. The growth of tal1-/- embryos was retarded and an 
absence of erythroid cells was observed. Histological analysis of embryos showed no 
difference between embryos at E7.5, but from E8.0 tal1+/+ and tal1+/- embryos were 
showing signs of haematopoiesis within the yolk sac whereas tal1-/- embryos showed 
no signs that haematopoiesis was occurring and they began to die around E9.5. Cells 
from the yolk sacs of wild-type, heterozygous and homozygous embryos were cultured 
and analysed to confirm that haematopoiesis was not occurring in the homozygous 
embryos. These results clearly show that Tal1 is essential for primitive haematopoiesis 
and that the developing embryo requires primitive haematopoiesis in order to survive. 
Shivdasani et al, 1995 have also observed similar findings using mice.  
 
Moreover, although these loss of function studies show that Tal1 is essential for 
haematopoiesis to occur a more recent study by Gering et al., 1998 reports that Tal1 
functions to specify the differentiation of HSCs from mesoderm. Ectopic expression of 
Tal1 in Zebrafish embryos caused the overproduction of haematopoietic progenitors 
with the ability to differentiate into haemoglobinised cells. These haematopoietic 
progenitors were formed from early mesoderm at the expense of other non-axial 




Mead et al, 1998 used WISH to follow the mRNA expression patterns of tal1 during 
Xenopus development (figure 1.8). Staining is first detected in the ventral region of 
stage 15 embryos and increases in this region as development proceeds. By stage 22, 
staining becomes clear in the VBI region, the site of primitive haematopoiesis. Staining 
increases as the size of the VBI increases. At stage 27 staining can be seen in the DLP, 
the site of definitive haematopoiesis. By stage 32 staining of the VBI is very intense but 
staining of the DLP has disappeared, as yet no one knows why it disappears. Primitive 
blood cells begin to circulate at around stage 37/38 so blood cells begin to leave the 
VBI, therefore from stage 37 staining of the VBI starts to decrease and by stage 40 
staining has disappeared. These RNA expression patterns clearly suggest that Tal1 has 
some involvement in primitive and definitive haematopoiesis. In adult blood cell 
lineages tal1 is selectively expressed in erythroid, mast, and megakaryocytic cells 
(Visvader et al., 1991). 
 
1.7.4 Lmo2 
Another HTF named Lmo2 or Rbtn2 has been found to interact physically with Tal1 
and is essential to primitive haematopoiesis (Valge-Archer et al., 1994). As with Tal1, 
Lmo2 has been shown to be involved in the development of T-ALL (reviewed by 
Rabbitts, 1994) and was first identified via a chromosomal translocation in T-ALL 
(Boehm et al, 1991).  
 
Lmo2 is a member of the LIM-only class of zinc finger proteins and as its name 
suggests it contains two LIM domains, although it does also contain a short amino-
terminal domain, which has transcriptional transactivation activity (Sanchez-Garcia et 
al., 1995). Unlike Tal1, Lmo2 is not believed to bind to DNA but may instead act as a 
bridging molecule between Tal1 and Gata1 by binding to both simultaneously 
(Wadman, 1997). 
 
High levels of lmo2 expression are detected in both sites of haematopoiesis (Foroni et 
al., 1992). Xenopus WISH using an lmo2 probe first detects lmo2 expression in the 
ventral region of stage 15 embryos. As development proceeds staining of the VBI 
region increases and by stage 21 lmo2 staining in the VBI region is very similar to that 
of tal1. By stage 26 the DLP is stained as well as the VBI, but by stage 33 staining of 
the DLP disappears as it does with tal1. VBI staining is maintained. Once the primitive 




































Figure 1.8: Whole embryo in situ analysis of Tal1 expression.  
(a) Ventral view of stage 15 Xenopus embryo. (b) Cross-section of stage 16 embryo. (c-
d) Ventral (c) and lateral (d) view of stage 26 embryos. (e-g) Embryos that have been 
cleared to show staining within the embryo. (e) Stage 22 embryo. (f-g) stage 24 
embryos. (h-i) Lateral and ventral-lateral view of stage 25 embryos. (j) stage 27 embryo 
(white arrow indicates the DLP, black arrow indicates neural tissue). (k) Stage 32 
embryo. (l) Stage 37/38 embryo (white arrow indicates that the most posterior VBI cells 
are still present (taken from Mead et al, 1998). 
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system as the lmo2 gene continues to be transcribed in circulating primitive erythrocytes 
(Mead et al., 2001). Figure 1.9 shows a comparison between lmo2, tal1 and gata1 
mRNA staining in stage 28 Xenopus laevis embryo, lmo2 and tal1 both show staining in 
the head as well the VBI. 
 
Gene Knock-out experiments using mice have been carried out in which the lmo2 gene 
is disrupted to produce homozygous mice null for lmo2. Like the tal1-/- mice, lmo2-/- 
embryos die at around E10.0 (Yamada et al., 1998). Results from all these studies 
strongly suggest that Lmo2 also plays a crucial role in haematopoiesis. 
 
1.7.5 Gata1 and Gata2 
The GATA family of proteins contain a zinc finger domain capable of mediating both 
DNA binding and protein dimerisation. Gata1 and Gata2 have both been found to play 
an important role in haematopoiesis and are preferentially expressed in haematopoietic 
tissues. A high level of gata1 expression is observed in mature erythroid cells, mast 
cells and megakaryocytes (Yamamoto et al., 1990; Martin et al., 1990 and Romeo et al., 
1990) but also at lower levels in haematopoietic progenitor cells (Sposi et al., 1992 and 
Leonard et al., 1993). gata1 expression is also reported in the Sertoli cells of testis (Ito 
et al., 1993 and Yomogida et al., 1994). Like gata1, high levels of gata2 expression are 
seen in mast cells and megakaryocytes (Zon et al., 1993) as well as in haematopoietic 
progenitors (Sposi et al., 1992 and Leonard et al., 1993). However, gata2 is more 
widely expressed in non-haematopoietic cells than gata1, including cells of the nervous 
system (Yamamoto et al., 1990) and endothelial cells (Wilson et al., 1990 and Dorfman 
et al., 1992). 
 
Kelley et al., 1994 produced results showing that by the end of Xenopus gastrulation 
gata2 was highly expressed in the ventral region of Xenopus embryos and later 
expressed in the VBI. These results coincide with results produced from another study 
conducted in 1994 by Walmsley et al. who report that gata2 expression can be detected 
by in situ hybridisation in the ventral region from as early as stage 19 in Xenopus laevis 
embryos. Although at this stage the cells are negative for αT4 globin expression, by 
stage 25/26 the VBI region co-expresses gata2 and αT4 globin strongly suggesting that 
gata2 is expressed in haematopoietic precursors from stage 19. A later study by Ciau-


























Figure 1.9: Whole embryo in situ hybridisations showing similar expression 
patterns between tal1/scl, lmo2 and gata1at the swimming tadpole stage.  
Whole Xla embryos were fixed at stage 28 and the mRNA expression patterns of 
tal1/scl, lmo2 and gata1were analysed using WISH. The expression patterns in the VBI 
are very similar for all three HTFs. However, tal1/scl and lmo2 also show non-


























Figure 1.10: Whole embryo in situ hybridisations showing gata2 mRNA expression 
in a stage 26 Xla embryo.  
Embryo was fixed at stage 26 and gata2 mRNA expression was analysed using WISH. 
Gata2 expression is seen in the DLP, VBI and in the head (taken from Ciau-Uitz et al., 
2000).  
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gata1 expression was found to be restricted to the blood cells of the VBI and cannot be 
detected by in situ hybridisation until late neurula stages. The mRNA expression 
patterns of tal1, lmo2 and gata1 are very similar at the swimming tadpole stage (figure 
1.9) (Mead et al., 2001). 
 
Again, as found in experiments using mice containing Tal1 and lmo2 null mutations, 
targeted disruption to gata1 and gata2 genes causes death to homozygous mutant mouse 
embryos (Pevny et al., 1991; Tsai et al., 1994). 
 
Based on the study by Wadman et al., 1997, Mead et al., 2001 decided to test the 
synergistic haematopoietic activity of Lmo2, Tal1 and Gata1. Previous studies by Mead 
et al., 1998 had shown that ectopic expression of lmo2, tal1 or gata1 alone to have no 
effect on development, although these results do contrast with results produced by 
Gering et al., 1998 who report that ectopic expression of Tal1 in zebrafish embryos 
causes overproduction of blood. The more recent experiments carried out by Mead et 
al., 2001 suggest that Tal1 and Lmo2 over-expression in whole Xenopus embryos 
causes expansion of the blood islands and when over-expressed along with Gata1 the 
embryos are ventralised and have blood throughout the dorsal ventral axis coinciding 




Hex (haematopoietically expressed homeobox), also known as PRH (proline-rich 
homeodomain) is a transcription factor that binds to DNA through a homeodomain 
consisting of a 60-amino acid helix-turn-helix structure. Hex is known to regulate cell 
development and differentiation using both transcriptional and post-transcriptional 
mechanisms as well functioning as a regulator of cell proliferation by making direct 
protein-protein interactions with many cellular proteins that influence the cell cycle 
(Soufi and Jayaraman, 2008).  
 
During early mouse development, hex is expressed in the extra embryonic tissues that 
are involved in anterioposterior axis formation and contribute to both haematopoietic 
and vascular systems. Following gastrulation, hex is expressed in the embryonic 
mesoderm of the embryo proper from which angioblasts arise and endocardial cells 
develop into cardiac tubes of the heart (Thomas et al., 1998). hex is later expressed in 
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the murine fetal liver and in the adult is expressed in the thyroid, lungs, liver and 
haematopoietic system (Bedford et al., 1993; Hromas et al., 1993; Manfioletti et al., 
1995 and Bogue et al., 2000). 
 
A homologue of Hex has also been identified in Xenopus that shows similar expression 
patterns to mouse during early development. Over-expression of Hex in Xenopus 
embryos leads to disorganisation of the vasculature and an increase in early endothelial 
progenitors (Newman et al., 1997). The effect of knocking out Hex expression was 
tested by Guo et al., (2003) using; in vitro Hex -/- embryonic stem (ES) cell 
differentiation, in vivo yolk sac hematopoietic progenitor assays, and chimeric mouse 
analysis. Their results suggest that formation of the haemangioblast is unaffected but 
that Hex is required for the differentiation of haemangioblasts into both haematopoietic 
and endothelial progenitors, which is consistent with Hex over-expression causing an 
increased number of endothelial progentitors. In contrast to these results Kubo et al., 
(2005) found that Hex -/- cells produced increased numbers of haemangioblasts. The 
endothelial cells derived from Hex -/- cells showed enhanced proliferative potential, the 
authors also show that Hex over-expression causes a decrease in haemangioblast 
numbers and a decrease in proliferation.  However, fewer committed haematopoietic 
cells are derived from Hex -/- cells. The discepancies could be due to the fact that Hex 
plays a complex role during haematopoietic and vascular development and has different 
functions at different stages. The exact role that Hex plays in haematopoiesis and 
vasculagenesis remains unclear. 
 
As with the previously mentioned HTFs, Hex has also been implicated in various 
human leukemias including acute myelogenous and chronic myelogenous leukemia 
cells in which Hex is either down-regulated or mislocalised in the cytoplasm 
(Topisirovic et al., 2003). Over-expression of hex through insertional mutagenesis has 
been linked to B and T-cell leukemias (Hansen and Justice, 1999 and Li et al., 1999). 
 
1.8 Gene regulatory networks  
During any developmental process the expression of genes is tightly regulated. Each 
gene must be expressed in a specific spatial and temporal pattern in order for normal 
development to proceed. Inappropriate expression of genes can lead to abnormal 
development or serious disease. As previously mentioned, the inappropriate expression 
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of many HTFs has been implicated in the development of various serious diseases 
emphasising the importance of tight transcriptional control over the expression of these 
genes. The complex control systems regulating gene expression are known as gene 
regulatory networks (GRNs). GRNs consist of the genes involved in any given 
developmental process and the TFs (activators and repressors) that regulate their 
expression by binding to specific DNA sequences (Davidson et al., 2002; Oliveri and 
Davidson, 2004). The reconstruction of GRNs is one way in which to depict the 
interactions between individual genes and their protein products, therefore providing a 
greater understanding of the underlying mechanisms involved in many developmental 
processes. 
 
Swiers et al. (2006) constructed a control logic GRN model describing the known 
interactions during erythroid development (figure 1.11). The model was predominantly 
deduced using data obtained from mouse models. The model represents each interaction 
as either activating or repressing and where known it gives some insight into whether 
proteins act alone or in synergy with one another on cis-regulatory elements. The timing 
of gene expression is also indicated by ordering earlier to later expressed genes from top 
to bottom of the model. As further knowledge on each individual interaction is acquired 
GRN models can be updated. For example, a more recent study by Liu et al., 2008 
suggests that fli1 acts at the top of the genetic cascade establishing the haematopoietic 
and endothelial programs within mesodermal cells of the early Xenopus laevis embryo 
(see section 1.7.1). 
 
The interactions that occur within a GRN have been derived from published expression 
profiles, gain and loss of function experiments and cis-regulatory elements identified in 
promoters and enhancers of target genes (Loose and Patient, 2004). 
 
The molecular steps involved in how gene activity is regulated during early 
haematopoiesis are yet to be fully determined but as further experimental evidence 
emerges a greater understanding of the GRN that produces blood and vasculature will 
be achieved. 
 
One way in which to gather further experimental evidence would be to raise antibodies 
against specific HTFs then use these antibodies to analyse the spatial and temporal 






Figure 1.11: Control logic GRN model for erythroid development.  
This describes the important known interactions during erythroid development. Genes 
expressed earlier in development are positioned towards the top of the model and genes 
expressed later on towards the bottom. The coloured background panels represent 
approximately where in the hierarchy of cellular differentiation each gene is expressed 
(Swiers et al., 2006). 
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antibodies could be used to identify novel target genes of the HTFs using chromatin 
immunoprecipitaion (ChIP). 
 
1.9 Project aim 
Although the HTFs mentioned above have been studied extensively at the level of 
mRNA during early development, little is known about their: post-transcriptional 
regulation; sub-cellular localisation; DNA binding activity or post-translational control 
during early development. Although the transcripts of HTFs have specific spatial and 
temporal expression patterns, this mRNA does not always get translated into protein 
and even if it does, post-translational regulation may alter the protein’s activity. The 
research described here aims to analyse the spatial and temporal protein expression 
patterns of HTFs and find out whether post transcriptional and/or post translational 
regulation of HTFs contributes to early haematopoietic development. This knowledge 
would enhance the current understanding of the GRNs that produce blood and 
vasculature. 
 
1.9.1 Specific aims 
• Identify unique regions of Xenopus HTFs (gata1, gata2, Tal1, Hex, Lmo2, fli1 
and Spi1). 
• Express and purify the selected unique regions of HTFs. 
• Raise antibodies in sheep against HTFs. 
• Characterise antibodies using Western blot analysis. 
• Analyse spatial and temporal expression patterns of HTFs 
• Analyse sub-cellular location of HTFs. 







Materials and Methods 
 
2.1 Suppliers 
All chemicals and reagents were obtained from the following companies: Sigma 
Aldrich, BioRad, Roche, New England Biolabs (NEB), Invitrogen, Fisher Scientific, 
Qiagen, Greiner, Flowgen, GE Healthcare, Promega, Abcam and Gene Tools. 
 
2.2 Solutions 
Alkaline phosphatase (AP) buffer: 100 mM Tris-HCl  pH 9.5, 150 mM NaCl and 25 
mM MgCl2.  
 
Ampicillin: 50 mg/mL stock, stored at -20 oC. 
 
APS: 10 % w/v stock, stored at -20 oC. 
 
Bleaching solution: 5 % formamide, 0.5 × SSC and 10 % v/v H2O2 added last. 
 
Blocking solution (in situ): 0.1 M Maleic acid pH 7.5, 0.1 M NaCl and 2 % blocking 
buffer (Boehringer Mannheinn). 
 
Buffer A: 20 mM PBS (5 Sigma tablets in 500 mL), 0.5 M NaCl, 7 M Urea and 20 mM 
Imidazole. Filter sterilise. 
 
Buffer B: 20 mM PBS (5 Sigma tablets in 500 mL), 0.5 M NaCl, 7 M Urea and 500 
mM Imidazole. Filter sterilise. 
 




Denhardt’s solution: 0.02 % w/v BSA, 2 % w/v PVP-20 and 2 % w/v Ficoll 400. 
 
DTT: 1 M stock, stored at -20 oC. 
 
Embryo extraction buffer (EEB): 10 mM HEPES pH 8.5, 2 mM MgCl2, 1 mM DTT 
and 75 mM NaCl. 
 
Ethidium bromide: 10 mg/mL stock, stored in the dark. 
 
FB1: 100 mM RbCl, 50 mM MnCl2.4H2O, 30 mM C2H5CO2K, 10 mM CaCl2.2H2o and 
15 % w/v Glycerol, pH to 6.8 with NaOH and filter sterilise. 
 
FB2: 10 mM MOPS, 10 mM RbCl, 75 mM CaCl2.2H2O and 15 % w/v Glycerol. pH to 
6.8 with NaOH and filter sterilise. 
 
Formaldehyde gel-loading buffer (10 X): 50 % w/v Glycerol dissolved in sH2O, 10 
mM EDTA pH 8.0, 0.25 % w/v Bromophenol blue and 0.25 % w/v Xylene Cyanol FF.  
 
Hybridisation mix (in situ): 50 % v/v formamide, 5 × SSC, 1 mg/mL tRNA (from E. 
coli. Strain MRE 600, Roche), 100 µg/mL heparin, 1 × Denhardt’s solution, 0.1 % v/v 
Tween-20 and 5 mM EDTA. 
 
IPTG (1 M): Dissolve 0.238 g in 1 mL sH2O, store at -20 oC. 
 
Kanamycin: 50 mg/mL stock, stored at -20. 
 
LB agar (Miller): Dissolve 40 g of agar in 1 L of dH2O. 
 
LB broth (Miller): Dissolve 20 g of broth in 1 L of dH2O. 
 
Maleic acid buffer (MAB): 100 mM maleic acid and 150 mM NaCl, adjust to pH 7.5. 
 
MEMFA: 0.1 M MOPS pH 7.4, 2 mM EGTA, 1 mM MgSO4 and 3.7 % formaldehyde. 
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Marc’s Modified Ringers (MMR) (20 X): 0.1M NaCl, 2mM KCl, 1mM MgSO4, 
2mM CaCl2, 5mM HEPES pH 7.8 and 0.1mM EDTA, pH 7.8. 
 
Modified barth’s saline (MBS) (10 X): 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 
0.82 mM MgSO4.7H2O, 0.33 mM Ca(NO3)2.2H2O, 0.41 mMCaCl2.6H2O and 10 mM 
HEPES. Adjust to pH 7.6 with 1 M NaOH.  
 
MOPS electrophoresis buffer (10 X): 0.2 M MOPS pH 7.0, 20 mM NaAc and 10 mM 
EDTA pH 8.0. Filter sterilised and protected from light. 
 
Murray’s clear: 1 volume Benzyl alcohol and 2 volumes Benzyl benzoate. 
 
NETS buffer: 300 mM NaCl, 1 mM EDTA, 20 mMTris-HCl (pH7.6) and 1 % SDS. 
 
Orange G loading buffer (6 X): 0.25 % w/v Orange G and 15 % Ficoll (type 400) 
made up in sH2O. 
 
Phosphate buffered saline (PBS): 1 tablet (Sigma) dissolved in 200 mL dH2O, 
producing: 10 mM phosphate buffer, 2.7 mM KCl and 137 mM NaCl, pH 7.4 at 25 oC. 
 
PBSTw: 1 × PBS and 0.1 % v/v Tween-20 
 
PBT: 0.1 % v/v Triton and 2 mg/mL BSA in 1 × PBS. 
 
Protein destain: 10 % v/v Acetic acid and 10 % v/v Methanol. 
 
Protein stain: 10 % v/v Acetic acid, 50 % v/v Methanol and 1 g/L Coomassie brilliant 
blue R-250. 
 
RIPA buffer: 50 mM Tris-HCl pH 7.4, 1 % v/v Igepal CA-360 (NP-40), 0.25 % w/v 
Sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 0.1 % SDS and 0.5 mM DTT 
made up in dH20. One protease inhibitor tablet (Roche) and one phosphatase inhibitor 
tablet (Roche) added per 10 mL. 
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SDS running buffer (10 X): 0.25 M Tris, 1 % SDS and 1.92 M Glycine, adjust to pH 
8.3. 
Schägger PAGE anode buffer: 200 mM Tris-HCl pH 8.9. 
 
Schägger PAGE cathode buffer: 100 mM Tris-HCl, 100 mM Tricine and 0.1 % SDS. 
 
Schägger PAGE gel buffer: 3 M Tris-HCl pH 8.45 and 0.3 % SDS. 
 
SDS loading dye (3 X): 0.36 M Tris-HCl pH 6.8, 9 % SDS, 15 % v/v Glycerol, 15 % 
v/v β-mercaptoethanol and 0.2 w/v Bromophenol blue. 
 
Sodium saline citrate (SSC) (20 X): 3 M NaCl and 0.3 M sodium citrate. 
 
Solution I: 50 mM Glucose, 25 mM Tris-HCl pH 8.0 and 10 mM EDTA. 
 
Solution II: 0.2 M Na OH and 1 % SDS 
 
Solution III: 3 M KAc, add glacial acetic acid until pH 4.5 then make up to 100 mL 
with dH2O. 
 
TBE (10 X): 890 mM Tris-borate pH 8.3 and 20 mM Na2EDTA. 
 
TBSTw (10 X): 100 mM Tris-HCl pH 8.0, 1.5 M NaCl and 0.5 % v/v Tween-20. 
 
Western blocking solution: 5 % w/v Marvel dissolved in 1 × TBSTw. 
 
Western solution I: 1.1 mM Luminol, 0.9 mM p-Coumaric acid, 100 mM Tris-HCl pH 
8.0 made up in dH2O.  
 
Western solution II: 0.06 % v/v hydrogen peroxide and 100 mM Tris-HCl pH 8.0 
made up in dH2O. 
 




2.3.1 Agarose gels 
DNA and RNA samples were analysed using horizontal submarine agarose slab gels, 
which separate DNA fragments according to their size. The gel solution consited of 1 × 
TBE and a percentage of agarose dependent on the size of DNA fragment being 
analysed. The mixture was heated in a microwave until all the agarose was dissolved. 
Once the solution had cooled to approximately 50 oC, 6 µL of EtBr stock was added per 
100 mL of gel solution. Whilst the gel solution was cooling, the gel sledge and comb 
were cleaned in dH2O. The gel sledge was then sealed at both ends by using a double 
layer of masking tape and the comb was inserted. The gel was then poured and allowed 
to set at room temperature. Once the gel was set, the tape was removed and the sledge 
placed inside the gel tank.  The tank was filled with 1 × TBE running buffer and the 
comb was removed. 
 
The DNA samples to be analysed had one-fifth their volume of 5 × Orange G added to 
them.  The DNA samples were then loaded along side a DNA ladder (figure 2.1). The 
gel was run at between 80 V and 140 V and the DNA was visualised using UV 
transillumination.  
 
2.3.2 Denaturing agarose gels 
RNA samples to be used in Northern blotting were separated using horizontal 
submarine denaturing agarose slab gels. Denaturing gels were made in a fume hood. 
The gel sledge and comb (specifically for RNA) were rinsed several times in dH2O with 
one final rinse in nuclease free H2O. The gel sledge was then sealed at both ends by 
using a double layer of masking tape and the comb was inserted. The gel solution was 
made by dissolving 1.5 g of agarose in 72 mL of nuclease-free H2O (Sigma). The 



































Figure 2.1: Three gel markers used for DNA and Protein analysis.  
(A) 1 kb Plus DNA ladderTM (Invitrogen) used for both plasmid and PCR product 
analysis. (B) BenchMarkTM Protein Ladder (Invitrogen) used for protein gels to be 
analysed by commassie blue staining. (C) SeeBlue® Plus2 Pre-Stained Standard 
(Invitrogen) used for protein gels to be analysed by Western blotting. 
A. B. C. 
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Once the solution had cooled to 55 oC, 10 mL of 10 × MOPS electrophoresis buffer and 
18 mL of 37 % formaldehyde was added. The gel was then poured and allowed to set at 
room temperature. Once set the gel was covered in Saran Wrap until the samples were 
ready to be loaded.  
 
Whilst the gel was setting the following denaturation reactions were set up in sterile 
microcentrifuge tubes: 2 µL of RNA (as described in 2.8.4), 2 µL of 10 × MOPS 
electrophoresis buffer, 4 µL of 37 % formaldehyde, 10 µL of formamide and 1 µL of 
ethidium bromide (200 µg/mL). The RNA solutions were then incubated at 55 oC for 60 
minutes followed by incubation on ice for 10 minutes. The samples were then briefly 
centrifuged for 5 seconds before the addition of 2 µL of 10 × formaldehyde gel-loading 
buffer. RNA samples were then replaced on ice.  
 
The denaturing agarose gel was then placed in a horizontal electrophoresis tank and 
covered with a sufficient amount of 1 × MOPS electrophoresis buffer to cover the gel to 
a depth of approximately 1 mm. Following removal of the gel comb the gel was pre-run 
for 5 minutes at 5 V/cm. The RNA samples were loaded into the wells of the gel and the 
gel was run submerged in 1 × MOPS electrophoresis buffer at 5 V/cm until the 
bromophenol blue had migrated approximately half way down the gel. 
 
Once removed from the gel tank, one corner of the gel was removed in order to simplify 
orientation during the succeeding operations The RNA was visualised by placing the gel 
on a piece of Saran Wrap on a UV transilluminator. The gel was photographed under 
UV illumination aligned against a transparent ruler. 
 
2.3.3 Tris-tricine polyacrylamide (Schägger) gels 
Where required protein samples were analysed by tris-tricine polyacrylamide gels  
(Schägger and Von Jagow, 1987), which can clearly resolve proteins of a molecular 
weight within the range of 1-100 kDa.  
 
Firstly, dH2O was used to clean the electrophoresis plates, rubber gasket and comb. A 
solution of 70 % v/v EtOH was used to degrease the electrophoresis plates. The 
electrophoresis plates and rubber gasket were then assembled and clamped. The 
stacking gel and 10 % resolving gel were made according to table 2.1a. The resolving 



































Table 2.1: (A) Composition of a 10% tris-tricine polyacrylamide gel and (B) 
composition of a 12% SDS polyacrylamide gel. 
Stock solutions Stacking gel 
Resolving 
gel 10% 
Protogel 405  µL 2.5 mL 
Tris-HCl pH 8.45 775  µL 2.5 mL 
dH2O 1.95 mL 1.7 mL 
Glycerol - 800  µL 
10% w/v APS 62.5  µL 12.5  µL 
TEMED 12.5  µL 5  µL 
Stock solutions Stacking gel 4% 
Resolving 
gel 12% 
Protogel 650  µL 4 mL 
4 x Resolving buffer 1.25 mL 2.5 mL 
dH2O 3.05 mL 3.39 mL 
10% w/v APS 25  µL 100  µL 




volume of isopropanol was then slowly added to ensure an even interface between the 
resolving and stacking gels. Once the resolving gel was set the isopropanol was 
removed using dH2O. The stacking gel was added and the comb placed carefully into 
the gel. Once the stacking gel had set, the clamps and gasket were removed and the gel 
was placed inside the gel tank. Anode buffer was added to the outside of the gel tank 
and any air bubbles were removed by gently tilting the tank. The cathode buffer was 
then added to the inside section of tank and the comb was removed. Using a syringe the 
wells were then cleaned with cathode buffer. 
 
Samples were prepared for electrophoresis by adding one volume of 3 × SDS loading 
buffer and one volume of 300 mM DTT then heating them at 100 oC for 5 minutes. The 
samples were then centrifuged at 14,000 rpm for 1 minute and loaded onto the gel. Each 
gel had either 10 µL of BenchmarkTM protein ladder or 10 µL of SeeBlue® Plus2 Pre-
Stained protein ladder (Invitrogen) loaded onto it (figure 2.1). The gels were run for 30 
minutes at 60 V, after which they were run at 140 V until the dye front reached the 
bottom of the resolving gel.Following electrophoresis, the gels were carefully removed 
from the electrophoresis plates and stained in Coomassie blue solution for at least 2 
hours at room temperature. The gel was then rinsed in dH2O and destained overnight in 
destain solution containing a piece of tissue to aid removal of the dye. Once destained, 
the gels were visualised and photographed.  
 
2.3.4 SDS polyacrylamide gel electrophoresis 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was set up in the same manner 
using the same equipment as described in section 2.1.3. The percentage of 
polyacrylamide used was dependant on the molecular weight of the protein being 
resolved, although typically a 12 % resolving gel and a 4 % stacking gel was necessary 
to give the required resolution. The stacking gel and resolving gel were made according 
to table 2.1b. Once the gel was placed inside the gel tank, 1 × Tris/Glycine/SDS buffer 
(National Diagnostics) was added to the outside of the gel tank and any air bubbles 
were removed by gently tilting the tank. Tris/Glycine/SDS buffer (1 × dilution) was 
then added to the inside section of tank and the comb was removed. Using a syringe the 
wells were then cleaned with buffer. The samples were loaded and the gels run as 
described in section 2.1.2. 
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2.4 Nucleic acid techniques  
2.4.1 Reverse transcription using Superscript II  
In order to transcribe mRNA into cDNA for reverse transcription PCR, reverse 
transcription reactions were prepared in microcentrifuge tubes. The following reagents 
were added and mixed together by gently pipetting up and down: 4 µL of RNA (1 ng-5 
µg total RNA), 4 µL of 5 × first strand buffer, 1 µL of 10 mM dNTP mix (10 mM of 
each dNTP) (NEB), 1 µL of RNaseOUT™ (Invitrogen), 2 µL of 100 µM random 
hexamer primers (Roche), 2 µL of 0.1 M DTT and 2 µL of Superscript II (Invitrogen). 
The reaction was made up to 20 µL with nuclease-free H2O (Sigma). Once the reagents 
were added together the reaction was allowed to proceed at 55 °C for 30-45 minutes. 
cDNA was stored at -70 °C. 
 
2.4.2 Reverse transcription using Superscript III 
The following reaction was set up in microcentrifuge tubes to transcribe cDNA from 
mRNA using Superscript III (Invitrogen) for the purpose of performing Real-time PCR: 
4 µL of 100 µM random hexamer primers (Roche), 8 µL of RNA (10 pg-5 µg) and 2 µL 
of 10 mM dNTP mix (10 mM of each dNTP) (NEB). The reaction was made up to 26 
µL with nuclease free H2O (Sigma). The mixture was incubated at 65 oC for 5 minutes 
then placed on ice for at least 1 minute. The contents of the microcentrifuge tube were 
collected by brief centrifugation then the following reagents were added: 8 µL of 5 × 
first strand buffer, 2 µL of 0.1 M DTT, 2 µL of RNaseOUT™ (Invitrogen) and 2 µL of 
Superscript III (Invitrogen). The reagents were mixed by gently pipetting up and down 
then incubated at 25 oC for 5 minutes. Reverse transcription was allowed to proceed by 
incubating the reagents at 55 oC for 45 minutes. The reaction was inactivated by 
incubation at 70 oC for 15 minutes. cDNA was stored at -70 oC. 
 
2.4.3 Reverse transcription Polymerase Chain Reaction (1) 
Reverse transcription polymerase chain reaction (RT-PCR) was used for the 
amplification of DNA sequences encoding antigen sequences from Xenopus tropicalis 
cDNA, the amplification of Hex and fli1 coding sequences from Xenopus laevis cDNA 
and the amplification of Tal1 coding sequence from Xenopus tropicalis cDNA. Specific 
primers were designed in order to allow amplification of target sequences and 
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subsequent cloning of the PCR product into the required vector as discussed in the 
following chapters. Appendix 1 lists all PCR primer sequences. 
 
Each 26.5 µL PCR reaction contained the following: 22.5 µL of Platinum® PCR 
SuperMix High Fidelity (Invitrogen), 2 µL of cDNA, 1 µL of 25 µM forward primer 
and 1 µL of 25 µM reverse primer (Invitrogen). The PCR mixtures were placed into a 
DNA Engine DYADTM PCR machine (MJ Research) and the following program was 
run: Denature at 94 oC for 2 minutes followed by 35 cycles of denaturing at 94 oC for 30 
seconds, annealing at 60 oC for 30 seconds and extension at 72 oC for 1 minute/1 kb 
template DNA. PCR products were analysed by running 5 µL of the PCR mixture on a 
2 % w/v agarose gel (section 2.1.1). 
 
2.4.4 Reverse transcription Polymerase Chain Reaction (2) 
RT-PCR was used for the amplification of Hex and fli1 DNA sequences from Xenopus 
laevis cDNA for subsequent analysis of mRNA expression. Specific primers used for 
the amplification of Hex, fli1 and ODC DNA fragments are listed in appendix I. 
 
Each 25 µL PCR reaction contained the following: 1 µL of cDNA plus 5 µL of sH2O 
for ODC or 2 µL of cDNA plus 4 µL of sH2O for Hex and fli1, 2.5 µL of mM dNTP, 
2.5 µL of 10 × buffer, 2 µL of 10 µM ODC forward primer or 1 µL of 25 µM Hex and 
fli1 forward primers, 2 µL of 10 µM ODC reverse primer or 1 µL of 25 µM Hex and 
fli1 reverse primers, 0.25 µL of Taq polymerase and 10 µL of sH2O for ODC or 12 µL 
of sH2O for Hex and fli1 amplification. The PCR mixtures were placed into a DNA 
Engine DYADTM PCR machine (MJ Research) and the following program was run: 
Denature at 94 oC for 2 minutes followed by 36 cycles of denaturing at 94 oC for 30 
seconds, annealing at 59 oC for 30 seconds and extension at 72 oC for 30 seconds for 
Hex and fli1. For ODC Denature at 94 oC for 2 minutes followed by 26 cycles of 
denaturing at 94 oC for 30 seconds, annealing at 55 oC for 30 seconds and extension at 
72 oC for 30 seconds. PCR products were analysed by running 10 µL of the PCR 




2.4.5 TOPO TA Cloning® 
Fresh Taq polymerase-amplified PCR products were cloned into pCR®2.1-TOPO® 
using the TOPO TA Cloning® kit (Invitrogen) according to the manufacturers 
instructions. 
 
2.4.6 pGEM®-T Easy Vector System 
Fresh Taq polymerase-amplified PCR products were cloned into pGEM®-T Easy using 
the pGEM®-T Easy Vector System (Promega) according to the manufacturers 
instructions. 
 
2.4.7 Small-Scale Plasmid Purification (mini-prep) 
A single colony of plasmid-containing E. coli was used to inoculate 5 mL of LB 
medium containing the appropriate selective antibiotic. The culture was then incubated 
overnight at 37 oC with shaking. Following incubation, 3 mL of culture was centrifuged 
at 4 oC at 14,000 rpm for 1 min for every 1 mL. The supernatant was removed and the 
cells resuspended in 100 µL of ice-cold solution 1. The samples were left on ice for 5 
minutes. Next, 200 µL of fresh, room temperature solution 2 was added and the samples 
were mixed by repeated inversion several times. Once the cells had lysed, and after 5 
minutes at room temperature, 150 µL of ice-cold solution 3 was added and mixed by 
repeated inversion.  After 30 minutes incubation on ice the samples were centrifuged at 
4 oC at 14,000 rpm for 10 minutes in order to pellet the white precipitated debris. The 
supernatant was transferred to a fresh microcentrifuge tube. RNA was digested by 
adding 10 µL of NEBuffer 2 and 5 µL of a 10 mg/mL RNAse A stock then incubating 
samples at 37 oC for 2 hours. Following incubation, phenol/chloroform extractions were 
performed to remove proteins from the sample (section 2.4.8), followed by ethanol 
precipitation of the DNA (section 2.4.9). The dried DNA pellet was then resuspended in 
50 µL of nuclease-free H2O (Sigma) and stored at -20 °C. 
 
2.4.8 Phenol/phenol-chloroform extraction  
Phenol and phenol-chloroform (Sigma) extractions were used in DNA/RNA 
purification procedures. If the aqueous DNA/RNA sample was less than 400 µL then 
the sample was made up to 400 µL using nuclease-free H2O (Sigma). An equal volume 
(400 µL) of phenol or phenol-chloroform was then added and the sample vortexed for 
30 seconds. The sample was then centrifuged at room temperature for 3 minutes at full 
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speed using a bench-top microcentrifuge (Eppendorf). The top layer (containing the 
DNA/RNA) was retained and placed into a fresh 1.5 mL microcentrifuge tube. To 
remove any residual phenol the sample was then chloroform extracted. An equal 
volume of chloroform was added and the sample vortexed for 30 seconds. The 
centrifugation step was then repeated and the top layer was placed into a fresh 1.5 mL 
microcentrifuge tube. The DNA/RNA was precipitated out of solution as described in 
section 2.4.9.  
 
2.4.9 Ethanol precipitation of DNA/RNA 
Two and one-half volumes of 100 % v/v ethanol and 0.1 volumes of 3 M NaAc were 
added to the sample and mixed thoroughly. This was then incubated at -70˚C for at least 
30 minutes, following which the sample was centrifuged using a bench-top 
microcentrifuge (Eppendorf) at 4 ˚C at full speed for 15 minutes. The supernatant was 
then carefully removed and the pellet washed by adding 500 µL of 70 % v/v ethanol and 
centrifuging at room temperature at full speed for five minutes. The supernatant was 
then carefully removed and the pellet dried for one minute under a lamp. The pellet was 
then resuspended in the required volume of nuclease-free H2O (Sigma) by pipetting up 
and down. 
 
2.4.10 DNase I treatment of isolated RNA samples 
DNA was removed from RNA samples by adding 12 µL of DNase I buffer (NEB), 2 µL 
of DNase I (NEB) and 1.5 µL of RNaseOUT™ (Invitrogen) to 50 µL of RNA sample. 
Samples were then incubated at 37 ˚C for 30 minutes after which a further 2 µL of 
DNase I was added followed by a further 30 minute incubation period at 37 ˚C.  
 
2.4.11 Restriction enzyme digest of DNA 
All restriction digests (NEB) were carried out according to the manufacturer’s 
instructions. Suitable buffers (NEB) were used and an appropriate concentration of 
bovine serum albumin (BSA) was added if required. 
 
2.4.12 DNA isolation from agarose gels 
DNA inserts were removed from either pCR®2.1-TOPO® or pGEM®-T Easy using the 
appropriate restriction enzymes (NEB) according to the manufacturer’s instructions. 
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Agarose gel electrophoresis was then used to separate the DNA insert from the vector. 
The DNA inserts were then excised from the gel using a clean scalpel on a UV 
transilluminator to visualise the ethidium bromide stained DNA. The QIAquick Gel 
Extraction Kit (Qiagen) was then used to purify the DNA from the gel according to the 
manufacturer’s instructions. 
 
2.4.13 Antarctic phosphatase treatment of vector DNA 
In order to ligate insert DNA into either pET-28a (+) (Novagen) or pBUT2-Sfi, vector 
DNA was firstly digested with the appropriate restriction enzymes (NEB) according to 
the manufacturer’s instructions. Following completion of digestion, 1 µL of Antarctic 
phosphatase and 3 µL of Antarctic phosphatase buffer were added to the reaction then 
incubated at 37 °C for 30 minutes. The Antarctic phosphatase removes the phosphate 
group from the 5´ ends of the vector and the excised fragments of DNA preventing 
them from religating. Antarctic phosphatase was then deactivated by incubating the 
reaction at 65 °C for 5 minutes.  
 
2.4.14 Sticky end ligation  
Ligation of DNA inserts into either pET-28a (+) (Novagen) or pBUT2-Sfi vector DNA 
was carried out in 15 µL reactions containing 1 µL of T4 DNA ligase and 1 × T4 DNA 
ligase buffer (NEB). The reaction was performed using an approximate 3:1 insert to 
vector molar ratio. Reactions were incubated overnight at 16°C. Following incubation, 2 
µL of the product was used to transform 100 µL of competent E. coli DH5α cells. 
 
2.4.15 Blunt end ligation  
Insertion of the ORF of Xla Hex into pBUT2-Sfi required blunt ended ligation to be 
carried out. A 15 µL reaction was set up containing 10 × ligation buffer: 250 mM Tris-
HCl pH 7.5; 50 mM MgCl2; 25 % w/v polyethylene glycol 8000 and 5 mM DTT. The 
reaction also contained 1 µL of T4 DNA ligase (NEB) and 0.5 µL of 100 mM ATP. The 
reaction was performed using an approximate 9:1 insert to vector molar ratio and was 
incubated at room temperature for four hours. Following incubation, 2 µL of the 
product was used to transform 100 µL of competent E.coli. DH5α cells. 
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2.4.16 Probe synthesis for Northern blotting 
XbaI and NcoI digests were set up according to manufactures instructions in order to cut 
a 728 bp fli1 fragment out of pBUT2-Sfi containing the whole fli1 coding sequence. 
This 728 bp fragment would act as a template for generating a fli1 northern blot probe 
(a smaller 300 bp fragment is also produced by this digest). The digest was then 
separated by agarose gel electrophoresis and the 728 bp fragment gel extracted using the 
QIAquick Gel Extraction Kit (Qiagen) according to manufactures instructions. Using 50 
ng of template DNA, the N5000 Amersham Nick Translation Kit (GE Healthcare) was 
then used to generate [α-32P]-dCTP labeled probe according to manufactures 
instructions. The reaction was cleaned up using an Illustra MicroSpin G-25 Column 
(GE Healthcare) according to manufacturer’s instructions. 
 
2.4.17 Northern blotting 
RNA samples were separated on denaturing agarose gels and photographed under UV 
illumination as described in section 2.1.2. Meanwhile, two pieces of 3MM paper the 
same size as the gel, one larger piece of 3MM paper (large enough to cover the support 
and drape under the transfer buffer – as shown in figure 2.2), and one piece of Hybond-
N nylon membrane (GE Healthcare) the same size as the gel were pre-soaked in 20 × 
SSC (transfer) buffer. An upturned plastic dish used as the gel support was then placed 
in a larger dish which was subsequently filled with 20 × SSC until the level of liquid 
reaches almost the top of the support. The larger piece of 3MM paper was then placed 
over the support with its edges draped in the buffer. Once visualised and photographed 
under UV illumination, the gel which had one corner removed prior to being 
photographed was rinsed several times in nuclease-free H2O (Sigma) before one rinse in 
20 × SSC. The gel was then placed onto the 3MM paper on the gel support in an 
inverted position. A corner of the pre-soaked nylon membrane was then removed prior 
to its positioning on the gel in the same orientation. Care was taken to avoid the 
formation of any air bubbles between the gel and nylon membrane. The final two pieces 
of 3MM paper were then placed over the membrane followed by several sheets of dry 
paper towel. Finally a glass plate and heavy weight were placed over the paper towels. 
Figure 2.2 shows a schematic diagram of how the Northern blot transfer apparatus were 
set up. The RNA was then left to transfer from the gel onto the nylon membrane 





















Figure 2.2: Upward capillary transfer of RNA from an agarose gel onto uncharged 
nylon membrane.  
Capillary transfer of RNA from an agarose gel onto uncharged nylon membrane is 
achieved by drawing the transfer buffer from the reservoir upward through the gel into 
the stack of paper towels. The RNA is eluted from the gel by the moving stream of 
transfer buffer and is deposited onto the nylon membrane. To ensure a tight connection 
between the gel and membrane a weight is placed on top of the paper towels. 
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Once transferred to the membrane the RNA was cross-linked to the membrane by a 12 
second exposure in a UV Stratalinker 2400 (Stratagene). The blot was then carefully 
placed in a hybridisation bottle and pre-hybridised in 15 mL of hybridisation buffer for 
two hours at 64 °C in a rotating hybridisation oven. When required the probe was 
denatured by heating at 100 °C in a heat block for three minutes and was then added 
directly to the blot and hybridisation mix. Hybridisation proceeded overnight at 64°C. 
Following hybridisation, the hybridisation mix and probe were removed and the blot 
washed for 15 minutes at room temperature in 2 × SSC. Two, 15 minute washes in 250 
mL of 2 × SSC, 1 % w/v SDS at 65 °C, and two, 15 minute washes in 250 mL of 0.2 × 
SSC, 1 % w/v SDS at 65°C then followed. After air-drying very briefly, the blot was 
carefully wrapped in Saran Wrap then placed on an imaging plate (Fujifilm). The blot 
and plate were placed in a Bas Cassette2 2352 (Fujifilm) and left to develop for two 
weeks. The image was visualised using a Fujifilm FLA-5000. 
 
2.5 Microbiological techniques 
2.5.1 Production of competent cells 
In order to effectively introduce plasmid DNA constructs into bacterial cells, the cells 
are required to be competent. To produce competent cells, strains of E. coli (DH5α and 
BL21 (DE3) Gold) were spread onto an agar plate containing no antibiotic. The plate 
was incubated overnight at 37 °C. A single colony was then used to inoculate 10 mL of 
LB medium. This was then incubated overnight at 37 oC with shaking. The overnight 
culture was used to inoculate 500 mL of LB medium, which was then incubated at 37 
°C with shaking until an OD600 of approximately 0.6 was achieved. The cells were 
collected by centrifugation in a swing out rota at 3000 rpm for 20 minutes at 4 °C. From 
this point onwards everything was kept cold. The cells were resuspended in 166 mL of 
ice-cold FB1 then incubated on ice for 20 minutes. The centrifugation step was 
repeated, the cells resuspended in 40 mL FB2 then incubated on ice for a further 20 
minutes. Aliquots of 500 µL were transferred to fresh microcentrifuge tubes on ice, 





2.5.2 Transformation of competent cells 
A 500 µL aliquot of competent cells was defrosted on ice and 100 µL transferred to a 
fresh microcentrifuge tube on ice, to which 0.5 µL of plasmid DNA was added. The 
tube was then incubated on ice for 10 minutes, heat shocked at 42 °C for 50 seconds and 
returned to ice for a further 2 minutes. Next, 900 µL of cold (4 oC) LB medium was 
added to the tube and incubated at 37 °C for approximately 1 hour (no longer than 90 
minutes or the cells start to divide). Following incubation, the cells were pelleted by 
centrifugation at 5000 rpm for 3 minutes. A 900 µL volume of the supernatant was 
removed and the cells resuspended in the remaining 100 µL.  The cells were then plated 
out onto agar plates containing the appropriate antibiotic and incubated overnight at 37 
°C. 
 
2.6 Protein techniques 
2.6.1 Overnight starter cultures 
Plasmid DNA containing a DNA sequence encoding a protein of interest was 
transformed into BL21 (DE3) Gold cells (as described in section 2.5.2). Following 
overnight incubation of the transformed cells, a single colony was taken from the plate 
and used to inoculate 10 mL LB medium containing kanamycin. The culture was 
incubated overnight at 37 °C in a shaking incubator.  
 
2.6.2 Preliminary expression tests 
To test for expression of the target protein, 1 x overnight starter culture was set up. 2 × 
100 µL from the overnight culture was used to inoculate 2 × 10 mL LB medium 
containing kanamycin. The cultures were incubated at 37 °C in a shaking incubator for 
2.5-3 hours at which point the cells should have reached an OD600 light scattering 
reading of approximately 0.6. Isopropyl-β-D-thiogalactopyranoside (IPTG) was then 
added at a 1 mM final concentration to one of the two cultures to induce expression of 
the target protein. Both cultures were further incubated for 3 hours. A 1 mL aliquot 
from each of the cultures was transferred microcentrifuge tubes. The cells were 
harvested from the 1 mL aliquots by centrifugation at 14000 rpm (20800 × g) for 1 
minute. The pellets were stored at -70 °C until required. When required the pellets were 
resuspended in 100 µL 1 × PBS, followed by the addition of an equal volume of 3 × 
SDS loading buffer and 300 mM DTT. The samples were placed in a beaker of ice and 
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cells were lysed by sonication. The amplitude was set to 30 % and a cycle of 10 x 9.9 
second sonic bursts interspersed with 9.9 second resting periods was carried out. 
Samples were then heated at 100 °C for 5 minutes. Total protein of induced and 
uninduced cells was compared using tris-tricine polyacrylamide gels (as described in 
section 2.3.3) 
 
2.6.3 Protein solubility tests 
To test whether the target protein was soluble or insoluble the same procedure was 
carried out as described in section 2.6.2. However, the harvested cells from induced 
culture were resuspended in 300 µL 1 × PBS containing protease inhibitor. The sample 
was sonicated as previously described in section 2.6.2 then centrifuged at full speed for 
2 minutes at 4 °C. A 100 µL volume of supernatant (containing soluble proteins) was 
transferred to a fresh microcentrifuge tube to which an equal volume of 3 × SDS 
loading buffer and 300 mM DTT was added. The remaining supernatant was discarded. 
The pellet (containing insoluble proteins) was resuspended in 100 µL 1 × PBS followed 
by, the addition of an equal volume of 3 × SDS loading buffer and 300 mM DTT. Both 
samples were heated at 100 °C for 5 minutes then soluble and insoluble cell fractions 
were compared using tris-tricine polyacrylamide gels (as described in section 2.3.3). 
 
2.6.4 Cell lysis 
Cell pellets obtained from 1 L of bacterial culture were resuspended in 50 mL of cold 1 
× PBS containing protease inhibitor. The cells were then lysed using a VibracellTM 
VCX 500 high intensity ultrasonic processor (Jencons-PLS) with the CV 33, ½ - inch 
probe attachment in a plastic beaker set in ice. The amplitude was set to 50 % and the 
temperature probe was inserted into the sample to ensure the temperature remained 
below 9 °C. The cells were lysed using two cycles of 18 × 5 second sonic bursts 
interspersed with 9.9 second resting periods. Following lysis, the sample was 
centrifuged at 18,000 rpm for 30 minutes at 4 °C. The supernatant or pellet would be 
used in further purification protocols depending on whether the target protein was 
soluble or insoluble.  
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2.6.5 Soluble protein purification using immobilised metal ion affinity 
chromatography  
After cell lysis and separation of soluble proteins from insoluble proteins and cell debris 
(as described in section?), soluble target proteins were further purified using a 1 mL 
His-Trap HP column (GE Healthcare) attached to an Äkta Purifier system (GE 
Healthcare). Immobilised metal ion affinity chromatography (IMAC) consisted of 
equilibrating the column in 5 column volumes (CV) of buffer A, injecting the sample 
from a 50 mL Superloop, 12 CV wash/equilibration and a 24 CV linear gradient (0-
100% buffer B). The flow-rate was 1 mL/min but reduced if the pressure exceeded 0.3 
MPa and the fraction size was 2 mL. Protein containing fractions were analysed by tris-
tricine polyacrylamide gel electrophoresis. 
 
2.6.6 Insoluble protein purification using immobilised metal ion affinity 
chromatography 
After centrifugation to separate soluble from insoluble proteins (as described in 
section?) the pellet was resuspended in 5 mL buffer A containing 7 M urea, the sample 
was left at room temperature for 0.5 hour to ensure all the protein was solubilised. The 
solubilised protein was then separated from the cell debris by centrifugation at 18,000 
rpm for 30 minutes at 4 °C. Further purification of the target protein was carried out 
using a 1 mL His-Trap HP column (GE Healthcare) attached to an Äkta Purifier system 
(GE Healthcare). IMAC consisted of equilibrating the column in 5 column volumes 
(CV) of buffer A containing 7 M urea, injecting the sample from a 5 mL loop, 12 CV 
wash/equilibration and a 24 CV linear gradient (0-100% buffer B containing 7 M urea). 
The flow-rate was 1 mL/min but reduced if the pressure exceeded 0.3 MPa and the 
fraction size was 2 mL. Protein containing fractions were dialysed overnight in 1 × PBS 
and analysed by tris-tricine polyacrylamide gel electrophoresis. 
 
2.6.7 Size exclusion chromatography of protein from Xenopus laevis embryos 
Hex and fli1 protein complexes in Xla embryos were analysed by size exclusion 
chromatography using a Superose 6 10/300 GL column attached to an Äkta Purifier 
system (GE Healthcare). Samples were prepared as follows: for the comparison 
between pre- and post-MBT, sets of 150 embryos at stage 5 and 150 embryos at stage 
18 were collected. For the comparison between the haemangioblast compartment and 
the remainder of the embryo at stage 18, 300 embryos were dissected and collected as 
 50 
described in section 2.8.6. Excess liquid was removed and samples were homogenised 
in 100 µL of embryo extraction buffer (EEB) containing protease and phosphatase 
inhibitors (Roche) and freon-extracted as described in section 2.8.5. All samples were 
then centrifuged at 10,000 g for 10 minutes at 4 ˚C to remove any cell debris. 
 
Size exclusion chromatography consisted of equilibrating the column in one CV of 
EEB, a 0.1 CV wash/equilibration, injecting the sample from a 200 µL loop and a 1.25 
CV isocratic gradient. The flow-rate was 1 mL/min, but was reduced if the pressure 
exceeded 1.5 MPa, and the fraction size was 0.5 mL. 
 
The Superose 6 10/300 GL column (GE Healthcare) was calibrated using four protein 
markers of known molecular mass (GE Healthcare). Ferritin, catalase, aldolase and 
chymotrypsinogen A were each dissolved in EEB buffer according to the 
manufacturer’s instructions. A 200 µL volume of each marker was then loaded and 
passed through the column separately.  
 
2.6.8 Trichloroacetic acid (TCA) protein precipitation 
In order to precipitate protein from solution following size exclusion chromatography 
250 µL of 100 % TCA was added to each 500 µL fraction to be analysed. Protein 
samples were then incubated overnight at 4 ˚C. The samples were then centrifuged at 
4˚C at 14,000 rpm for 30 minutes using a bench-top microcentrifuge (Eppendorf). The 
supernatant was carefully removed and the pellet was washed gently by adding 200 µL 
ice-cold acetone then centrifuging at 4 ˚C at 14,000 rpm for five minutes. The acetone 
was carefully removed and the pellet was allowed to dry. Finally, the protein pellet was 
resuspended in 40 µL of 3 × SDS loading dye for Western blot analysis. 
 
2.6.9 Single protein immunoprecipitation  
Staged embryos were collected and placed in microcentrifuge tubes (Eppendorf) in 
batches of 100 and frozen at -70 °C. When required, two tubes of embryos were 
defrosted, one tube for the immune-serum immunoprecipitation (IP) and one tube for a 
pre-immune control IP. Embryos were homogenised in 200 µL of RIPA buffer 
containing protease inhibitor (Roche). An equal volume of Freon was added and the 
samples were vortexed for 30 seconds then centrifuged in a microcentrifuge 
(Eppendorf) at full speed for 4 minutes at room temperature. The upper-phase was 
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carefully transferred to a fresh microcentrifuge tube. A 10 µL aliquot of the sample was 
removed and placed into a fresh tube to which 3 × SDS loading dye was added to allow 
analysis of the starting protein content. An appropriate amount of antibody was then 
added to the sample. An equivalent amount of pre-immune IgG was added to the 
control sample. The tubes containing protein/IgG mixture were then placed inside a 
falcon tube (Greiner), placed on a roller at 4 °C and incubated over two nights to allow 
the antibody time to bind to its antigen. Following incubation, the samples were 
centrifuged in a microcentrifuge (Eppendorf) at full speed at 4 °C for 10 minutes to 
remove any embryo debris. The supernatant was transferred to a fresh tube.  
 
To every 200 µL of sample 0.02 g of Protein G SepharoseTM (GE Healthcare) was 
added. The Protein G SepharoseTM (GE Healthcare) came pre-swollen in 20% ethanol. 
A volume of 80 µL gel slurry was equal to 0.02 g of Protein G SepharoseTM. The 
Protein G SepharoseTM (GE Healthcare) was centrifuged in a microcentrifuge 
(Eppendorf) at 6.4 rpm for 1 minute at room temperature. The ethanol was removed and 
the resin was washed twice in 500 µL RIPA buffer to remove any remaining ethanol 
prior to adding the Protein G SepharoseTM (GE Healthcare) to the protein/IgG mixture. 
The protein/IgG/Protein G SepharoseTM mixture was then placed on a roller and 
incubated at 4°C for 2.5 hours to allow the Protein G SepharoseTM to bind to the IgG. 
Following incubation, the samples were centrifuged in a microcentrifuge (Eppendorf) at 
6.4 rpm for 1 minute at room temperature. The supernatant containing the unbound 
protein was transferred to a fresh tube to which 3 × SDS loading dye was added. The 
protein/IgG/Protein G SepharoseTM was then washed six times in 500 µL of RIPA 
buffer and centrifuged at 6.4 rpm for 1 minute at room temperature between each wash 
to remove any remaining unbound protein. Once washed the protein/IgG/Protein G 
SepharoseTM was resuspended in 50 µL of RIPA buffer and 3 × SDS loading dye was 
added. 
 
The starting protein content, unbound protein and immune and pre-immune IP samples 
were then separated by SDS-PAGE (section 2.3.4) and Western blotting (section 2.6.10) 
was used to analyse whether or not the IP had been successful.  
 
2.6.10 Western blotting  
Protein samples were separated by SDS-PAGE as described in section 2.3.4. Proteins 
were run alongside Seeblue plus 2 pre-stained protein marker (Invitrogen) (figure 2.1). 
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Four pieces of 3MM paper and a piece of nitrocellulose membrane were cut to roughly 
the same size as the gel. These were pre-soaked along with two fibre pads in Western 
transfer buffer.  
 
Following separation, the gel was carefully removed from the electrophoresis plates and 
rinsed in Western transfer buffer. One of the fibre pads was placed on one side of the 
gel holder followed by two pieces of 3MM paper. The gel was then placed on top of the 
two pieces of 3MM paper and smoothed out using a little Western transfer buffer. The 
nitrocellulose membrane was carefully placed over the gel, avoiding the formation of 
any air bubbles and the other two pieces of 3MM paper placed on top of the 
nitrocellulose membrane. Finally the second fibre pad was placed on top and the gel 
holder was closed. The gel holder was inserted into the transfer tank with the membrane 
towards the cathode and the tank filled with Western transfer buffer.  The proteins were 
transferred onto the nitrocellulose membrane at 300 mA for two-three hours. 
 
Next, the membrane was blocked in 20 mL of blocking solution over one or two nights 
at 4 °C with gentle agitation. The blocking solution was replaced with 20 mL of fresh 
blocking solution containing the required dilution of primary antibody. The membrane 
was then incubated at room temperature for 2 hours with gentle agitation. The primary 
antibody solution was removed and the membrane washed four times for 15 min with 
20 mL of blocking solution. Following the final wash, 20 mL of blocking solution 
containing the required dilution of secondary antibody was added to the membrane and 
incubated for 1 hour at room temperature with gentle agitation. The secondary antibody 
was removed and replaced with 4 × 15 min washes in 20 mL blocking solution. The 
final wash was replaced with two, 5 minute washes in TBST and finally several washes 
in 1 × PBS. Western solutions I and II were mixed together and poured on the 
membrane. Following a 30 second period of agitation the blot was left to stand for 30 
seconds. The blot was then placed in a FujiFilm LAS 3000, exposed for 5 – 10 minutes 
then quantified by ImageGauge software. 
 
2.7 Antibody purification 
2.7.1 Caprylic acid precipitation 
In order to purify IgG from anti-sera, two volumes of 60 mM sodium acetate pH 4.0 
was added to 15 mL of serum. Caprylic acid was added slowly by single drops to a final 
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concentration of 2.5 % v/v over a period of 30 minutes whilst stirring at room 
temperature. The serum was then centrifuged using an AvantiTM J-20XP equipped with 
a JA-25.50 rotor (Beckman Coulter) at 30,000 g for 30 minutes at 4 °C to pellet the 
precipitated proteins. The supernatant containing the IgG was filtered through grade 4 
filter paper, dialysed overnight into 1 × PBS and quantified using UV spectroscopy. 
 
2.7.2 Preliminary cleaning procedure for affinity columns 
The immunogen peptide sequences for Hex and fli1 were synthesised on controlled pore  
glass (CPG) beads (Alta Bioscience) and used to recover specific antibody on the 
immunogen beads. Prior to using the peptide-CPG columns for affinity purification of 
specific antibodies from total IgG the columns were treated as follows: The columns 
were washed with 10 CV 100 % v/v ethanol followed by 10 CV H2O to remove the 
ethanol. The column was then washed with 10 CV 6 M guanidine-HCl. To remove any 
trace of 6 M guanidine-HCl the column was washed with 10 CV H2O followed by 10 
CV 1 × PBS. The columns were stored in 1 × PBS containing sodium azide at 4 °C. 
 
2.7.3 Antibody purification process 
Firstly, 10 CV 1 × PBS were passed through the column to remove any traces of sodium 
azide. Approximately 50 mg of total IgG were then passed through the column – this 
step was repeated twice more to ensure maximal binding of the antibody to its antigen. 
The column was then washed with 10 CV 1 × PBS, 10 CV 1 × PBS containing 0.5 M 
NaCl and a further 10 column volumes of 1 x PBS. Specific antibody was eluted with 4 
CV 3.5 M potassium thiocyanate. In order to prevent denaturation of the antibody the 
eluent was immediately desalted on a 1.5 cm × 175 cm G25 column equilibrated with 1 
× PBS at a flow rate of 2 mL/min, collecting 7.5 mL fractions. The antibodies were 
quantified by UV spectrophotometry. Aliquots were stored short term at 4 °C and long 
term at -20 °C.  
 
2.8 Embryological techniques 
Where required all procedures were carried out by appropriately trained and licensed 




2.8.1 Fertilisation and preparation of Xenopus laevis embryos 
Staging of embryos for all experiments followed the Normal Table of Nieuwkoop and 
Faber (1967). 
 
Unfertilised Xenopus laevis eggs were obtained by injecting the dorsal lymph sac of a 
female with 600-800 units (dependant on the size of the frog) of human chorionic 
gonadtrophin (Intervet) ~16 hours prior to egg collection in order to induce ovulation. 
The female is kept at 19-21 ˚C overnight. Male frogs were killed by tricane anaesthesia 
and the testes were removed in a temperature-controlled room at 18 ˚C. The testes were 
placed into 1 x MBS and can be stored intact at 4˚C for up to one week. Prior to 
fertilisation, one quarter of the testis was crushed in 800 µl of 1 x MBS. The oocytes 
were gently squeezed from the female and the crushed testis pipetted over the eggs. The 
eggs were then gently spread into a monolayer and left for 5-10 minutes to allow 
fertilisation to occur, before being covered in 0.1 × MBS. Approximately 20-30 minutes 
after fertilisation the pigmented animal pole of the fertilised egg orientates upward. The 
embryos were then de-jellied by gently agitating them in 0.1 × MBS, 2 % w/v cysteine 
pH8 (Sigma) in a 50 mL centrifuge tube (Greiner) until the embryos packed closely 
together. The cysteine was then removed by washing the embryos five times in 0.1 × 
MBS. The embryos were then placed in Petri dishes (Greiner) with 0.1 × MBS and 
allowed to develop until the appropriate stage whilst being incubated between 14-22 ˚C. 
The embryos were checked regularly in order to remove unfertilised eggs and dying 
embryos, which if left cause healthy embryos to dye. Embryos to be used for micro-
injection were placed into 1 × MBS, 3 % w/v Ficoll (Sigma) to prevent blebbing from 
the injection wound. These were subsequently moved into 0.1 × MBS at around stage 6. 
 
2.8.2 Preparation of Xenopus tropicalis embryos 
Following fertilisation, Xenopus tropicalis embryos were allowed to develop in 0.05 % 
Marc’s Modified Ringers (MMR) and incubated between 23 °C and 25 °C. 
 
2.8.3 Isolation of whole Xenopus tropicalis embryo RNA for antigen production 
Xenopus tropicalis embryo mRNA for antigen production was isolated by transferring 
ten stage 18 Xenopus tropicalis embryos into microcentrifuge tubes. Excess liquid was 
removed and the embryos were stored at -70 °C until required. Samples were thawed at 
room temperature then 400 µL of Trizol (Invitrogen) was added. The samples were 
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vortexed and the embryos homogenised using a 200 µL pipette tip. Next, 0.2 volumes 
of chloroform was added and the samples were vortexed then centrifuged at full speed 
in a bench-top microcentrifuge (Eppendorf) for four minutes at room temperature. 
Centrifugation separates the sample into three phases. The upper aqueous layer, 
containing nucleic acids was carefully removed and placed into a fresh microcentrifuge 
tube to which 0.5 starting volumes of isopropanol was added. Samples were vortexed 
then incubated at room temperature for 15 minutes. Samples were then centrifuged at 
full speed in a bench-top microcentrifuge (Eppendorf) for 15 minutes at 4 °C and the 
isopropanol was removed prior to the addition of 1 mL 70 % v/v ethanol. Following a 
further centrifugation step at full speed for five minutes at room temperature the 70 % 
v/v ethanol was removed and the pellet air-dried. Nuclease-free H2O (Sigma) was used 
to dissolve the RNA pellet (4 µL of H2O per embryo). 
 
2.8.4 Isolation of whole Xenopus laevis embryo RNA (non-Trizol method)  
Sets of ten Xenopus laevis embryos at various stages were defrosted and homogenised 
in 600 µL of NETS buffer using a yellow pipette tip. An equal volume of room 
temperature phenol was added and the sample immediately vortexed for 30 seconds 
(these first steps were performed as quickly as possible). Samples were then centrifuged 
at full speed in a bench-top microcentrifuge (Eppendorf) for five minutes at room 
temperature. The top aqueous layer was removed and transferred to a fresh 
microcentrifuge tube containing 600 µL phenol/chloroform followed by vortexing for 
30 seconds. The sample was then centrifuged again at full speed for five minutes at 
room temperature. The phenol/chloroform step was repeated until a clean interface was 
achieved. The aqueous layer was placed in a fresh 2 mL microcentrifuge tube and 
ethanol precipitated as described in section 2.4.9. The RNA pellet was resuspended in 
100 µL of nuclease-free H2O (Sigma). 
 
DNA was removed from samples by DNase I-treating 50 µL of RNA sample as 
described in section 2.4.10. Following DNase I treatment samples were 
phenol/chloroform extracted and ethanol precipitated as described in sections 2.4.8 and 
2.4.9. RNA pellets were resuspended in 4 µL of nuclease-free H2O (Sigma) for 
subsequent Northern blot analysis and RNA pellets for subsequent RT-PCR analysis 
were resuspended in 2 µL of of nuclease-free H2O (Sigma) per embryo or oocyte. 
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2.8.5 Freon extraction 
Either whole embryo, or dissected embryo protein extracts, were prepared by 
homogenising 10-150 embryos in the appropriate buffer by pipetting up and down using 
a 200 µL yellow pipette tip. Typically the embryos were homogenised in EEB but 
immunoprecipitations required the embryos to be homogenised in RIPA buffer. An 
equal volume of freon was then added and vortexed for 30 seconds. The sample was 
then centrifuged using a bench-top microcentrifuge (Eppendorf) at room temperature at 
full speed for four minutes. The upper aqueous layer containing the protein was retained 
and placed in a fresh 1.5 mL microcentrifuge tube for subsequent analysis.  
 
2.8.6 Dissection of Xenopus laevis embryos 
All dissections were carried out using a pair of Dumont No 5 forceps and performed on 
1 % w/v agarose/1 × MBS plates. When dissecting out the haemangioblasts from stage 
15 and stage 18 embryos, parallel left-right incisions were made immediately posterior 
to the forming cement gland and half way down the embryo. Incisions joining the 
previous ones were made half way up the dorsal-ventral axis and the anterior ventral 
region was removed. The haemangioblasts and the remainder of the embryo were 
pipetted into separate microcentrifuge tubes containing EEB and protease inhibitors. 
Dissections to stage 27 embryos were carried out as follows; the head was removed by a 
cut immediately posterior to the branchial arches and a cut was made from the base of 
the ventral fin one-third to one-half way toward the dorsal. The final cut was made 
parallel to the ventral to remove the region containing the VBI. The head, VBI and 
remainder of the embryo were pipetted into separate microcentrifuge tubes containing 
EEB and protease inhibitors, excess liquid was removed and the samples stored at -70 
˚C. When required samples were freon-extracted and either used directly for Western 
blot analysis or separated using a Superose 6 10/300 GL (GE Healthcare). 
 
2.8.7 Micro-injection of embryos 
The injection apparatus was regulated to an injection pressure of 9.8 bars and a clear 
pressure of >100 bars. A pre-pulled glass injection needle (Clark Electromedical 
GC100-10 needle) was prepared using a Sutter p-97 puller and assembled into the 
needle holder apparatus with the retaining collar tightened. The needle was calibrated 
by the binocular microscope was focussed on the tip of the needle at 1× magnification 
and fine watchmakers forceps were used to break the tip of the needle until the injected 
 57 
droplets measured 0.2 eyepiece units across (equivalent to 4 nL volume), using an 
injection time of 0.5 seconds. Next an aliquot of sample was prepared (either mRNA or 
anti-sense mopholino oligonucleotides). Synthetic mRNA for injection was vortxed and 
centrifuged for one minute prior to injection. 50 pg – 1 ng of mRNA was injected per 
embryo. AMOs were defrosted and heated at 65˚C prior to injection followed by brief 
centrifugation. AMO was injected at a concentration of 2 ng/nL. To load a needle 5 µL 
of sample was pipetted onto a fresh piece of parafilm.  The needle tip was then 
positioned into the sample and sample drawn into the needle using the load function of 
the injector. Embryos were placed on a mesh grid in 3 % ficoll and were injected at one 
cell stage into the animal hemisphere. Embryos were kept in 3% ficoll at 14 ˚C for one 
hour to allow them to recover. After one hour the embryos were transferred to 0.1 × 
MBS are incubated at 14 – 23 ˚C until they had reached the appropriate stage. 
 
2.8.8 Preparation of synthetic mRNA 
Approximately 10 µg of pBUT2-sfi plasmid DNA containing cDNA encoding either 
Xenopus laevis Hex, Xenopus laevis fli1 or Xenopus tropicalis Tal1 was linearised with 
SfiI in a 50 µL reaction incubated overnight at 50 °C according to manufacturer’s 
instructions. A Proteinase K digestion was then performed by adding 2.5 µL 10 % w/v 
SDS and 1 µL 23 mg/mL Proteinase K (NEB) to the reaction which was then incubated 
at 37 °C for 30 minutes. The reaction was then made up to 400 µL with nuclease-free 
H2O (Sigma) and phenol/chloroform extracted (section 2.4.8) followed by an ethanol 
precipitation (section 2.4.9). The DNA pellet was resuspended in10 µL nuclease-free 
H2O (Sigma).  
 
A 50 µL transcription reaction was set up as follows: 5 µL 10 × transcription buffer; 5 
µL 100 mM DTT; 2 µL RNaseOUT™ (Invitrogen); 1.25 µL 100 mM CTP; 1.25 µL 
100 mM ATP; 1.25 µL 100 mM UTP; 0.25 µL 100 mM GTP (Roche); 1 µL 100 mM 
cap analogue (NEB); 4 µL 1 µg/µL template DNA; and 2 µL T3 RNA polymerase 
(Promega). The transcription reaction was incubated at 37 °C for 2 hours. After two 
hours, a 2 µL aliquot was removed from the reaction and added to 5 × Orange G 
loading buffer and stored on ice. A 5 µL aliquot of 10 × DNase I buffer and 2 µL of 
DNase I (NEB) was then added to the remainder of reaction then further incubated at 37 
°C for 30 minutes. Following incubation a 2 µL aliquot was removed from the reaction 
and added to 5 × Orange G loading buffer. Agarose gel electrophoresis (section 2.3.1) 
was then used to analyse the reactions before and after DNase I digestion. Providing 
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mRNA had been transcribed and the DNA removed the reaction was cleaned up using 
an Illustra MicroSpin G-25 Column (GE Healthcare) according to the manufacturer’s 
instructions. The approximate yield was calculated by UV spectrophotometry. mRNA 
was stored at -70 °C.  
 
2.8.9 In vitro translation 
In vitro translations were performed using Wheat Germ Extract Plus (Promega) in order 
to check that synthesised mRNA transcripts translate into protein. Individual 50 µL 
reactions were set up on ice as follows: 6-12 µg purified mRNA was added to 30 µL 
Wheat Germ Extract Plus. If required, reactions were made up to 50 µL using nuclease-
free H2O (Promega). Reactions were mixed by gently pipetting up and down. Control 
reactions were also set up to which nuclease-free H2O was added in place of mRNA. 
Aliquots of 10 µL from both the mRNA reaction and the control reaction were removed 
and placed into fresh microcentrifuge tubes (Eppendorf), to which 2 µL of 
FluoroTect™ GreenLys tRNA (Promega) was added. All reactions were incubated at 25 
°C for 2 hours.  
 
Following incubation, 3 × SDS loading dye was added to the mRNA and control 
reactions containing FluoroTect™ GreenLys tRNA. The protein produced from these 
reactions were then resolved alongside BenchMarkTM Protein Ladder (Invitrogen) using 
SDS-PAGE. Synthesised proteins were visualised by fluorescent-imaging using a 
Fujifilm FLA-5000. The presence of a band on the gel in the reaction containing mRNA 
and its absence from the control reaction indicates that a protein has been translated 
from the mRNA transcript. The size of synthesised proteins was calculated by staining 
the gel using SimplyBlue™ SafeStain (Invitrogen) in order to visualise the protein 
ladder. 
 
Control and mRNA in vitro reactions containing no FluoroTect™ GreenLys tRNA were 
added to 3 × SDS loading dye and used for Western blot analysis. 
 
2.8.10 Fixation of embryos in MEMFA 
Staged embryos were transferred to a glass vial, excess liquid was removed and fresh 
MEMFA was added. Embryos were allowed to fix for 45-50 minutes at room 
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temperature. Three, 30 minute washes in methanol then followed. Embryos were stored 
in the final change of methanol at room temperature. 
 
2.8.11 Bleaching of embryos 
MEMFA-fixed embryos were rehydrated through a 75 %, 50 %, 25 %, 0 % methanol in 
PBS series with 5 minutes’ incubation at each concentration. The embryos were then 
transferred to 5 % v/v formamide in 0.5 × SSC, with 10 % v/v hydrogen peroxide added 
last. This was made up immediately prior to use and kept cool. Embryos were bleached 
on a light box for 10-15 minutes, occasionally turning the tube. Bleaching solution was 
removed by three, five minute washes in PBST. 
 
2.8.12 Wholemount immunohistochemistry (Sharpe, C.) 
Bleached embryos were washed twice for 5 minutes in PBST followed by one 5 minute 
wash in PBT. They were blocked for 2 hours at room temperature in PBT containing 10 
% non-immune donkey serum (Sigma), that had been heat inactivated at 56 °C for 30 
minutes. The embryos were then incubated over two nights at 4 °C with the primary 
antibody in PBT containing 10 % non-immune donkey serum (various concentrations of 
primary antibody were tested). Pre-immune controls were also carried out. Excess 
primary antibody was removed by three, one hour washes in PBST and the embryos 
were then re-blocked in PBT containing 10 % non-immune donkey serum for 2 hours at 
room temperature. Following re-blocking embryos were incubated overnight in a 1:500 
dilution of secondary antibody – donkey anti-sheep, HRP-conjugated (Sigma) in PBT 
containing 10 % non-immune donkey serum. Five one-hour washes in PBST preceded 
development with the HRP substrate – Fast-DAB (Sigma), following the 
manufacturer’s instructions. The reaction was stopped by washing five times in PBS 
and the embryos were photographed and observed under a Zeiss Lumar V12 
stereoscopic microscope with an AxioCam MRc5 camera.  
 
2.8.13 Wholemount in situ hybridisation 
Staged embryos were fixed and bleached as described in sections 2.8.10 and 2.8.11. 
Embryos were then deacetylated by washing twice in 0.1 M triethanolamine, for 5 min 
each. To the second wash 2.5 µL of acetic anhydride was added. After 5 min a further 
2.5 µL of acetic anhydride was added. Triethanolamine and acetic anhydride were 
removed by 2 x 5 min washes in PBST. The final wash was replaced with 0.5 mL 
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hybridisation buffer twice. The embryos were then prehybridised at 60°C for at least 6 
hours. After prehybridisation, the buffer was removed and replaced with fresh 
hybridisation buffer containing 200 ng/mL – 1 µg/mL of digoxigenin labelled 
riboprobe. Embryos were incubated overnight at 60°C.  
 
Following overnight hybridisation, the probe was removed and replaced with 50% 
deionised formamide/5 x SSC and incubated for 10 min at 60°C. Subsequent post-
hybridisation washes were all carried out at 60°C with 25% deionised formamide/2 x 
SSC for 10 min, 12.5% deionised formamide/2 x SSC for 10 min, 2 x SSC, 0.1% tween 
for 10 min and finally 0.2 x SSC, 0.1% tween for 30 min. Next, the embryos were 
washed in PBST for 3 x 5 min at room temperature. The final wash in PBST was 
replaced with MAB for 10 min. The MAB was then replaced with MAB containing 2% 
block and embryos were blocked at room temperature for 4 – 5 hours. For antibody 
detection of probes, a 1/2000 dilution of anti-digoxygenin antibody fragments 
conjugated to alkaline phosphatase in MAB blocking solution was added to the 
embryos. Embryos were incubated overnight at 4°C with gentle rocking.  
 
Excess, unbound antibody was removed by 5 x 1 hour washes in MAB at room 
temperature with gentle rocking. For the alkaline phosphatase catalysed colour reaction 
embryos were equilibrated with 2 x 5 min washes in AP buffer. After the second wash, 
embryos were immediately transferred to small petri dishes 1 mL of BCIP/NBT 
solution (1 tablet of SigmaFast BCIP/NBT dissolved in 10 mL H2O) was added. The 
embryos were protected from the light, the colour change was observed periodically. To 
stop the colour reaction embryos were washed several times in either PBST or AP 
buffer. Non-specific background staining was removed by washing the embryos in 
methanol if required. After a final wash in AP buffer embryos were refixed and stored 
in methanol. Embryos were photographed and observed in methonal or Murray’s clear 
under a Zeiss Lumar V12 stereoscopic microscope with an AxioCam MRc5 camera. 
 
2.9 Preparation of Xenopus oocytes 
Staging of oocytes for all experiments followed the staging of Dumont (1972). 
 
Ovaries were cut into small clumps and put into a 50 mL centrifuge tube containing 1 × 
MBS. After washing in six changes of 1 × MBS the buffer was decanted and one 
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volume of type II collagenase, 2 mg/mL in 1 × MBS, was added. The oocytes were 
rocked gently and checked every 15 minutes. Once separated they were washed six 
times in 1 × MBS and transferred to a Petri dish where oocytes whose follicle cells had 
been completely removed were selected. Follicle cells were also removed manually 
using a pair of Dumont No 5 forceps. Oocytes that had not had all of the follicle cells 
removed were identified by staining with SYBR-14 to reveal the nuclei of the follicle 
cells. 10 µL of SYBR-14 was added to 1 mL of 1 × MBS. Oocytes were placed in the 
SYBR-14 stain for 15 minutes then visualised under a Zeiss Lumar V12 stereoscopic 
microscope with an AxioCam MRc5 camera. Prior to dissection or staging Xenopus 
laevis oocytes were kept at 14-18 °C and Xenopus tropicalis oocytes were kept at 23 °C.  
Once staged sets of 20 oocytes were collected from each developmental stage (10 
oocytes from each of stages I and II were combined), homogenised in 100 µL of EEB 
containing protease inhibitors and the yolk proteins removed by freon extraction as 
described in section 2.8.5.  
 
In order to analyse the sub-cellular localisation of Hex and fli1 in Xenopus laevis 
oocytes the germinal vesicles of 20 stage VI oocytes were carefully removed using a 
pair of Dumont No 5 forceps. The cytoplasm and germinal vesicles were immediately 
pipetted to separate microcentrifuge tubes containing EEB and protease inhibitors. 
Excess liquid was then removed and the samples were homogenised in 100 µL of EEB 
containing protease inhibitors and the yolk proteins removed by freon extraction as 










Transcription factors that are known to play important roles in haematopoiesis and 
vasculogenesis have been studied extensively at the level of mRNA. However, little is 
known about when and where these proteins are being expressed in the early embryo. 
Furthermore, there is a gap in our knowledge about the DNA binding activity of HTFs 
and their transcription regulation activity during development.  
 
One way in which to analyse the protein expression patterns of HTFs is to raise and 
characterise antibodies against as many HTFs as possible. Antibodies are 
immunoglobulin proteins (Ig) produced by the immune system of vertebrates in 
response to bacteria, viruses or large molecules identified as foreign to target them for 
destruction. Any pathogen or molecule capable of eliciting an immune response is 
called an antigen. Immunoglobulin G (IgG) is the major class of antibody and one of the 
most abundant proteins found in the blood. IgG molecules are made up of four 
polypeptide chains; two identical light chains and two identical heavy chains. These 
polypeptide chains are linked by noncovalent and disulphide bonds to form a Y-shaped 
molecule (figure 3.1). The base of the Y-shaped molecule is known as the Fc 
(Fragment, crystalisable) region and the branches of the Y-shaped molecule are known 
as Fab (Fragment, antigen binding) region because each branch has an antigen-binding 
site (Reviewed in Schroeder and Cavacini, 2010). 
 
 Antibodies are capable of specifically identifying and binding to the antigen they were 
raised against and it is because of this characteristic that antibodies have become 
essential biological tools that allow the visualisation of specific proteins (antigens) 
when used in experimental techniques such as immunohistochemistry, Western blotting 
and Electrophoretic Mobility Shift Assay (EMSA) assays. These techniques, when used 
in conjunction with one another, can provide a large amount of information about the 
































Figure 3.1: Two-dimensional model of an IgG molecule. 
 Pairs of heavy (H) and light (L) chains combine to form a Y-shaped molecule. The H 
and L chains at the top deconstruct the antibody at a nucleotide level. The chains at the 
bottom deconstruct the protein sequence. Each polypeptide chain consists of one or 
more COOH-terminal constant (C) domains and one NH2-terminal variable (V) 
domain. The two antigen-binding sites are formed by the combination of the V domains 
from one L (VL) and one H (VH) chain. V and C domains are each encoded by 
independent elements: V(D)J gene segments for the V domain and individual exons for 
the C domains. The primary amino acid sequence of the V domain is functionally 
divided into three hypervariable intervals known as complementarity-determining 
regions (CDRs) that are situated between four regions of stable sequence known as 
framework regions (FRs). This model also shows the cleavage sites for papain and 
pepsin digestion (taken from Schroeder and Cavacini, 2010). 
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The aim of the work in this chapter was to raise antibodies against seven different 
HTFs: Tal1, Spi1, fli1, Hex, Gata1, Gata2 and Lmo2. The reason for choosing seven 
different HTFs was to allow for any problems, which meant that either an antigen could 
not be produced or the antibody was not raised or was non-specific. 
 
3.2 Sequence selection 
The first step in raising an antibody against a protein of interest was to locate a region 
of DNA sequence coding for a unique part of the protein. The DNA sequence must code 
for a unique part of the protein to promote specificity of the antibody to the antigen.  
 
The transcripts for each of the seven HTFs in Xenopus tropicalis were identified using 
the following web databases; National Centre for Biotechnology Information (NCBI), 
Ensembl and Metazome. Once the transcripts were found, the Basic Local Alignment 
Search Tool (BLAST) was used to search the translated nucleotide sequences against 
the translated nucleotide database. Regions of similarity between peptide sequences are 
then displayed and can be used to select regions of DNA coding for peptide sequences 
unique to the protein of interest. Figures 3.2 to 3.8 inclusive show the selected regions 
of DNA sequence and their protein translation. All of these were unique in the genome 
and had no more than six amino acids found in sequence in any other Xenopus protein, 
with the exception of Gata2 that had thirteen in sequence identical to Gata3. 
 
3.3 PCR primer design 
To amplify the selected regions of DNA sequence it was necessary to design two 
primers (one forward and one reverse for each of the DNA sequences), each primer 
being complementary to one of the 5′ ends of the DNA sequences, directing initiation of 
their amplification. Tal1 and Hex forward primers (figures 3.2 and 3.3) contained six-
base, non-complementary tails at the 5′ ends containing an NheI restriction site. Spi1, 
fli1, Lmo2, GATA1 and GATA2 forward primers (figures 3.4-3.8) contained nine-base, 
non-complementary tails at the 5′ ends containing a NheI restriction site and an ATG 
start codon immediately prior to the coding DNA sequence. All reverse primers 
contained nine-base non-complementary tails at the 5′ ends containing XhoI restriction 
sites and a TCA stop codon immediately prior to the coding DNA sequence. The 








     atgatggagaggttggggacagacatcgatggcacccacgatgtt 
     M  M  E  R  L  G  T  D  I  D  G  T  H  D  V  
     gcatctcccccagcacaacaagacgcagcagagccagagagaact 
     A  S  P  P  A  Q  Q  D  A  A  E  P  E  R  T  
     gtggagctgagtggggtgaaagaaggggcggcccccaactccccc 
     V  E  L  S  G  V  K  E  G  A  A  P  N  S  P  
     cccagagctgtcccggtgattgagttgcacagaaggggggaggga 
     P  R  A  V  P  V  I  E  L  H  R  R  G  E  G  
     tcggggaatataaaggccagagagcaggagctgaggctgcagagc 
     S  G  N  I  K  A  R  E  Q  E  L  R  L  Q  S  
     att      
     I 
 
                                 
B. 
 
              5′ GCTAGCATGATGGAGAGGTTGGGGAC 3′ 
                                            stop 





Figure 3.2: Selected region of Tal1 DNA sequence and protein translation and Tal1 
PCR primers.  
(A) The black letters indicate the selected region of DNA sequence coding for a unique 
region of Xenopus tropicalis Tal1 protein. The red letters indicate the DNA sequence 
translated into protein. (B) To amplify the target DNA sequence it was necessary to 
design two primers, each being complementary to one or other of the 5′ ends of the 
selected region of Tal1 DNA sequence. The blue letters indicate the added NheI 
restriction site on the forward primer and the pink letters indicate the added XhoI 





     atgcagtaccagcaccccagctcctcagccctggggctcagtgtc 
     M  Q  Y  Q  H  P  S  S  S  A  L  G  L  S  V  
     cccctgtacgcacccacccctctgcagccagtgcacccaactccc 
     P  L  Y  A  P  T  P  L  Q  P  V  H  P  T  P  
     ttctacattgatgatatcctgggaaggagcagcgcctctaatggg 
     F  Y  I  D  D  I  L  G  R  S  S  A  S  N  G  
     accccagccttacccaccccaaccctgccatcgcccaactcttcc 
     T  P  A  L  P  T  P  T  L  P  S  P  N  S  S  
     ttcaccagcctggtggctacctacaggactcccatctatgagcct 
     F  T  S  L  V  A  T  Y  R  T  P  I  Y  E  P  
     actcccattcaccctgccttcacccaccccggggcagccctggca 
     T  P  I  H  P  A  F  T  H  P  G  A  A  L  A  
     gcttcctatggagccagcacctatgccaaccctctgtaccccttc 
     A  S  Y  G  A  S  T  Y  A  N  P  L  Y  P  F  
     tccaggccggtcagcgagtacacccatgccctcatccggcacgac 
     S  R  P  V  S  E  Y  T  H  A  L  I  R  H  D  
     accctgggcaaacccttgctatggagccccttcatccagaggcct 
     T  L  G  K  P  L  L  W  S  P  F  I  Q  R  P  
     cttcacaagcggaaaggcggccaagtgcggttttca 
     L  H  K  R  K  G  G  Q  V  R  F  S 
 
B. 
          5′ GCTAGCATGCAGTACCAGCACCCCAG 3′ 
                                stop 
          5′ CTCGAG[TCA]TGAAAACCGCACTTGGCCGC 3′ 
                               
 
Figure 3.3: Selected region of Hex DNA sequence and protein translation and Hex 
PCR primers.  
(A) The black letters indicate the selected region of DNA sequence coding for a unique 
region of Xenopus tropicalis Hex protein. The red letters indicate the DNA sequence 
translated into protein. (B) To amplify the target DNA sequence it was necessary to 
design two primers, each being complementary to one or other of the 5′ ends of the 
selected region of Hex DNA sequence. The blue letters indicate the added NheI 
restriction site on the forward primer and the pink letters indicate the added XhoI 









     tctcatctcaactacctcagggatagtagttcatcattgggttat 
     S  H  L  N  Y  L  R  D  S  S  S  S  L  G  Y 
     aacactcaggcacatacagaccagtcaccacgtttgacagccaaa 
     N  T  Q  A  H  T  D  Q  S  P  R  L  T  A  K 
     gaggatccctcctatgaagcagtaagaagatctggatggggaaat 
     E  D  P  S  Y  E  A  V  R  R  S  G  W  G  N 
     tccctgagctcacctgtcacaaaaagccctcct 





                                          start 
             5′ GCTAGC[ATG]TCTCATCTCAACTACCTCAG 3′ 
                                           stop 





Figure 3.4: Selected region of fli1 DNA sequence and protein translation and Fli1 
PCR primers.  
(A) The black letters indicate the selected region of DNA sequence coding for a unique 
region of Xenopus tropicalis fli1 protein. The red letters indicate the DNA sequence 
translated into protein. (B) To amplify the target DNA sequence it was necessary to 
design two primers, each being complementary to one or other of the 5′ ends of the 
selected region of Fli1 DNA sequence. The blue letters indicate the added NheI 
restriction site on the forward primer and the pink letters indicate the added XhoI 








            
A. 
     atgaactgcaaatggagcacggtgccctttaaggcacatccggag 
     M  N  C  K  W  S  T  V  P  F  K  A  H  P  E  
     gagctgatcgcttatgatgccgagctttaccgccaacatcatgaa 
     E  L  I  A  Y  D  A  E  L  Y  R  Q  H  H  E  
     tactacccgtacctcagtgacagtgagagccatgaacattactgg 
     Y  Y  P  Y  L  S  D  S  E  S  H  E  H  Y  W  
     gagtatcccacccctcatctacatggagaactggaaggattccct 
     E  Y  P  T  P  H  L  H  G  E  L  E  G  F  P  
     gattcccagctgacggaactgcagagtgttcaacctccccagctg 
     D  S  Q  L  T  E  L  Q  S  V  Q  P  P  Q  L  
     cagcaactctacagacatatggaggagcagatgcatgttctggaa 
     Q  Q  L  Y  R  H  M  E  E  Q  M  H  V  L  E  
     cctgggttgcccacgccacacccacacctcagcataggccatcag 
     P  G  L  P  T  P  H  P  H  L  S  I  G  H  Q  
     gtctcctacatg      




                                           start 
             5′ GCTAGC[ATG]AGCACGGTGCCCTTTAAGGC 3′ 
                                           stop 
             5′ CTCGAG[TCA]CATGTAGGAGACCTGATGGC 3′ 
                                                                 
 
 
Figure 3.5: Selected region of Spi1 DNA sequence and protein translation and Spi1 
PCR primers.  
(A) The black letters indicate the selected region of DNA sequence coding for a unique 
region of Xenopus tropicalis Spi1 protein. The red letters indicate the DNA sequence 
translated into protein. (B) To amplify the target DNA sequence it was necessary to 
design two primers, each being complementary to one or other of the 5′ ends of the 
selected region of Spi1 DNA sequence. The blue letters indicate the added NheI 
restriction site on the forward primer and the pink letters indicate the added XhoI 

















     ttcggccaggacggactgtgcgcctcttgcgacaagcggatccga 
     F  G  Q  D  G  L  C  A  S  C  D  K  R  I  R 
     gccttcgaaatgacgatgcgggtgaaggacaaagtataccacctg 
     A  F  E  M  T  M  R  V  K  D  K  V  Y  H  L 
     gagtgcttcaagtgtgcagcctgccaaaagcacttctgcgtgggg 
     E  C  F  K  C  A  A  C  Q  K  H  F  C  V  G 
     gaccgctacctgctcattaactcggacattgtgtgcgagcag 





                                           start 
                5′ GCTAGC[ATG]TTCGGCCAGGACGGACTGTG 3′ 
                                           stop 
             5′ CTCGAG[TCA]CTGCTCGCACACAATGTCCG 3′ 
                                                       
 
 
Figure 3.6: Selected region of Lmo2 DNA sequence and protein translation and 
Lmo2 PCR primers. 
(A) The black letters indicate the selected region of DNA sequence coding for a unique 
region of Xenopus tropicalis Lmo2 protein. The red letters indicate the DNA sequence 
translated into protein. (B) To amplify the target DNA sequence it was necessary to 
design two primers, each being complementary to one or other of the 5′ ends of the 
selected region of Lmo2 DNA sequence. The blue letters indicate the added NheI 
restriction site on the forward primer and the pink letters indicate the added XhoI 













     gcccatcaccacaacccttggactgtcagcccctttgccaagacc 
     A  H  H  H  N  P  W  T  V  S  P  F  A  K  T 
     ccacttcaccccgcggccgccggtggctccttgtacccgggcacc 
     P  L  H  P  A  A  A  G  G  S  L  Y  P  G  T 
     ggctcctctggcggcccctcctcccacacgagtccgcacctgttt 
     G  S  S  G  G  P  S  S  H  T  S  P  H  L  F 
     ggtttcccccccaccccccccaaggacgtgtcccccgacccaggc 
     G  F  P  P  T  P  P  K  D  V  S  P  D  P  G 
     accgcggcctccccgccctcctcttcccggcttgaggataaggac 
     T  A  A  S  P  P  S  S  S  R  L  E  D  K  D 
     agcattaagtaccaggtgtccctatctgagggcatgaagatggaa 
     S  I  K  Y  Q  V  S  L  S  E  G  M  K  M  E 
     g 




                                            start 
              5′ GCTAGC[ATG]GCCCATCACCACAACCCTTG 3′ 
                                            stop 
              5′ CTCGAG[TCA]CTTCATGCCCTCAGATAGGG 3′ 
                                                       
 
 
Figure 3.7: Selected region of Gata2 DNA sequence and protein translation and 
Gata2 PCR primers.  
(A) The black letters indicate the selected region of DNA sequence coding for a unique 
region of Xenopus tropicalis Gata2 protein. The red letters indicate the DNA sequence 
translated into protein. (B) To amplify the target DNA sequence it was necessary to 
design two primers, each being complementary to one or other of the 5′ ends of the 
selected region of Gata2 DNA sequence. The blue letters indicate the added NheI 
restriction site on the forward primer and the pink letters indicate the added XhoI 











A.    actctgaccacacaggagcccctccctaattatacagagtcagct 
     T  L  T  T  Q  E  P  L  P  N  Y  T  E  S  A 
     cttgcaagcacttctgaggactcagagttcctgtatggtctgggg 
     L  A  S  T  S  E  D  S  E  F  L  Y  G  L  G 
     ggtgaaagcagccctggtcattatggggggacagtgagctcccga 
     G  E  S  S  P  G  H  Y  G  G  T  V  S  S  R 
     gcagtggggggattccgacattctccagtgcttcagacattccct 
     A  V  G  G  F  R  H  S  P  V  L  Q  T  F  P 
     ttacattggccagaaaccagtgttgggatcccccacagcctgaca 
     L  H  W  P  E  T  S  V  G  I  P  H  S  L  T 
     gcatatgggagaagcccaggaacagtgcctttatacccctcagct 
     A  Y  G  R  S  P  G  T  V  P  L  Y  P  S  A 
     gcttcgtcctttggccctattacgtctcctcctttgtacaatgct 
     A  S  S  F  G  P  I  T  S  P  P  L  Y  N  A 
     gctcctttcttgttgggctcagctcctccagcagagcatgaaggt 
     A  P  F  L  L  G  S  A  P  P  A  E  H  E  G 
     agtccaaagttcctggagaccttaaagacggagaggacaagccca 
     S  P  K  F  L  E  T  L  K  T  E  R  T  S  P 
     ctgaccactgatcttttgcccttggaatcaagaagccccagtttg 
     L  T  T  D  L  L  P  L  E  S  R  S  P  S  L 
     ccccaggtggggtatctaggagtaggaggacaggagttc 
     P  Q  V  G  Y  L  G  V  G  G  Q  E  F               
 
 
B.                                        start  
             5′ GCTAGC[ATG]ACTCTGACCACACAGGAGCC 3′ 
                                           stop 




Figure 3.8: Selected region of Gata1 DNA sequence and protein translation and 
Gata1 PCR primers.  
(A) The black letters indicate the selected region of DNA sequence coding for a unique 
region of Xenopus tropicalis Gata1 protein. The red letters indicate the DNA sequence 
translated into protein. (B) To amplify the target DNA sequence it was necessary to 
design two primers, each being complementary to one or other of the 5′ ends of the 
selected region of GATA-1 DNA sequence. The blue letters indicate the added NheI 
restriction site on the forward primer and the pink letters indicate the added XhoI 
restriction site on the reverse primer. 
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restriction site, which guarantees position and orientation of the DNA sequences once 
cloned into the vector. 
 
3.4 Polymerase Chain Reaction 
The primers described in section 3.2 were used to amplify the selected DNA sequences 
by the polymerase chain reaction (PCR). The DNA template used for amplification was 
complementary DNA (cDNA) from stage 17 Xenopus tropicalis embryos. The cDNA 
was synthesised from the purified mRNA of stage 17 Xenopus tropicalis embryos using 
reverse transcriptase as described in sections 2.4.1 and 2.8.3.  
 
Taq DNA polymerase was used for the extension reaction as it has a non-template-
dependent terminal transferase activity that adds a single deoxyadenosine (A) to the 3′ 
ends of PCR products. (Clark, 1988). For this reason pCR 2.1-TOPO (Invitrogen) was 
used as an intermediate vector before cloning into pET-28a (+). pCR 2.1-TOPO is 
supplied as a linearised vector with single 3′-thymidine (T) overhangs allowing efficient 
ligation of Taq PCR amplified cDNA sequences into the vector. The PCR products 
were analysed on a 2% agarose gel (figure 3.9). 
 
Work on Gata1 was stopped at this point since it was not possible to PCR amplify this 
part of the Gata1 cDNA sequence. 
 
3.5 Cloning and sub-cloning 
The selected regions of cDNA sequence coding for unique regions of Hex, Spi1, fli1, 
Tal1, Lmo2 or Gata2 protein were successfully amplified as described in section 3.3. 
The PCR products were then sequentially cloned then sub-cloned into two different 
vectors. Firstly, they were cloned into pCR 2.1-TOPO (Invitrogen) (figure 3.10) and 
then sub-cloned into pET-28a (+) (Novagen) (figure 3.11). 
 
3.5.1 pCR 2.1-TOPO 
As already stated in section 3.3, pCR 2.1-TOPO (Invitrogen) is supplied as a linearised 
vector with single 3′-thymidine (T) overhangs allowing efficient ligation of Taq PCR-






























Figure 3.9: PCR-amplified Spi1, Gata2, Hex, Lmo2, fli1 and Tal1 cDNA sequences, 
analysed by agarose gel electrophoresis and visulised by ethidium bromide 
staining.  
Selected regions of cDNA sequence for Spi1, Gata1, Gata2, Hex, Lmo2, fli1 and Tal1 
were PCR-amplified and analysed on a 2 % agarose gel. M is the 1kb plus marker. Lane 
1 is PCR amplified Spi1 DNA sequence. A band corresponding to a PCR product of 
between 300 and 400 bps is present, the expected size of Spi1 is 324 bp. Lane 2 is from 
the Gata1 PCR reaction but no PCR product was produced. Lane 3 is PCR amplified 
Gata2 cDNA sequence. A band corresponding to a PCR product of just under 300 bps is 
present, the expected size of Gata2 is 264 bp. Lane 4 is PCR amplified Hex cDNA 
sequence. A band corresponding to a PCR product between 400 and 500 bps is present, 
the expected size of Hex is 441 bp. Lane 5 is PCR amplified Lmo2 cDNA sequence. A 
band corresponding to a PCR product of approximately 200 bps is present, the expected 
size of Lmo2 is 177 bp. Lane 6 is PCR amplified fli1 cDNA sequence. A band 
corresponding to a PCR product of just under 200 bps is present, the expected size of 
fli1 is 168 bp. Lane 7 is PCR amplified Tal1 cDNA sequence. A band corresponding to 














































Figure 3.10: Diagrammatic representation of cloning a PCR product into the pCR 
2.1-TOPO vector.  
The PCR product and multiple cloning site (MCS) have been enlarged to indicate where 
the PCR product gets ligated into the vector. The vector is linearised with overhanging 










































Figure 3.11: Diagrammatic representation of cloning an HTF DNA insert into the 
pET-28a (+) vector.  
The DNA insert and multiple cloning site (MCS) have been enlarged to indicate where 
the DNA insert gets ligated into the vector following digestion with NheI and XhoI 








     
  






and ampicillin resistance genes (enabling recombinant screening), M13 forward and 
reverse primer sites for sequencing and the LacZ reporter gene (figure 3.10). PCR 
products were cloned into pCR 2.1-TOPO as described in section 2.4.5.  DNA inserts  
were removed from pCR 2.1-TOPO using the restriction enzymes NheI and XhoI as 
described in section 2.4.11.  
 
3.5.2 pET-28a (+) 
Following removal of the DNA inserts from pCR 2.1-TOPO, the pET-28a (+) 
(Novagen) plasmid was also cut using NheI and XhoI restriction enzymes as described 
in section 2.4.11. These restriction enzyme digests allowed insertion of the DNA inserts 
into the multiple cloning site (MCS) of pET-28a (+).  
 
pET-28a (+) is a bacterial expression vector containing a sequence coding for an N-
terminal hexa-histidine tag (His-tag) adjacent to the MCS. This fusion tag allows 
purification of the target protein by immobilised metal ion affinity chromatography. 
Expression of the target protein is under the control of the T7lac promoter, a 
combination of the phage T7 promoter and the lac operator sequence, and is highly 
inducible in the presence of IPTG. pET-28a (+) also contains a kanamycin resistance 
gene enabling recombinant screening (figure 3.11). 
 
3.5.3 Recombinant screening 
To screen for both recombinant pCR 2.1-TOPO and pET-28a (+) plasmid DNA, 
transformed E.coli DH5α cells were plated onto Kanamycin plates. In each case, 10 of 
the resulting colonies were selected and used for small-scale plasmid purification as 
described in section 2.4.7.  Purified plasmid DNA was digested using NheI and XhoI 
restriction enzymes. Agarose gel electrophoresis was then used to determine whether 
DNA inserts of the correct size had been excised from the plasmid DNA. 
 
To verify that the inserts cut from the plasmid DNA were the correct sequence, plasmid 
DNA samples were sequenced by Lark using M13 forward and reverse primers for pCR 
2.1-TOPO plasmid DNA, and T7 promoter and terminator primers for pET-28a (+) 
plasmid DNA. Sequencing results were analysed using Bio-Open software.  
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3.6 Protein expression tests 
3.6.1 Preliminary expression tests 
Preliminary protein expression tests were carried out as described in section 2.6.2. The 
purpose of these tests was to determine whether or not the E.coli BL21 (DE3) cells 
transformed with pET-28a (+)/DNA insert were in fact expressing the target protein. 
For each of the target proteins (Hex, Spi1, Lmo2, Tal1, Gata2 and fli1) a comparison 
was made between the total protein from induced and uninduced cells. Cells were 
induced to express the target protein using IPTG. As mentioned in section 3.4.2, the T7 
lac promoter is highly inducible by IPTG, which mimics the effect of allolactose by 
inducing transcription of the lacZ gene. However in this case, the lacZ gene is replaced 
with a DNA insert. 
 
Analysis of the tris-tricine gels on which the protein samples were resolved showed that 
Hex, Spi1 and Tal1 His-tagged proteins were being expressed (figures 3.12-3.14). 
However, induced cells did not appear to be expressing Lmo2, fli1 or Gata2. 
 
3.6.2 Protein solubility tests 
Different protein purification protocols are required depending on the solubility of a 
target protein. For this reason, protein solubility tests were carried out as described in 
section 2.6.3 for Hex, Spi1 and Tal1 to determine their solubility. Soluble and insoluble 
fractions from total protein were compared using tris-tricine polyacrylamide gel 
electrophoresis (figures 3.15-3.17). It was not possible to carry out these tests for Lmo2, 
fli1 or Gata2 since previous expression tests had been unsuccessful.  
 
3.7 Protein purification 
3.7.1 Purification of Hex, Spi1, Lmo2, Tal1, Gata2 and fli1 His-tagged antigens 
Following cell lysis, the protein samples were centrifuged in order to separate out the 
soluble proteins from the insoluble proteins. Previous expression and solubility tests had 
shown Hex and Spi1 to both be insoluble proteins and Tal1 to be a soluble protein 
(figures 3.15-3.17). However, Lmo2, fli1 and Gata2 expression tests had been 
unsuccessful so it was not possible to test the solubility of these proteins. Therefore, in 
















                                                                                                      
                                                                                                             
                               





Figure 3.12: Tric-tricine polyacrylamide gel showing whole cell protein of induced 
and uninduced cells containing the pET-28a (+)/Hex plasmid construct.  
Two, 10 mL aliquots of culture containing cells with the pET-28a (+) plasmid and two, 
10 ml aliquots of culture containing cells with the pET-28a (+)/Hex plasmid construct 
were grown at 37˚C. After three hours, one 10 mL aliquot of culture containing cells 
with the pET-28a (+) plasmid and one 10 mL aliquot of culture containing cells with the 
pET-28a (+)/Hex plasmid construct were induced with 1 mM isopropyl-β-D-
thiogalactopyranoside (IPTG). After a further three hours, cells were harvested and 
resuspended in SDS loading buffer. Following sonic disruption, samples were loaded 
adjacent to Benchmark ladder (M). Lane 1 is the total protein from uninduced cells 
containing the pET-28a (+) plasmid, lane 2 is the total protein from induced cells 
containing the pET-28a (+) plasmid, lane 3 is the total protein from uninduced cells 
containing the pET-28a (+)/Hex plasmid construct and lane 4 is the total protein from 
induced cells containing the pET-28a (+)/Hex plasmid construct. A band corresponding 
to a Mr of 20 kDa was present in lane 4 but not lanes 1, 2 or 3 (the expected size of Hex 
is approximately 16.8 kDa).  
Hex 20 kDa 
15 kDa 








                                                                                                                 











                                                                                                                        
                                                                                                                  
                                                                                                                








Figure 3.13: Tric-tricine polyacrylamide gel showing whole cell protein of induced 
and uninduced cells containing the pET-28a (+)/Spi1 plasmid construct.  
Two, 10 mL aliquots of culture containing cells with the pET-28a (+) plasmid and two, 
10 ml aliquots of culture containing cells with the pET-28a (+)/Spi1 plasmid construct 
were grown at 37˚C. After three hours, one 10 mL aliquot of culture containing cells 
with the pET-28a (+) plasmid and one 10 mL aliquot culture containing cells with the 
pET-28a (+)/Spi1 plasmid construct were induced with 1mM IPTG. After a further 
three hours, cells were harvested and resuspended in SDS loading buffer. Following 
sonic disruption, samples were loaded adjacent to Benchmark ladder (M). Lane 1 is the 
total protein from uninduced cells containing the pET-28a (+) plasmid, lane 2 is the 
total protein from induced cells containing the pET-28a (+) plasmid, lane 3 is the total 
protein from uninduced cells containing the pET-28a (+)/spi1 plasmid construct and 
lane 4 is the total protein from induced cells containing the pET-28a (+)/Spi1 plasmid 
construct. A band corresponding to a Mr of 15 - 20 kDa was present in lane 4 but was 































                                  
                                                                                                            
                                                                                                      








Figure 3.14: Tric-tricine polyacrylamide gel showing whole cell protein of induced 
and uninduced cells containing the pET-28a (+)/Tal1 plasmid construct.  
Two, 10 mL aliquots of culture containing cells with the pET-28a (+)/Tal1 plasmid 
construct were grown at 37˚C. After three hours, one 10 mL aliquot of culture was 
induced with 1mM IPTG. After a further three hours, cells were harvested and 
resuspended in SDS loading buffer. Following sonic disruption, samples were loaded 
adjacent to Benchmark ladder (M) and electrophoresed. Lane 1 is the total protein from 
uninduced cells containing the pET-28a (+)/Tal1 plasmid construct and lane 2 is the 
total protein from induced cells containing the pET-28a (+)/Tal1 plasmid construct. A 
band corresponding to a Mr of just over 15 kDa was present in lane 2 but was not 
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Figure 3.15: Tris-tricine polyacrylamide gel showing whole cell protein of induced 
and uninduced cells containing the pET-28a (+)/Hex plasmid construct and soluble 
and insoluble fractions.  
Two, 10 ml aliquots of culture containing cells with the pET-28a (+)/Hex plasmid 
construct were grown at 37˚C. After three hours, one of the 10 mL cultures was induced 
with 1 mM IPTG. After a further three hours incubation, a 1 mL sample of uninduced 
cells was removed and two, 1 mL samples of induced cells were removed. The cells 
were harvested from the three samples. Two pellets - induced and uninduced total 
protein - were resuspended in SDS loading buffer. One pellet (soluble/insoluble) was 
resuspended in 1 x PBS containing protease inhibitor.  Following sonic disruption of all 
three samples and centrifugation of the soluble/insoluble sample, samples were loaded 
adjacent to Benchmark ladder (M). Lane 1 is the total protein from uninduced cells 
containing the pET-28a (+)/Hex plasmid construct, lane 2 is the total protein from 
induced cells containing the pET-28a (+)/Hex plasmid construct, lane 3 is the soluble 
protein fraction and lane 4 is the insoluble protein fraction. Hex is present in total 



































Figure 3.16: Tris-tricine polyacrylamide gel showing whole cell protein of induced 
and uninduced cells containing the pET-28a (+)/Spi1 plasmid construct and 
soluble and insoluble fractions.  
Two 10 ml aliquots of culture containing cells with the pET-28a (+)/Spi1 plasmid 
construct were grown at 37˚C. After three hours, one of the 10 mL cultures was induced 
with 1 mM IPTG. After a further three hours, incubation, a 1 mL sample of uninduced 
cells was removed and two, 1 mL samples of induced cells were removed. The cells 
were harvested from the three samples. Two pellets - induced and uninduced - total 
protein were resuspended in SDS loading buffer. One pellet (soluble/insoluble) was 
resuspended in 1 x PBS containing protease inhibitor.  Following sonic disruption of all 
three samples and centrifugation of the soluble/insoluble sample, samples were loaded 
adjacent to Benchmark ladder (M). Lane 1 is the total protein from uninduced cells 
containing the pET-28a (+)/Spi1 plasmid construct, lane 2 is the total protein from 
induced cells containing the pET-28a (+)/Spi1 plasmid construct, lane 3 is the soluble 
protein fraction and lane 4 is the insoluble protein fraction. Spi1 is present in total 































Figure 3.17: Tris-tricine polyacrylamide gel showing whole cell protein of induced 
and uninduced cells containing the pET-28a (+)/Tal1 plasmid construct and 
soluble and insoluble fractions.  
Two 10 ml aliquots of culture containing cells with the pET-28a (+)/Tal11 plasmid 
construct were grown at 37˚C. After three hours, one of the 10 mL cultures was induced 
with 1 mM IPTG. After a further three hours, incubation, a 1 mL sample of uninduced 
cells was removed and two, 1 mL samples of induced cells were removed. The cells 
were harvested from the three samples. Two pellets - induced and uninduced - total 
protein were resuspended in SDS loading buffer. One pellet (soluble/insoluble) was 
resuspended in 1 x PBS containing protease inhibitor.  Following sonic disruption of all 
three samples and centrifugation of the soluble/insoluble sample, samples were loaded 
adjacent to Benchmark ladder (M). Lane 1 is the total protein from uninduced cells 
containing the pET-28a (+)/Tal11 plasmid construct, lane 2 is the total protein from 
induced cells containing the pET-28a (+)/Tal1 plasmid construct, lane 3 is the insoluble 
protein fraction and lane 4 is the soluble protein fraction. Tal1 is present in total protein 
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synthesis, both the soluble and insoluble protein purification protocols were carried out 
for these proteins. Once the soluble and insoluble proteins were separated from one 
another, the target proteins were further purified following either the protocol for 
soluble or insoluble protein purification using a 1 mL HisTrapTM HP column (GE 
Healthcare) attached to an Äkta Purifier system (GE Healthcare) as described in 
sections 2.6.5 and 2.6.6. 
 
3.7.2 Immobilised metal ion affinity chromatography using a HisTrapTM HP column 
The HisTrapTM HP column (GE Healthcare) contains pre-charged Ni2+ (nickel) 
SepharoseTM. The Ni2+ metal ions form complexes with many amino acids, including 
histidine. His-tagged proteins have a strong affinity for the Ni2+ metal ions in the 
column causing them to bind to the column while the majority of other proteins 
produced by the E. coli cells pass straight through the column. Target proteins were 
eluted from the column using a 20 mM-500 mM linear imidazole gradient. As the 
concentration of imidazole increases it displaces the His-tagged proteins from the Ni2+ 
metal ions causing them to elute from the column.  
 
3.7.3 Fraction selection 
By analysing the absorbance at 280 nm on the elution profiles for each of the target 
proteins it was possible to select the fractions from the purification which were most 
likely to contain the target protein (figures 3.18-3.22). In each of the elution profiles for 
the five target proteins, a peak in the absorbance is observed as the gradient of 
imadazole increases. The fractions corresponding to the peak in absorbance were 
selected and analysed using tris-tricine polyacrylamide gel electrophoresis.  
 
Analysis of the selected fractions by tris-tricine polyacrylamide gel electrophoresis 
showed that Hex, Spi1 and Lmo2 His-tagged proteins were successfully purified using 
the protocol for insoluble proteins (figures 3.18-3.20). Tal1 and fli1 His-tagged proteins 
were successfully purified using the soluble method (figures 3.21 and 3.22).  The Gata2 
His-tagged protein was unable to be expressed and purified so no further work was 
carried out for this protein. 
 
3.7.4 Preparation of purified proteins for injection into sheep 






















Figure 3.18: His-trapTM HP elution profile of Hex and 10% tris-tricine PAGE of 
selected fractions.  
(A) The elution profile of Hex is shown with the absorbance at 280 nm in blue and the 
concentration of buffer B as a % in pink.  The Hex sample was loaded onto the His-
trapTM HP column and eluted using a 20 mM – 500 mM imidazole gradient (0-100% 
buffer B) over 24 column volumes and collected as 2 mL fractions. (B) The numbers 
above the tris-tricine polyacrylamide gel correspond to the elution volume (mL). The 
experimental lanes were run adjacent to BenchmarkTM ladder (M). The gel shows the 
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Figure 3.19: His-trapTM HP elution profile of Spi1 and 10% tris-tricine PAGE of 
selected fractions.  
(A) The elution profile of Spi1 is shown with the absorbance at 280 nm in blue and the 
concentration of buffer B as a % in pink.  The Spi1 sample was loaded onto the His-
trapTM HP column and eluted using a 20 mM – 500 mM imidazole gradient (0-100% 
buffer B) over 24 column volumes and collected as 2 mL fractions. (B) The numbers 
above the tris-tricine polyacrylamide gel correspond to the elution volume (mL). The 
experimental lanes were run adjacent to BenchmarkTM ladder (M). The gel shows the 
majority of Spi1 protein to have been eluted between 42 mL and 46 mL, which 
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Figure 3.20: His-trapTM HP elution profile of Lmo2 and 10% tris-tricine PAGE of 
selected fractions.  
(A) The elution profile of Lmo2 is shown with the absorbance at 280 nm in blue and the 
concentration of buffer B as a % in pink.  The Hex sample was loaded onto the His-
trapTM HP column and eluted using a 20 mM – 500 mM imidazole gradient (0-100% 
buffer B) over 24 column volumes and collected as 2 mL fractions. (B) The numbers 
above the tris-tricine polyacrylamide gel correspond to the elution volume (mL). The 
experimental lanes were run adjacent to BenchmarkTM ladder (M). The gel shows the 
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Figure 3.21: His-trapTM HP elution profile of Tal1 and 10% tris-tricine PAGE of 
selected fractions.  
(A) The elution profile of Tal1 is shown with the absorbance at 280 nm in blue and the 
concentration of buffer B as a % in pink.  The Tal1 sample was loaded onto the His-
trapTM HP column and eluted using a 20 mM – 500 mM imidazole gradient (0-100% 
buffer B) over 24 column volumes and collected as 2 mL fractions. (B) The numbers 
above the tris-tricine polyacrylamide gel correspond to the elution volume (mL). The 
experimental lanes were run adjacent to BenchmarkTM ladder (M) and the load (L). The 
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Figure 3.22: His-trapTM HP elution profile of fli1 and 10% tris-tricine PAGE of 
selected fractions. 
 (A) The elution profile of fli1 is shown with the absorbance at 280 nm in blue and the 
concentration of buffer B as a % in pink.  The fli1 sample was loaded onto the His-
trapTM HP column and eluted using a 20 mM – 500 mM imidazole gradient (0-100% 
buffer B) over 24 column volumes and collected as 2 mL fractions. (B) The numbers 
above the tris-tricine polyacrylamide gel correspond to the elution volume (mL). The 
experimental lanes were run adjacent to BenchmarkTM ladder (M) and load (L). The gel 
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were used to select the fractions containing the most amount of target protein with the 
least amount of contamination. These fractions were lyophilised to remove liquid from 
the sample. One milligram of each purified target protein was sent away for injection 
into sheep (Scottish National Blood Transfusion). When injected into a sheep the 
purified proteins will act as antigens inducing an immune response in the sheep, and 




The work carried out in this chapter aimed to produce antigens so that antibodies could 
be raised against Gata1, Gata2, Hex, Spi1, Tal1, Lmo2 and fli1. DNA sequences coding 
for unique regions of each of the seven HTFs were PCR-amplified then sequentially 
cloned into two different vectors. The antigen sequences were carefully selected so that 
the antigens would be as unique as possible whilst being at least fifty amino acids in 
length. Fifty amino acids was the suggested minimum length required in order to elicit 
an immune response in the sheep (Alan Thorne, personal communication). The Gata1 
sequence was unable to be amplified via PCR. One possible reason for this is that stage 
17 Xenopus tropicalis embryos were too early for gata1 mRNA expression. PCR 
products were firstly cloned into pCR 2.1-TOPO and then sub-cloned into pET-28a (+). 
The pET-28a (+) vector added a His-tag onto the N-terminus of the expressed proteins. 
The His-tag enabled the target proteins to be purified using a 1 mL HisTrapTM HP 
column (GE Healthcare) attached to an Äkta Purifier system (GE Healthcare). 
 
Hex, Spi1 and Lmo2 were successfully purified using the insoluble protein purification 
method and Tal1 and fli1 were successfully purified using the method for soluble 
protein purification. Attempts at purifying the Gata2 antigen were unsuccessful.  
 
The purified proteins were then sent away for injection into sheep (Scottish National 
Blood Transfusion) in an attempt to produce antibodies that recognise and bind to the 






It is essential that any antibody intended for use in experiments such as 
immunohistochemical, ChIP and supershift assays are well characterised. The 
specificity of an antibody for its antigen can be characterised by Western blot analysis. 
Western blotting originated from the laboratory of George Stark at Stanford (Renart et 
al., 1979) and involves the following steps: Firstly, gel electrophoresis is used to 
separate denatured proteins. The separated proteins are then transferred onto a 
nitrocellulose membrane. Once the nonspecific binding sites on the membrane have 
been blocked, the membrane is incubated with the primary antibody (the anti-serum 
being characterised). Following removal of any excess primary antibody, the membrane 
is incubated with a secondary antibody. The secondary antibody is an antibody that has 
been raised in a different animal to the primary antibody and recognises 
immunoglobulins produced by the animal in which the primary antibody was raised. 
The secondary antibody is conjugated to an enzyme such as alkaline phosphatase or 
horseradish peroxidase, which when incubated with an analog of the enzyme’s natural 
substrate allows the position of the primary antibody/antigen to be visualised. 
 
The aim of the work in this chapter was to characterise the anti-serum produced by 
sheep following injection of either Hex, Spi1, Tal1, Lmo2 or fli1 antigens. 
 
4.2 Western blots using anti-serum against Xenopus laevis whole 
embryo extract 
The first step in characterising the anti-sera was to determine whether or not antibodies 
had been produced that were capable of detecting a protein of the expected size within 
whole embryo extract. Although the antibodies were raised against Xenopus tropicalis 
proteins, initial Western blot experiments were carried out using Xenopus laevis whole 
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embryo extract because a larger number of Xenopus laevis embryos were available at 
that time.  
 
The expression patterns of the proteins to be detected are not known, unlike their 
mRNA expression patterns. For this reason three different stages of embryo were 
chosen for these experiments: Stage seven to cover blastula development, stage 18 to 
cover neurula development and stage 27 to cover tailbud development. Following 
homogenisation of embryos, protein extractions were performed using freon as 
described in sections 2.8.5. The freon removes the yolk lipo-proteins. Two embryo 
equivalents of protein was loaded onto the appropriate gel.  
 
For each of the five antigens, four bleeds of anti-serum had been produced. Each one of 
the bleeds was tested on the three stages of Xenopus laevis whole embryo extract using 
Western blot analysis. Pre-immune controls were also carried out to show that the pre-
immune serum from the same animal as the anti-serum does not contain antibodies that 
bind to the protein believed to be the protein of interest. Western blots were carried out 
as described in section 2.6.10. The results for each anti-serum are discussed below. 
 
4.2.1 Hex 
The results for testing the four different bleeds of Hex anti-serum and pre-immune 
serum on Xenopus laevis whole embryo extract are shown in figure 4.1. A strong band 
corresponding to a Mr of approximately 30 kDa is seen in all three stages of extract on 
the membrane probed with fourth bleed anti-serum (starred in figure 4.1), this is the 
expected size of Hex protein (30.445 kDa –NCBI, accession number: NP_001079059). 
This band is not present on the membrane probed with pre-immune serum, strongly 
suggesting that antibodies have been raised against Hex. The same bands are present on 
the membranes probed with second and third bleed anti-serum but are not as strong. 
 
4.2.2 fli1 
Figure 4.2 shows a comparison of the membranes probed with the four bleeds of fli1 
anti-serums and pre-immune serum. The results show that there is a very strong band 
corresponding to a Mr of approximately 50 kDa (* in figure 4.2) present on the 
membrane probed with fli1 fourth bleed anti-serum in all three developmental stages 





































Figure 4.1: Western blots using Pre-immune serum and four different bleeds of 
Hex anti-serum on Xenopus laevis whole embryo extract.   
Protein from whole embryos was separated alongside SeeBlue® Plus2 Pre-Stained 
protein ladder (Invitrogen) using tris-tricine PAGE and transferred to a nitrocellulose 
membrane. The numbers above each lane indicate the stage of the embryo. Protein 
equivalent to two embryos was loaded for each stage. The Western blot was probed 
with a 1/500 dilution of Hex anti-serum. Following removal of the primary antibody the 
blot was probed with a 1/5000 dilution of donkey anti-sheep secondary antibody 
conjugated to HRP. The blot was developed using ECL (GE Healthcare). A strong band 
corresponding to a protein approximately of 30 kDa (*) can be seen in all three stages 
on the membrane probed with Hex 4th bleed anti-serum but not the membrane probed 
with pre-immune serum. The expected size of Hex is 30.4 kDa (NCBI). 
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Figure 4.2: Western blots using Pre-immune serum and four different bleeds of 
fli1 anti-serum on Xenopus laevis whole embryo extract.  
Protein from whole embryos was separated alongside SeeBlue® Plus2 Pre-Stained 
protein ladder (Invitrogen) using SDS-PAGE and transferred to a nitrocellulose 
membrane. The numbers above each lane indicate the stage of the embryo. Protein 
equivalent to two embryos was loaded for each stage. The Western blot was probed 
with a 1/500 dilution of fli1 anti-serum. Following removal of the primary antibody the 
blot was probed with a 1/5000 dilution of donkey anti-sheep secondary antibody 
conjugated to HRP. Following development of the membranes using ECL (GE 
Healthcare) strong bands corresponding to proteins of approximately 50 kDa (*) and 36 
kDa (**) were found to be present on the membrane probed with fli1 4th bleed anti-
serum but not the membrane probed with pre-immune serum. The expected size of fli1 
is 50.9 kDa (NCBI). 
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and NP_001084372). This band is not present on the membrane probed with pre-
immune serum, strongly suggesting that this band is fli1. However, there is also a very 
strong band corresponding to a Mr of approximately 36 kDa (** in figure 4.2) present 
on both the membranes probed with third and fourth bleed anti-serum in stages 18 and 




The results produced when probing for Tal1 protein using all four bleeds of anti-serum 
suggest that antibodies may have been raised against Tal1 protein as there appear to be 
two faint bands between 50 and 64 kDa (* in figure 4.3) that are not present on the pre-
immune membrane as well as a faint band just above 36 kDa (** figure 4.3) that is not 
on the pre-immune membrane (figure 4.3). The expected size of Tal1 is 42.912 kDa 
(NCBI, accession number: NP_001135468). However, none of these bands are 
particularly strong.  
 
4.2.4 Lmo2 and Spi1 
Western blot results (results not shown) suggest that antibodies have not been raised 
against Lmo2 or Spi1 since no difference is seen between pre-immune serum probed 
membranes and membranes probed with any one of the four bleeds of Lmo2 or Spi1 
anti-serum.  
 
4.3 Western blots using anti-serum against Xenopus tropicalis whole 
embryo extract 
The next step was to test the anti-sera on Xenopus tropicalis whole embryo extract 
using Western blot analysis. Hex and fli1 fourth bleed anti-sera were tested to determine 
whether or not the same strong bands that were produced when using Xenopus laevis 
whole embryo extract were also produced when using Xenopus tropicalis whole embryo 
extract. All four bleeds of Tal1 anti-serum were tested because previous results (figure 
4.3) showed that no particular bleed of Tal1 anti-serum worked any better than the 
other. Also, all four bleeds of Lmo2 and Spi1 anti-serum were tested on Xenopus 






































Figure 4.3: Western blots using Pre-immune serum and four different bleeds of 
Tal1 anti-serum on Xenopus laevis whole embryo extract.  
Protein from whole embryos was separated alongside SeeBlue® Plus2 Pre-Stained 
protein ladder (Invitrogen) using SDS-PAGE and transferred to a nitrocellulose 
membrane. The numbers above each lane indicate the stage of the embryo. Protein 
equivalent to two embryos was loaded for each stage. The Western blot was probed 
with a 1/500 dilution of Tal11 anti-serum. Following removal of the primary antibody 
the blot was probed with a 1/5000 dilution of donkey anti-sheep secondary antibody 
conjugated to HRP. Following development of the membranes using ECL (GE 
Healthcare) there appear to be two faint bands between 50 kDa and 64 kDa (*) that are 
not present on the pre-immune membrane as well as a faint band just above 36 kDa (**) 
that is not on the pre-immune membrane. The expected size of Tal1 is 42.9 kDa 
(NCBI). 
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antibodies had been raised that recognise the Xenopus laevis proteins, the antibodies 
were raised against Xenopus tropicalis proteins. Therefore, it may be that antibodies 
have been raised that recognise the Xenopus tropicalis proteins but not the Xenopus 
laevis proteins.  
 
Xenopus tropicalis protein extractions were carried out as described in section 2.8.5, 
however as Xenopus tropicalis embryos are smaller than Xenopus laevis the protein 
equivalent to eight embryos was loaded onto the gel. Western blots were carried out as 
described in section 2.6.10. The results for each anti-serum are discussed below. 
 
4.3.1 Hex and fli1 
The results for testing fourth bleed Hex anti-serum on Xenopus tropicalis whole embryo 
extract are shown in figure 4.4. Unexpectedly, the results show that the band believed to 
be Xenopus tropicalis Hex at approximately 30 kDa (* in figure 4.4) is not as strong as 
the band thought to be Xenopus laevis Hex. Figure 4.5 shows the results for testing fli1 
fourth bleed anti-serum on Xenopus tropicalis whole embryo extract and again these 
results also show that the band believed to be Xenopus tropicalis fli1 at approximately 
50 kDa (* in figure 4.5) is not as strong as the band thought to be Xenopus laevis fli1. 
These results are surprising since the antibodies were raised against Xenopus tropicalis 
proteins, although this result may reflect the amount of protein in Xenopus tropicalis 
embryos rather than the affinity of these antibodies for their antigens. The fli1 anti-




All four bleeds of Tal1 anti-serum were tested on Xenopus tropicalis whole embryo 
extract. The results for second, third and fourth bleeds are not shown because the results 
are similar to those obtained using Xenopus laevis whole embryo extract. No specific 
strong bands are seen that are not present on the pre-immune membrane. However, the 
membrane probed with Tal1 first bleed anti-serum does show a very strong band that is 
not present on the pre-immune membrane (figure 4.6). The strong band corresponds to a 
Mr of approximately 64 kDa. The expected size of Tal1 is 42.9 kDa (NCBI) so the 


























Figure 4.4: Western blots using Pre-immune serum and fourth bleed Hex anti-
serum on Xenopus tropicalis whole embryo extract.  
Protein from whole embryos was separated alongside SeeBlue® Plus2 Pre-Stained 
protein ladder (Invitrogen) using tris-tricine PAGE and transferred to a nitrocellulose 
membrane. The numbers above each lane indicate the stage of the embryo. Protein 
equivalent to eight embryos was loaded for each stage. The Western blots were probed 
with a 1/500 dilution of either Hex pre-immune or Hex 4th bleed anti-serum. Following 
removal of the primary antibody the blot was probed with a 1/5000 dilution of donkey 
anti-sheep secondary antibody conjugated to HRP. Following development of the 
membranes using ECL (GE Healthcare) a band corresponding to a protein of just under 
34 kDa (*) is present on the 4th bleed anti-serum membrane that is not present on the 
pre-immune membrane. This band is observed in all three embryonic stages. The 
expected size of Hex is 30.4 kDa (NCBI). 
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Figure 4.5: Western blots using Pre-immune serum and fourth bleed fli1 anti-
serum on Xenopus tropicalis whole embryo extract.  
Protein from whole embryos was separated alongside SeeBlue® Plus2 Pre-Stained 
protein ladder (Invitrogen) using SDS-PAGE and transferred to a nitrocellulose 
membrane. The numbers above each lane indicate the stage of the embryo. Protein 
equivalent to two embryos was loaded for each stage. The Western blot was probed 
with a 1/500 dilution of either fli1 pre-immune or fli1 4th bleed anti-serum. Following 
removal of the primary antibody the blot was probed with a 1/5000 dilution of donkey 
anti-sheep secondary antibody conjugated to HRP. Following development of the 
membranes using ECL (GE Healthcare) a band corresponding to a protein of just over 
50 kDa (*) is present on the 4th bleed anti-serum membrane that is not present on the 
pre-immune membrane. This band is observed in all three embryonic stages. The 
expected size of fli1 is 50.9 kDa (NCBI). There is also a very strong band observed just 
under 36 kDa (**) that is not present on the pre-immune membrane and is found in 
stage 27 embryos. 
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Figure 4.6: Western blots using Pre-immune serum and first bleed Tal1 anti-serum 
on Xenopus tropicalis whole embryo extract.  
Protein from whole embryos was separated alongside SeeBlue® Plus2 Pre-Stained 
protein ladder (Invitrogen) using SDS-PAGE and transferred to a nitrocellulose 
membrane. The numbers above each lane indicate the stage of the embryo. Protein 
equivalent to two embryos was loaded for each stage. The Western blot was probed 
with a 1/500 dilution of either Tal1 pre-immune or Tal1 1st bleed anti-serum. Following 
removal of the primary antibody the blot was probed with a 1/5000 dilution of donkey 
anti-sheep secondary antibody conjugated to HRP. Following development of the 
membranes using ECL (GE Healthcare) a band corresponding to a protein of just under 
64 kDa (*) is present on the 1st bleed anti-serum membrane that is not present on the 
pre-immune membrane. This band is observed in all three embryonic stages. The 
expected size of Tal1 is 42.9 kDa (NCBI). 
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4.3.3 Lmo2 and Spi1 
The results (not shown) for testing all four bleeds of Lmo2 and Spi1 anti-serum on 
Xenopus tropicalis whole embryo extract produced the same results as Western blots 
performed with Xenopus laevis whole embryo extract. No difference was seen between 
immune and pre-immune membranes. A wide range of concentrations of anti-serum 
was tested but still no difference was seen, suggesting that antibodies have not been 
raised against Xenopus tropicalis Lmo2 and Spi1 proteins. 
 
4.3.4 Initial discussion  
The preliminary results produced from Western blots carried out using both Xenopus 
laevis and Xenopus tropicalis whole embryo extract strongly suggest that Hex and fli1 
fourth bleed anti-sera contain antibodies capable of detecting both Xenopus laevis and 
Xenopus tropicalis Hex and fli1 proteins respectively. However, both Hex and fli1 
antibodies appear to be most effective in detecting the Xenopus laevis proteins since the 
signal believed to be Xenopus laevis Hex and Xenopus laevis fli1 is stronger than the 
signal thought to be Xenopus tropicalis Hex and Xenopus tropicalis fli1, although this 
may reflect the protein expression levels in each species. Further antibody 
characterisation is needed to test whether these bands are in fact Hex and fli1. 
 
Initial results from Western blots using Xenopus laevis whole embryo extract showed 
that all four bleeds of Tal1 immune serum produced very weak bands that were not 
present when probing with pre-immune serum. However, when the Western blots were 
carried out using Xenopus tropicalis whole embryo extract a very strong band was seen 
when probing with Tal1 first bleed anti-serum that was not present when probing with 
pre-immune serum. This band corresponds to a protein of approximately 64 kDa, which 
is larger than the expected size of Tal1, although it is possible that the protein has been 
modified and runs aberrantly increasing its apparent molecular mass. Further antibody 
characterisation is needed to determine whether or not this band is Tal1. 
 
The results produced when probing with Lmo2 and Spi1 anti-sera in Western blots 
using both Xenopus laevis and Xenopus tropicalis whole embryo extract suggest that 
antibodies have not been raised against Lmo2 and Spi1 proteins because no difference 
was seen between immune and pre-immune membranes. Therefore, no further antibody 
characterisation using these anti-sera was undertaken. 
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4.4 Antisense morpholino oligonucleotide micro-injections 
Although the preliminary results strongly indicate that antibodies have been raised 
against Hex, fli1 and Tal1, these antibodies must be further characterised to determine 
whether the proteins they recognise are actually the intended targets. One way in which 
to show this is to use an antisense technology, by injecting antisense morpholino 
oligonuleotides (AMOs).  
 
AMOs can be used to knock down expression of a specific gene. They are synthetic 
molecules made of nucleotide bases but have a morpholino ring backbone instead of 
deoxyribose rings and these are linked through phosphorodiamidate groups instead of 
phosphates. The morpholino backbone is synthetic, so it is not recognised by nucleases 
or any other nucleic acid binding proteins making it more stable than deoxyribose 
oligonucleotides (Hudziak et al, 1996). Morpholino oligonuleotides are about 25 bases 
in length and through complimentary base pairing bind to the 5'-untranslated region of 
mRNA transcripts block translation of its target transcript (Summerton et al., 1997 and 
Heaseman et al., 2000). AMOs can also be used to block the splicing of a specific exon 
making it possible to study the function of a specific isoform of a gene  (Kenwrick et 
al., 2004 and reviewed in Eisen and James, 2008). 
 
In conjunction with Western blotting, AMOs provide one possible way in which to 
show whether or not the antibodies are detecting the correct protein. AMOs specific for 
the mRNA transcripts coding for the proteins that the antibodies were designed to detect 
can be delivered into the cytosol of a one-cell Xenopus embryo via microinjection. The 
AMOs diffuse across the whole zygote thus are present in all blastomeres, where they 
hybridise to their target mRNA and block its translation. Western blot analysis can then 
be used to compare protein extracts of injected and control embryos of the same stage. 
A decrease in band intensity of the band thought to be the protein of interest should be 
observed in the protein extracts from AMO injected embryos since less protein is 
synthesised. However, one limitation to this experiment is if the protein is present as a 
maternal protein, the experiment will only be successful if the protein is rapidly turned 
over. 
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4.4.1 Hex AMO injection experiments 
This experiment was first carried out using Xenopus laevis Hex specific AMOs (a gift 
from Prof. Roger Patient) which were injected into one-cell Xenopus laevis embryos as 
described in section 2.8.7. Sets of 25 un-injected control embryos and 25 AMO-injected 
embryos were collected and frozen at stages 7, 17 and 27. Protein extractions were 
carried out as described in section 2.8.5 and protein from the equivalent of two embryos 
was loaded onto the appropriate gel. Section 2.6.10 describes the procedure for Western 
blotting, a 1/500 dilution of Hex fourth bleed antiserum was used for protein detection. 
A decrease in band intensity is seen in the 30 kDa band believed to be Hex in stages 7 
and 17 of AMO-injected embryos compared to stages 7 and 17 of control embryos 
(figure 4.7). No difference in band intensity of the non-specific bands is observed 
suggesting that this is a true result. This result provides strong evidence that the band 
believed to be Hex is indeed Hex, however it was not possible to repeat this result 
consistently. One reason for this could be that Hex is present as a maternal protein that 
is not rapidly turned over.  
 
4.4.2 fli1 and Tal1 MO injection experiments 
The experiment described above in section 4.5.1 was repeated for AMOs specific for 
Xenopus laevis fli1 and Xenopus laevis Tal1 (Gene tools Inc.), however no difference 
was seen in band intensity between control and AMO injected embryos (data not 
shown). One reason for this could be that Xenopus laevis are pseudotetraploid (Hughes 
and Hughes, 1993). Therefore, the experiment was repeated in Xenopus tropicalis since 
they are diploid but still no difference was seen in band intensity (data not shown). 
Again this could be because fli1 and Tal1 are present as maternal proteins or possibly 
that the bands thought to be fli1 and Tal1 are actually not these proteins. 
 
4.5 Antigen over-expression: preparation of synthetic mRNA 
An alternative way in which to test whether or not the Hex, fli1 and Tal1 anti-sera are 
detecting the correct proteins is to over-express the protein of interest in Xenopus 
embryos then use Western blot analysis to compare the protein levels in control 
embryos and in embryos that have been injected with the mRNA coding for the protein 
of interest. An increase in band intensity should be observed in the protein extracts from 























                  Lane 1 = stage 7 Xla control          Lane 2 = stage 7 Xla Hex MO 
                  Lane 3 = stage 17 Xla control        Lane 4 = stage 17 Xla Hex MO  




Figure 4.7: Western blot using Hex anti-serum on control and Hex AMO injected 
whole Xenopus laevis embryo extracts.  
Protein from whole embryos (from both control embryos and Hex AMO injected 
embryos) was separated alongside SeeBlue® Plus2 Pre-Stained protein ladder 
(Invitrogen) by tris-tricine PAGE then transferred to a nitrocellulose membrane. Protein 
equivalent to two embryos was loaded for each stage. The Western blot was probed 
with a 1/500 dilution of Hex anti-serum. Following removal of the primary antibody the 
blot was probed with a 1/5000 dilution of donkey anti-sheep secondary antibody 
conjugated to HRP. Following development using ECL (GE Healthcare) the membrane 
shows strong bands corresponding to a protein of approximately 30 kDa. However, in 
lanes 2 (stage 7 Hex AMO injected embryos) and 4 (stage 17 Hex MO injected 
embryos) the signal is reduced suggesting that the band corresponds to Hex protein. 




4.5.1 PCR primer design 
The NCBI web database was used to identify the coding regions of Xenopus laevis hex, 
Xenopus laevis fli1 and Xenopus tropicalis tal1. Once identified, PCR primers were 
designed that would allow amplification of these coding regions via PCR. It was 
necessary to design two primers (one forward and one reverse for each of the DNA 
sequences), each primer being complementary to the 5′ ends of each strand of the DNA 
sequences, directing initiation of their amplification. All primers were 26 base pairs 
long and included six-base, non-complementary tails at the 5′ ends containing 
restriction sites that would later allow the DNA sequences to be cloned into pBUT2-Sfi 
(figure 4.8). Tal1 and fli1 forward primers contained six-base, non-complementary tails 
at the 5′ ends containing an XbaI restriction site immediately prior to the coding DNA 
sequence and the Hex forward primer contained a PvuII restriction site immediately 
prior to the coding DNA sequence. Tal1 and fli1 reverse primers contained six-base 
non-complementary tails at the 5′ ends containing XhoI restriction sites immediately 
prior to the coding DNA sequence and the Hex reverse primer contained a PvuII 
restriction site immediately prior to the coding DNA sequence.  
 
4.5.2 Polymerase Chain Reaction 
The primers described in section 4.5.1 were used to amplify the selected cDNA 
sequences by PCR. The DNA template used for amplification was cDNA from stage 17 
Xenopus laevis embryos for Hex and fli1 and cDNA from stage 17 Xenopus tropicalis 
embryos for Tal1.  
 
Taq DNA polymerase was used for the extension reaction as it has a non-template-
dependent terminal transferase activity that adds a single deoxyadenosine (A) to the 3′ 
ends of PCR products (Clark, 1988), allowing the PCR products to be cloned into 
pGEM®-T Easy vector (figure 4.9) which was used as an intermediate vector before 
sub-cloning into pBUT2-Sfi. pGEM®-T Easy vector is supplied as a linearised vector 
with single 3′-thymidine (T) overhangs allowing efficient ligation of Taq PCR 
















Figure 4.8: Plasmid map of pBUT2-Sfi.  
The open reading frames of either Xenopus laevis hex, Xenopus laevis fli1 or Xenopus 
tropicalis tal1 were sub-cloned  into the MCS of pBUT2-Sfi following their removal 
from pGEM®-T Easy vector. Prior to in vitro transcription pBUT2-Sfi was linearised 
by SfiI digestion. mRNA for in vitro translation and micro-injection was synthesised by 
transcribing with T3 RNA polymerase. The 5’ and 3’ UTRs are derived from Xenopus 


































Figure 4.9: Diagrammatic representation of cloning a PCR product into the 
pGEM®-T Easy vector.  
The PCR product and multiple cloning site (MCS) have been enlarged to indicate where 
the PCR product gets ligated into the vector. The vector is linearised with overhanging 





















Figure 4.9: Diagrammatic representation of cloning a PCR product into the pGEM®-
T Easy vector. The PCR product and mul ple cloning site (MCS) have been enlarged to 
indicate where the PCR product gets ligated into the vector. The vector is linearised with 
ov rhanging T ends allowing insertion of th  PCR product that has overhang g A ends.  
MCS 






4.5.3 Sub-cloning into pGEM®-T 
pGEM®-T Easy vector (figure 4.9) contains T7 and SP6 RNA polymerase promoters 
flanking a multiple cloning region within the α-peptide coding region of the enzyme β-
galactosidase. When a PCR product is successfully cloned into pGEM®-T Easy the 
coding sequence for β-galactosidase is interrupted allowing identification of 
recombinants by blue/white screening on indicator plates. This vector also contains the 
gene for Ampicillin resistance. 
 
Tal1 and fli1 DNA sequences were removed from pGEM®-T Easy using the restriction 
enzymes XbaI and XhoI and Hex was removed using the restriction enzyme PvuII. 
 
4.5.4 Sub-cloning into pBUT2-Sfi 
Following removal of the DNA sequences from pGEM®-T Easy, pBUT2-Sfi (figure 
4.8) was also cut using either XbaI and XhoI for Tal1 and fli1 cloning or EcoRV for 
Hex cloning. These restriction enzyme digests allowed insertion of the DNA fragments 
into the MCS of pBUT2-Sfi.  
 
pBUT2-Sfi  contains the 5’ and 3’ untranslated regions of β-globin. and a synthetic 
polyA stretch of nucleotides which, with the introduction of a synthetic 5’ cap analogue 
(NEB) during in vitro translation ensures the synthesis of an efficient and stable mRNA 
(Kreig and Melton, 1984). The plasmid also contains ampicillin resistance and an SfiI 
site to allow linearisation of the plasmid. 
 
4.5.5 Screening for recombinants  
To screen for recombinant pGEM®-T Easy plasmid DNA, transformed DH5α E.coli 
cells were plated onto plates containing ampicillin and X-Gal. Colonies containing 
recombinant plasmid DNA appear white. In each case, 12 of the resulting colonies were 
selected and used for small-scale plasmid purification as described in section 2.4.7.  
Purified plasmid DNA thought to contain either Tal1 or fli1 DNA sequences was 
digested using XbaI and XhoI restriction enzymes and purified plasmid DNA thought to 
contain the Hex DNA sequence was digested with PvuII. Agarose gel electrophoresis 
was then used to determine whether DNA inserts of the correct size had been excised 
from the plasmid DNA. To verify that the inserts cut from the plasmid DNA were the 
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correct sequence, plasmid DNA samples were sequenced commercially (GATC Ltd.) 
using the T7 promoter primer. Sequencing results were checked using BLAST.  
 
To screen for recombinant pBUT2-Sfi plasmid DNA, transformed DH5α E.coli cells 
were spread onto agar plates containing ampicillin. Again 12 of the resulting colonies 
were selected and used for small-scale plasmid purification.  Purified plasmid DNA 
thought to contain either Tal1 or fli1 DNA sequences was digested using XbaI and XhoI 
restriction enzymes. Purified plasmid DNA thought to contain the Hex DNA sequence 
were digested with XbaI, this digestion would not only show whether or not the Hex 
cloning had been successful but would also show the orientation of the Hex sequence 
which is important when carrying out blunt ended ligations because the insert can get 
ligated into the vector in different orientations. Agarose gel electrophoresis was then 
used to determine whether DNA inserts of the correct size had been excised from the 
plasmid DNA. 
 
Plasmid DNA samples thought to contain the correct sequence were sequenced 
commercially (GATC Ltd.) using the T3 promoter primer. Sequencing results were 
checked using BLAST.  
 
4.6 In vitro translation 
Synthetic hex, fli1 and tal1 mRNA transcripts were produced by in vitro transcription as 
described in section 2.8.9. To check that each of the transcripts translated into proteins 
of the correct size Wheat Germ Extract Plus (Promega) in vitro translation experiments 
were performed. The wheat germ extract contains all the cellular components necessary 
for protein synthesis so just the addition of the appropriate mRNA is required. Control 
reactions were also set up to which RNase free H2O was added in place of the mRNA. 
Incorporation of fluorescently labelled lysine residues into the nascent proteins during 
translation (FluoroTectô GreenLys tRNA – Promega) allowed visulisation of 
synthesised proteins using a phospho-imager.  
 
The Hex in vitro translation produced a single protein product of just under 40 kDa that 
was not present in the control reaction (figure 4.10). The protein product was larger than 
expected as the approximate size of Hex is 30 kDa and in whole Xenopus embryo 

































Figure 4.10: Hex mRNA, analysed by gel electrophoresis and visualised by 
ethidium bromide staining and in vitro translation products visualised by 
fluorescent-imaging and Western blot analysis.  
(A) Hex mRNA was synthesised by in vitro transcription. (1) Before DNase I digestion.  
(2) After DNase I digestion. (B) Hex protein was synthesised by in vitro translation 
using Wheat Germ Extract Plus (Promega). The incorporation of fluorescently labeled 
lysine residues into the nascent proteins during translation (FluoroTectô GreenLys 
tRNA – Promega) allowed visulisation of synthesised proteins (*) using fluorescent-
imaging (Fujifilm FLA-5000). (1) Control reaction to which RNase free H2O was 
added. (2) Reaction to which Hex mRNA was added. The protein was separated 
alongside BenchMark™ Protein Ladder (Invitrogen) by SDS-PAGE. (C) Western blot 
using Hex 4th bleed anti-serum on  (1) control and (2) Hex in vitro translated protein. 
The protein was separated alongside SeeBlue® Plus2 Pre-Stained protein ladder 
(Invitrogen) by SDS-PAGE. Figure B shows that a protein between 30 and 40 kDa was 
synthesised by in vitro translation (*). This protein can be detected using Hex 4th bleed 
anti-serum (**), however the protein is larger than expected as the expected size of Hex 
is 30.4 kDa (NCBI). 
B. 
A.     1                        2 









about 30 kDa. For this reason a Western blot was performed to compare the sizes of the 
Hex in vitro translated protein and the protein believed to be Hex in whole Xenopus 
embryo extract directly (figure 4.11). 
 
The addition of fli1 mRNA to the wheat germ extract resulted in the synthesis of a 
single protein just above 50 kDa that was not present in the control reaction (figure 
4.12). The expected size of fli1 is 51 kDa.  
 
A single protein product was also translated from tal1 mRNA, which was not present in 
the control reaction (figure 4.13). This was also of an unexpected size. The protein 
product was just above 50 kDa and the expected size of Tal1 is 42 kDa. However, the 
band believed to be Tal1 protein in whole Xenopus embryo extract corresponds to a 
protein of an apparent Mr of 64 kDa. 
 
4.6.1 Western blot analysis of protein products synthesised by in Vitro translation 
Next to test whether or not the anti-sera were capable of detecting the in vitro translated 
proteins Western blots were performed. Results show that for fli1, Hex and Tal1, each 
of the anti-sera were in fact capable of detecting the intended protein (figures 4.10c, 
4.12c and 4.13c). 
 
4.7 Protein over-expression in Xenopus embryos 
mRNA encoding either Hex, fli1 or Tal1 proteins was delivered into the cytosol of one 
cell stage Xenopus embryos via microinjection. Injected embryos were allowed to 
develop until an appropriate stage. The mRNA gets translated into protein causing an 
increase in protein expression. Un-injected embryos and embryos injected with H2O 
were used as controls. Western blot analysis was then used to compare the protein 
extracts from injected and control embryos of the same stage. An increase in band 
intensity of the protein thought to be the protein of interest should be observed in the 
protein extracts of mRNA injected embryos as more protein is synthesised.  
 
Hex protein over-expression experiments in Xenopus laevis were unsuccessful. 
Although the Hex mRNA was shown to translate into protein in vitro no protein was 

































Figure 4.11: Western blot showing the size difference between in vitro translated 
Hex and the protein believed to be Hex in Xenopus embryos.  
Hex protein synthesised by in vitro translation using Wheat Germ Extract Plus 
(Promega) (lane1) was separated alongside whole Xenopus laevis embryo extract (lane 
2) and SeeBlue® Plus2 Pre-Stained protein ladder (Invitrogen) using SDS-PAGE and 
transferred to a nitrocellulose membrane. The Western blot was probed with purified 
Hex antibody. Following removal of the primary antibody the blot was probed with a 
1/5000 dilution of donkey anti-sheep secondary antibody conjugated to HRP. The blot 
was developed using ECL (GE Healthcare). The developed blot shows that the protein 
produced by in vitro translation is between 36 and 50 kDa where as the protein thought 
to be Hex in Xenopus laevis embryo extract is just under 36 kDa. The expected size of 
Hex is 30.4 kDa (NCBI). 




































Figure 4.12: fli1 mRNA, analysed by gel electrophoresis and visualised by 
ethidium bromide staining and in vitro translation products visualised by 
fluorescent-imaging and Western blot analysis.  
(A) Xenopus laevis fli1 mRNA was synthesised by in vitro transcription. (1) Before 
DNase I digestion.  (2) After DNase I digestion. (B) fli1 protein was synthesised by in 
vitro translation using Wheat Germ Extract Plus (Promega). The incorporation of 
fluorescently labeled lysine residues into the nascent proteins during translation 
(FluoroTectô GreenLys tRNA – Promega) allowed visulisation of synthesised proteins 
(*) using fluorescent-imaging (Fujifilm FLA-5000). The protein was separated 
alongside BenchMark™ Protein Ladder (Invitrogen) by SDS-PAGE. (C) Western blot 
using fli1 4th bleed anti-serum on  (1) control and (2) fli1 in vitro translated protein. The 
protein was separated alongside SeeBlue® Plus2 Pre-Stained protein ladder (Invitrogen) 
by SDS-PAGE. Figure B shows that a protein of just under 50 kDa was synthesised by 
in vitro translation (*) and the expected size of fli1 is 50.9 kDa (NCBI). Figure C shows 
that this protein can be detected using fli1 4th bleed anti-serum (**). 
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Figure 4.13: Tal1 mRNA, analysed by gel electrophoresis and visualised by 
ethidium bromide staining and in vitro translation products visualised by 
fluorescent-imaging and Western blot analysis.. 
(A) Xenopus tropicalis Tal1 mRNA was synthesised by in vitro transcription. (1) 
Before DNase I digestion.  (2) After DNase I digestion. (B) Tal1 protein was 
synthesised by in vitro translation using Wheat Germ Extract Plus (Promega). The 
incorporation of fluorescently labeled lysine residues into the nascent proteins during 
translation (FluoroTectô GreenLys tRNA – Promega) allowed visulisation of 
synthesised proteins (*) using fluorescent-imaging (Fujifilm FLA-5000). (1) Control 
reaction to which RNase free H2O was added. (2) Reaction to which Tal1 mRNA was 
added. The protein was separated alongside BenchMark™ Protein Ladder (Invitrogen) 
by SDS-PAGE. (C) Western blot using Tal1 1st bleed anti-serum on  (1) control and (2) 
Tal1 in vitro translated protein. The protein was separated alongside SeeBlue® Plus2 
Pre-Stained protein ladder (Invitrogen) by SDS-PAGE. In figures B (*) and C (**) a 
band is observed between 50 and 64 kDa that is not present in control reactions strongly 
suggesting that Tal1 anti-serum does detect Tal1 protein, however the expected size of 
Tal1 is 42.9 kDa (NCBI). 
A. 
B. C. 
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Xenopus laevis embryos were injected with either 2.5 nl (approximately 400 pg), 5 nl 
(approximately 800 pg) or 10 nl (approximately 1600 pg) of fli1 mRNA. Injected and 
control embryos were collected at stage 17, homogenised then freon extracted. Western 
blots were then carried out using fli1 4th bleed anti-serum. An increase in intensity of 
the band believed to correspond to fli1 is observed between control embryos and 
embryos that had been injected with either 5 nl or 10 nl of fli1 mRNA. Protein from the 
fli1 in vitro translation was also analysed along side the embryo extracts to show that 
the band believed to be fli1 in embryos is the same size as the protein synthesised by in 
vitro translation (figure 4.14).  
 
Tal1 protein over-expression experiments in Xenopus embryos were also successful. 
Xenopus tropicalis embryos were injected with either 2.5 nl (approximately 500 pg) or 
5 nl (approximately 1000 pg) of Tal1 mRNA. Injected and control embryos were 
collected at stage 12, homogenised then freon extracted. Western blots were then 
carried out using Tal1 1st bleed anti-serum. The results show that a band the same size 
as the Tal1 in vitro translated protein appears in the extracts from embryos injected with 
either 2.5 nl or 5 nl of Tal1 mRNA (figure 4.15). This band is not present in the extracts 
of un-injected or H2O injected embryos. This result does show that Tal1 1st bleed anti-
serum is capable of detecting Tal1 protein, however the band originally thought to 
possibly be a modified form of Tal1 does not increase in intensity. Two possible 
explanations for this are that: The anti-serum is cross reacting with another protein 
which is not Tal1 and that there is too little endogenous Tal1 protein in Xenopus 
embryos to produce a band; another possibility is that the larger band is a modified form 
of Tal1 but the protein gets modified in oocytes therefore the protein synthesised from 
exogenous mRNA injected after fertilisation does not get modified. 
 
4.8 Single protein immunoprecipitation using Hex and Tal1 Antibodies 
To confirm whether Hex and Tal1 anti-sera are detecting their intended target proteins, 
immunoprecipitations (IP) were performed in order to isolate the proteins in question. 
Firstly, the antibody was directly added to whole Xenopus embryo extract and the 
embryo/antibody mixture allowed to incubate. This incubation step gives the antibody 
time to bind to any of its target proteins in the embryo extract. Secondly, protein G 
coupled to Sepharose beads is added to the embryo/antibody mixture. Protein G has a 

























                  Lane 1 = uninjected control              Lane 2 = H2O injected control 
                  Lane 3 = 400 pg injection                 Lane 4 = 800 pg injection 
                  Lane 5 = 1600 pg injection               Lane 6 = in vitro translated fli1 
 
 
Figure 4.14: Western blot analysis of fli1 protein over-expression in Xenopus laevis 
embryos.  
One-cell stage Xenopus laevis embryos were injected with either H2O as a control or 
increasing amounts of fli1 mRNA. The embryos were allowed to develop until stage 17. 
Embryos were then homogenised and freon-extracted and the proteins were separated 
by SDS-PAGE alongside SeeBlue® Plus2 Pre-Stained protein ladder (Invitrogen) then 
transferred to a nitrocellulose membrane. The protein from un-injected embryos was 
also analysed as a control. The Western blot was probed with a 1/500 dilution of fli1 
anti-serum. Following removal of the primary antibody the blot was probed with a 
1/5000 dilution of donkey anti-sheep secondary antibody conjugated to HRP. The blot 
was developed using ECL (GE Healthcare). The band corresponding to fli1 protein 
increases in intensity with increasing fli1 mRNA injection amounts. The last lane (lane 
6) is the protein from a fli1 in vitro translation (Promega) showing that the fli1 protein 
produced by in vitro translation is exactly the same size as fli1 protein in Xenopus laevis 
embryos. 
fli1 50 kDa 



























                    Lane 1 = uninjected control               Lane 2 = H2O injected control 
                    Lane 3 = 500 pg injection                  Lane 4 = 1000 pg injection 
 
 
Figure 4.15: Western blot analysis of Tal11 protein over-expression in Xenopus 
tropicalis embryos.  
One-cell stage Xenopus tropicalis embryos were injected with either H2O as a control or 
increasing amounts of Tal1 mRNA. The embryos were allowed to develop until stage 
12. Embryos were then homogenised and freon-extracted and the proteins were 
separated by SDS-PAGE alongside SeeBlue® Plus2 Pre-Stained protein ladder 
(Invitrogen) then transferred to a nitrocellulose membrane. The protein from uninjected 
embryos was also analysed as a control. The Western blot was probed with a 1/500 
dilution of Tal1 anti-serum. Following removal of the primary antibody the blot was 
probed with a 1/5000 dilution of donkey anti-sheep secondary antibody conjugated to 
HRP. The blot was developed using ECL (GE Healthcare). The band originally believed 
to be Tal1 protein does not increase in intensity following injection of exogenous Tal1 
mRNA. However, a band just above 50 kDa appears in the extracts from Tal1 injected 
embryos that is not present in control embryos.  







that the protein Sepharose G will bind to the antibody, which is bound to its antigen.  
 
The Sepharose beads act as a solid-phase support. Following a centrifugation step and 
washing off any unbound protein, the protein Sepharose G/antibody/antigen can be 
resuspended in gel loading buffer then denatured and the protein Sepharose G, antibody 
and antigen separated by SDS PAGE. Once the gel has been Coomassie stained the 
isolated protein of interest can be removed from the gel and sent off for tryptic digest 
mass spectrometry (University of Leeds) for identification.  
 
Control IPs were also carried out using pre-immune serum. Western blot analysis was 
used to compare the starting protein sample against the unbound protein fraction 
(protein not bound to the antibody), protein that had bound to the antibody during the IP 
and also the control IP.  
 
4.8.1 Tal1 immunoprecipitation 
Previous results (figure 4.13) have shown that Tal1 1st bleed anti-serum is capable of 
detecting Xenopus tropicalis Tal1 protein. However, the protein originally thought to be 
Tal1 in Xenopus tropicalis embryo extracts is larger (just under 64 kDa) than the protein 
produced by in vitro translation and by over-expression in Xenopus tropicalis embryos 
(just above 50 kDa). The protein produced by over-expression is not detectable in 
control Xenopus tropicalis embryo extract (figures 4.13 and 4.15). Therefore, in order to 
identify whether the larger protein detected by Tal1 anti-serum is a modified 
form/splice variant of Tal1 or whether the anti-serum is cross-reacting with another 
protein, a Tal1 IP was carried out using approximately 42 µg of caprylic acid purified 
Tal-1 1st bleed anti-serum. Western blot analysis shows that the Tal1 IP was 
unsuccessful (figure 4.16). The Tal1 anti-serum does not bind to the protein of interest 
during this procedure.  
 
4.8.2 Hex immunoprecipitation 
Previous results strongly suggest that Hex anti-serum does detect Hex protein (sections 
4.2.1 and 4.4.1). However, since the Hex over-expression experiments in Xenopus 
laevis were unsuccessful an IP using approximately 13 µg of purified Hex antibody was 




























                         Lane 1 = starting protein             Lane 2 = unbound protein 
                         Lane 3 = Tal1 anti-serum IP       Lane 4 = pre-immune IP 
 
 
Figure 4.16: Western blot analysis of Tal1 immuno-precipitation.  
200 x stage eight Xenopus tropicalis embryos were homogenised in RIPA buffer then 
Freon extracted. The embryo extract was then incubated overnight with 42 µg of 
caprylic acid purified Tal1 1st bleed anti-serum. Following centrifugation the embryo 
extract/antibody mixture was incubated with 0.02 g of Protein G SepharoseTM (GE 
Healthcare) per 200 µL of extract for 2.5 hours. Several centrifugation steps and RIPA 
buffer washes were then carried out to remove any unbound protein. The Protein G 
SepharoseTM, antibody and bound protein were then resuspended in 50 µL RIPA buffer 
and 3 x SDS loading dye was added. A control IP was also carried out using pre-
immune serum. Western blotting was then used to compare the starting protein content, 
unbound protein content and immune and pre-immune IPs. The protein samples were 
separated alongside SeeBlue® Plus2 Pre-Stained protein ladder (Invitrogen) by SDS-
PAGE. The Western blot shows that the possible Tal1 protein (*) is present in the 
starting protein content and the unbound protein content but has not bound to the 
antibody during the IP. 
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                                                 Lane 1= starting protein        
                                                 Lane 2 = unbound protein 
                                                 Lane 3 = Hex IP 
 
 
Figure 4.17: Western blot analysis of Hex immuno-precipitation.  
100 x stage eight Xenopus laevis embryos were homogenised in RIPA buffer then Freon 
extracted. The embryo extract was then incubated overnight with 13 µg of purified Hex 
antibody. Following centrifugation the embryo extract/antibody mixture was incubated 
with 0.02 g of Protein G SepharoseTM (GE Healthcare) per 200 µL of extract for 2.5 
hours. Several centrifugation steps and RIPA buffer washes were then carried out to 
remove any unbound protein. The Protein G SepharoseTM, antibody and bound protein 
were then resuspended in 50 µL RIPA buffer and 3 x SDS loading dye was added. A 
control IP was also carried out using pre-immune serum. Western blotting was then 
used to compare the starting protein content, unbound protein content and immune and 
pre-immune IPs. The protein samples were separated alongside SeeBlue® Plus2 Pre-
Stained protein ladder (Invitrogen) by SDS-PAGE. The Western blot shows that the 
protein believed to Hex (*) is present in the starting protein content, the unbound 
protein content and shows that the protein has bound to the antibody during the IP. 
* 







successful (figure 4.17), the protein believed to be Hex does bind to the antibody during 
the procedure. However, although this protein was detectable in the IP protein fraction 
by Western blot it was not detectable by staining with Coomassie blue. Therefore, the 
protein could not be removed from the gel and sent off for tryptic digest mass 
spectrometry analysis. Attempts were made at scaling up the amount of precipitated 
Hex protein but were still unsuccessful. 
 
4.9 Antibody characterisation discussion 
4.9.1 fli1  
Fli1 4th bleed anti-serum has been shown to recognise and bind to fli1 protein in both 
Xenopus laevis and Xenopus tropicalis by Western blotting. The anti-serum detects a 
protein corresponding to a Mr of approximately 51 kDa that cannot be detected when 
probing with pre-immune serum (figures 4.2 and 4.5) and the expected size of fli1 is 
50.885 kDa (NCBI). This result is consistent with results produced by Western blotting 
with a commercial fli1 antibody (ab49045-Abcam), which reacts with human fli1. 
When using ab49045 (Abcam) to probe Jurkat (Human T cell lymphoblast-like cell 
line) Whole Cell Lysate a band corresponding to a protein with a Mr of 51 kDa is 
observed (Abcam).  
 
When fli1 protein is synthesised in vitro, Western blot analysis has shown that fli1 anti-
serum is capable of detecting this protein. Furthermore, over-expression of fli1 in 
Xenopus laevis causes an increase in band intensity in the protein believed to be fli1. In 
conclusion fli1 anti-serum does detect its intended antigen. However, the anti-serum 
also detects a protein with a Mr of approximately 36 kDa that cannot be detected when 
probing with pre-immune serum (figures 4.2 and 4.5). It is unknown whether or not this 
protein is also fli1 or if the anti-serum is cross-reacting with another protein, this will be 
discussed further in chapter 6.  
 
4.9.2 Hex  
Western blot analysis has also shown that Hex 4th bleed anti-serum recognises and binds 
to a protein of the expected size to be Hex in both Xenopus laevis and Xenopus 
tropicalis. The anti-serum detects a protein corresponding to a Mr of approximately 30 
kDa (figures 4.1 and 4.4), which is not present when probing with pre-immune serum 
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and the expected size of Hex is 30.445 kDa (NCBI). This result is consistent with 
results produced by Western blotting with a commercial Hex antibody (ab34222-
Abcam), which reacts with human and mouse Hex. When using ab34222 (Abcam) to 
probe both HepG2 (Human hepatocellular liver carcinoma cell line) whole cell lysate 
and NIH 3T3 (Mouse embryonic fibroblast cell line) whole cell lysate a band 
corresponding to a protein with a Mr of 30 kDa is observed (Abcam). 
 
Furthermore, the signal intensity of the band believed to Hex can be reduced by 
knocking down Hex expression using AMOs (figure 4.7). Hex over-expression 
experiments were unsuccessful. Western blotting did show that Hex anti-serum is 
capable of detecting Hex protein produced by in vitro translation (figure 4.10) but when 
the same Hex mRNA was injected into Xenopus laevis embryos no increase in signal 
intensity was observed in the band believed to be Hex nor did a new band appear 
showing that the Hex mRNA was not being translated in embryos. The reasons for this 
are unknown. It seems unlikely that any translational control is occurring since the 
protein thought to be Hex is expressed at the stages that were analysed and previous 
experiments (Newman et al., 1997) have successfully over-expressed Hex in Xenopus 
embryos. The Hex mRNA is capable of synthesising a protein as shown by in vitro 
translation (figure 4.10), although the protein is approximately 5-10 kDa larger than the 
expected size of Hex. One possibility could be that the ORF of Hex somehow interacts 
the globin UTR preventing translaion of Hex. However, since the band observed in 
embryos is the correct size to be Hex, the signal intensity of this band is reduced 
following AMO knock down of Hex and the antibody recognises a protein produced in 
vitro from Hex mRNA, the balance of evidence would suggest that Hex anti-serum does 
detect its intended target protein. 
 
4.9.3 Tal1  
Tal1 1st bleed anti-serum does detect a protein in Xenopus tropicalis that is not present 
when probing with pre-immune serum during Western blotting. However, this protein is 
larger (just under 64 kDa) than the expected size of Tal1, which is 42.912 kDa (NCBI) 
(figure 4.6). The expected size of Xenopus Tal1 (42.912 kDa-NCBI) is different to that 
of other species, for example; the expected size of human Tal1 is 34.140 kDa, the 
expected size of mouse Tal1 is 34.148 kDa and the expected size of zebrafish Tal1 is 
35.574 kDa (NCBI). This is because of a repeat sequence in Xenopus Tal1 that is not 
present in these other species. When probing Jurkat Whole Cell Lysate with a 
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commercial human Tal1 antibody (ab75738-Abcam) a band corresponding to a protein 
with a Mr of 38 kDa is observed by Western blotting (Abcam). Since the expected size 
of human Tal1 is 34.140 kDa (NCBI) this suggests that not a big difference in size 
would be observed between the expected size of Xenopus Tal1 and the observed size of 
Xenopus Tal1.  
 
Although the anti-serum is capable of detecting Tal1 in vitro translated protein (figure 
4.13), the protein produced by in vitro translation is again smaller (just over 50 kDa) 
than the protein observed in embryos. Moreover, when Tal1 is over-expressed in 
Xenopus tropicalis embryos no signal increase is observed in the unknown protein but a 
band not present in control embryos appears in Tal1 mRNA injected embryos (figure 
4.15). These results show that Tal1 anti-serum is capable of detecting Tal1 protein but it 
is unclear whether the larger protein being detected by the anti-serum is also Tal1, 
possibly a splice variant or modified form, or if the anti-serum is cross reacting with 
another protein. This is discussed further in chapter 7. 
 
4.9.4 Lmo2 and Spi1 
There is no evidence from Western blot results to suggest that antibodies have been 









Haematopoietically Expressed Homeobox 
 
5.1 Introduction 
Western blot analysis, as discussed in chapter 4 has shown that Hex anti-serum 
recognises and binds to a protein of the correct size to be Hex in both Xenopus laevis 
and Xenopus tropicalis. The anti-serum detects a protein corresponding to a Mr of 
approximately 30 kDa (figures 4.1 and 4.4) and the expected size of Hex is 30.4 kDa 
(NCBI). This band is not observed when probing with pre-immune serum. The protein 
was confirmed as being Hex by using AMO to knock down expression of Hex protein 
in Xenopus laevis embryos then using Western blot analysis to compare protein from 
control and from Hex AMO injected embryos. Results showed a decrease in band 
intensity in the band thought to be Hex in embryos that were injected with AMO. 
Furthermore, Hex anti-serum has been shown to be capable of detecting Hex protein 
produced by in vitro translation. It was therefore concluded that Hex anti-serum does 
recognise and bind to Hex protein. All subsequent experiments using the Hex antibody 
have been carried out using the protein from Xenopus laevis embryos since fewer 
embryos are required and the embryos are easier to care for and maintain than Xenopus 
tropicalis embryos. 
 
5.2 Purification of Hex antibody 
The anti-serum produced by sheep containing the Hex antibodies also contains many 
other proteins including other immunoglobulin proteins, albumin, transferrin as well as 
other serum proteins. These proteins can bind non-specifically to proteins in embryo 
extract causing non-specific background bands to be observed on membranes that have 
been probed with either pre-immune or immune serum. In order to clean up the 
appearance of Western blots and make the anti-serum more usable in other techniques 
such as IHC, the anti-serum can be purified. This will reduce the appearance of any 
background non-specific bands or staining.  The first purification step involves carrying 
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out caprylic acid precipitation of serum proteins and the second purification step 
involves the purification of a specific antibody using affinity column chromatography. 
 
5.2.1 Caprylic acid precipitation 
The addition of caprlylic acid to serum precipitates the majority of serum proteins out of 
solution but leaving the total IgG fraction in solution (Steinbuch and Audran, 1969). 
This is the first step in antibody purification since serum lipoproteins can block 
antibody affinity columns. Section 2.7.1 describes the procedure for caprylic acid 
precipitation. This purification step alone can yield a relatively pure antibody 
preparation but in order to isolate specific IgGs the serum must be further purified using 
affinity column chromatography.  
 
5.2.2 Affinity purification of Hex antibodies 
Due to the non-covalent interactions formed between an antibody and its antigen it is 
possible to produce affinity columns containing the antigen peptide attached to a solid 
inert substance through which specific antibodies can be purified from total IgG. In 
order to isolate Hex antibodies from total IgG, Hex antigen peptide-CPG (Controlled 
Pore Glass) affinity columns were synthesised (Alta Bioscience, University of 
Birmingham). The recommended length of a peptide to be immobilised on a CPG bead 
was 30 amino acids. Since it is unknown which part of the Hex antigen antibodies have 
been raised against and since the Hex antigen peptide consists of 147 amino acids it was 
necessary to produce six affinity columns that cover the whole of the Hex antigen 
peptide sequence. The peptides also overlapped each other by five amino acids in case 
the antibodies had been raised against a part of the peptide that was split between two 
affinity columns. Figure 5.1 shows the six different peptide sequences immobilised to 
CPGs.  
 
Approximately 50 mg of total IgG was passed through each column three times to 
ensure maximal binding of Hex IgG to the column. Several PBS washes then followed 
to remove non-specific and weakly bound IgG from the column. Hex antibodies were 
then eluted from the column using 3.5 M potassium thiocyanate, which is a chaotropic 
agent capable of disrupting the non-covalent interactions between antibody and antigen. 
To prevent denaturation of the antibodies by prolonged exposure to potassium 
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thiocyanate the eluent was immediately desalted using a G-25 gel filtration column 
(section 2.7).  
 
Measuring the absorbance of the eluent at 280 nm produced two peaks in the 
absorbance profile. The first peak contained any eluted IgG and the second contained 
the potassium thiocyanate. The fractions corresponding to the first peak were quantified 
using UV spectrophotometry and were then tested for the presence of Hex antibodies by 
Western blot analysis using stage 27 whole Xenopus laevis extract.  Approximately 400 
ng of IgG per one ml of blocking solution was used to probe the blot. Results showed 
that only the affinity column containing peptide four (highlighted in figure 5.1) was 
capable of purifying Hex antibodies. Purified Hex antibody was used in all subsequent 
experiments. 
  
5.3 Hex expression during early embryonic development 
Although previous research has been carried out into the mRNA expression patterns of 
hex it is also important to analyse the protein expression patterns since the temporal and 
spatial expression patterns of an mRNA and it’s translated protein product are not 
necessarily coincident and it is protein that carries out essential functions within a cell. 
Therefore, the first question that needed to be answered using the Hex antibody was “At 
which stages of early Xenopus development is Hex protein expressed?” 
 
Previous results obtained from characterising the Hex antibody have shown Hex protein 
to be expressed in stages 6, 18 and 27 (figure 4.1). Therefore, it is already known that 
Hex must be present as a maternal protein.  This result in its self is surprising since 
Newman, et al., (1997) who first identified the hex gene report that hex transcripts are 
first expressed in the gastrula stage embryo and Jones, et al., (1999) later observed that 
hex mRNA expression begins in the animal hemisphere of stage eight embryos. 
Previous research reporting earlier expression of Hex mRNA in Xenopus is unknown. 
 
In order to analyse at which stages of development Hex protein is expressed, Western 
blotting of a developmental stage series was carried out. Eleven stages of Xenopus 
laevis early development were selected. These included; two-cell stage, stage six, stage 































Figure 5.1: Amino acid sequences of the six peptides immobilised to CPG beads for 
Hex antibody purification.  
The six peptide sequences cover the whole of the Hex antigen sequence. The peptides 
overlap each other by five amino acids. The peptides immobilised to CPG beads were 
used in attempts to affinity purify Hex antibody. Only peptide four (highlighted in the 

















Figure 5.1: Amino acid sequences of the six peptides immobilised to CPG beads for 
Hex antibody purification. The six peptide sequences cover the whole of the Hex 
antigen sequence. The peptides overlap each other by five amino acids. The peptides 
immobilise  to CPG beads were used in att mpts to affinity purify Hex antibody. Only 
peptide four ( ighlighted in the purple box) was capable of binding Hex antibody. 
 
 
                     Peptide 1 
M  Q  Y  Q  H  P  S  S  S  A  L  G  L  S  V 




                    Peptide 2 
V  H  P  T  P  F  Y  I  D  D  I   L  G  R  S 




                   Peptide 3 
T  P  T  L  P  S  P  N  S  S  F  T  S  L  V 




                    Peptide 4 
T  P   I   H  P  A  F  T  H  P  G  A  A  L  A 




                     Peptide 5 
P   L  Y  P  F  S  R  P  V  S  E  Y  T  H  A 




                     Peptide 6 
L  L  W  S  P  F  I  Q  R  P  L  H  K  R  K   
G  G  Q  V  R  F  S 
!
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of 20 embryos were collected for each stage all from the same female Xenopus laevis. 
The embryos were then homogenised and freon-extracted. For each stage two-embryo 
equivalents of protein was separated by SDS-PAGE. Western blot analysis of the 
protein samples was then carried out using Hex antibody. The result shows that Hex is 
expressed throughout early development, from two-cell stage until at least stage 40 
(figure 5.2). The expression levels of Hex appear to be fairly consistent, increasing 
slightly as development proceeds. However, there appears to be a slight peak in Hex 
expression at stage 28.  
 
5.3.1 Hex protein expression in oocytes 
Since it was shown that Hex is expressed throughout early embryo development the 
next question to be answered was “Can Hex protein also be detected in ooctyes?” 
Oocytes are immature egg precurs of cells stored in the ovarian lobes of female frogs. 
They are classified in stages from stage I to stage VI. Following surgical removal of the 
oocytes from a female Xenopus laevis the follicle cell layer must be removed from the 
oocytes by collagenase digestion as described in section 2.9. Sets of 20 oocytes were 
then collected from each developmental stage (10 oocytes from each of stages I and II 
were combined), homogenised and freon extracted. Expression of Hex was then 
examined by Western blotting. Figure 5.3 shows that Hex protein is expressed 
throughout oogenesis with expression levels increasing with advancing oocyte 
development. This oocyte and maternal expression was unexpected due to previous 
mRNA expression data but is reminiscent of another embryonic HTF, Gata2 (Partington 
et al., 1997). 
 
5.3.2 Hex mRNA expression during early development 
In order to check the current hex mRNA data, RT-PCR was carried out because 
previous research suggests that hex mRNA transcripts are present in the Xenopus laevis 
embryo no earlier than stage 8 (Newman, et al., 1997; Jones, et al., 1999; Zorn et al., 
1999).  
 
RT-PCR of a developmental stage series was carried out in order to analyse whether or 
not hex mRNA transcripts are present in embryos prior to the mid-blastula stage. Ten 
stages of Xenopus laevis early development were selected. These included; stage VI 



























Figure 5.2: Western blot using purified Hex anti-serum on whole Xenopus laevis 
embryo extract.  Protein from whole embryos (approximately two embryo equivalents) 
was separated alongside SeeBlue® Plus2 Pre-Stained protein ladder (Invitrogen) using 
SDS-PAGE and transferred to a nitrocellulose membrane. The numbers above each lane 
indicate the stage of embryonic development. The Western blot was probed with 
approximately 750 ng/ml of purified Hex anti-serum. Following removal of the primary 
antibody the blot was probed with a 1/5000 dilution of donkey anti-sheep secondary 
antibody conjugated to HRP. The blot was developed using ECL (GE Healthcare). The 
blot shows that Hex is expressed throughout early development. The expression levels 
of Hex appear to increase very slightly as development proceeds. At stage 28 a slight 
peak in expression is observed which decreases by stage 32. 



























Figure 5.3: Western blot using purified Hex anti-serum on Xenopus laevis oocyte 
extract.  Protein from whole oocytes (approximately three oocyte equivalents) was 
separated alongside SeeBlue® Plus2 Pre-Stained protein ladder (Invitrogen) using SDS-
PAGE and transferred to a nitrocellulose membrane. The Roman numerals above each 
lane indicate the stage of oocyte development. The Western blot was probed with 
approximately 750 ng/ml of purified Hex anti-serum. Following removal of the primary 
antibody the blot was probed with a 1/5000 dilution of donkey anti-sheep secondary 
antibody conjugated to HRP. The blot was developed using ECL (GE Healthcare). The 
blot shows that Hex protein is expressed in oocytes. Its expression levels although low, 
are detectable in stages I and II of oocyte development. Hex expression levels, then 
increase throughout oocyte development. 
36 kDa 
Hex 
   I/II          III            IV            V            VI 
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stage 24 and stage 32. Stage VI oocytes and unfertilised eggs were selected to be part of 
the stage series since it is possible that Hex protein is synthesised during oogenesis then 
the mRNA transcripts are degraded following fertilisation. The stage VI oocytes used in 
the RT-PCR experiment were surgically removed from a female Xenopus laevis then 
treated with collagenase (section 2.9). Any remaining follicle cells were removed 
manually. In order to check that all follicle cells had been removed the oocytes were 
stained with the fluorescent nucleic acid stain SYBR-14 (section 2.9). Figure 5.4 shows 
a comparison between a stained stage VI oocyte covered in follicle cells and a stained 
stage VI oocyte with the follicle cells removed. The stained nuclei of the follicle cells 
make the ooctye covered in follicle cells appear to be covered in green spots. These 
green spots are absent from the ooycte with removed follicle cells. Only oocytes which 
had all of the follicle cells removed were selected for the RT-PCR experiment to ensure 
that any PCR amplification was due to hex mRNA transcripts in the oocyte and not 
from the follicle cells.  
 
Preparation of RNA extracts, cDNA synthesis and RT-PCR were carried out by Dr 
Colin Sharpe as described in sections 2.8.4, 2.4.2 and 2.4.4. The primers used for RT-
PCR are listed in appendix I. The house keeping gene ornithine decarboxylase (ODC) 
was used as a control to monitor the cDNA levels in each sample. Figure 5.5a shows 
that odc is present in each developmental stage indicating that each of the cDNA 
synthesis reactions were successful. odc is absent from the two negative controls 
(cDNA synthesis reactions set up using stage VI oocyte RNA extract and stage 24 RNA 
extract minus reverse transcriptase) indicating that that the odc amplification observed 
is not due to genomic DNA or any other contamination. Figure 5.5b shows that a cDNA 
fragment of just over 500 base pairs is present in each of the developmental stages. The 
expected size of the Hex fragment is 526 base pairs showing that hex mRNA is 
expressed in stage VI oocytes, unfertilised eggs and throughout early development. The 
hex cDNA fragment appears to be slightly smaller at stage 32. hex is absent from the 
two negative controls. 
 
5.3.3 Hex immunohistochemistry 
The Hex developmental time course carried out allows the analysis of the temporal 
expression pattern of Hex, however it does not show the spatial expression pattern of 
















Figure 5.4: Stage VI oocytes were stained with SYBR-14 to reveal nuclei of the 
follicle cells of a control oocyte (left) and an oocyte from which the follicle cells 
were removed manually (right).  
The oocytes were photographed and observed under a Zeiss Lumar V12 stereoscopic 






















Figure 5.5: Reverse Transcription-Polymerase Chain Reaction carried out on a 
Xenopus laevis developmental stage series using primers for odc and hex, analysed 
by agarose gel electrophoresis and visualised by ethidium bromide staining.  
cDNA was prepared from 10 different stages of Xenopus laevis development including; 
stage VI oocytes, unfertilised eggs, 2-cell stage, stage 5, stage 8, stage 10, stage 12.5, 
stage 18, stage 24 and stage 32. Two minus reverse transcription controls were also 
prepared using stage VI oocyte RNA extract and stage 24 RNA extract. RT-PCR was 
carried out on each of the cDNA samples using primers for either odc or hex. For odc 
0.025 embryo equivalent of RNA and for hex 0.1 embryo equivalent of RNA was 
analysed by agarose gel electrophoresis alongside 100 bp ladder (M). (A) The expected 
size of the odc cDNA fragment was 228 bp and a band just above the 200 bp mark was 
observed on the gel. (B) The expected size of the hex cDNA fragment was 526 bp and a 
band just above the 500 bp mark was observed on the gel. odc and hex are expressed in 





egg M      
VI -
RT      
VI -





oocyte 5          8        10       12.5      18        24        32 

















the spatial and temporal expression patterns of a protein. IHC works in a similar manner 
to that of Western blotting but the antibody is used for the detection of protein in situ 
rather than on a membrane. IHC can be carried out on either whole Xenopus embryos or  
on embryo sections. The embryos are firstly fixed, typically using MEMFA which is a 
formaldyhyde based fixative. The process of fixing preserves the embryo as close to its 
natural state as possible by forming covalent bonds (crosslinking) between 
proteins/nucleic acids and the surrounding tissue. Once fixed, non-specific binding sites 
on the embryo are blocked prior to probing the embryo with a specific primary 
antibody. As with carrying out a Western blot a secondary antibody conjugated to an 
enzyme such as alkaline phosphatase or horseradish peroxidase is then added, which 
when incubated with an analog of the enzyme’s natural substrate allows the position of 
the primary antibody/antigen to be visualised. This would allow a direct comparison to 
be made between protein expression and mRNA expression previously analysed by in 
situ hybridisation. 
 
Wholemount IHCs were performed using the Hex antibody and pre-immune serum as a 
control. Initial attempts were carried out on various stages of MEMFA fixed embryos 
(sections 2.8.1 and 2.8.12) but no difference was observed between control and Hex 
probed embryos, an example of the non-specific staining pattern observed can be seen 
in appendix VI. Other fixatives were tested including DENTs and Bouins solution but 
again no specific staining was observed. IHC on embryo sections was carried out but 
was also unsuccessful.  
 
5.4 Hex expression in haemangioblasts and the ventral blood islands 
To overcome the problem of unsuccessful IHC experiments, embryo dissections were 
carried out. Since the focus of this thesis is analysing the expression patterns and 
activity of transcription factors in the context of early blood cell development the 
regions dissected from embryos included: the anterior-ventral regions of stage 15 and 
stage 18 embryos (figure 5.6 and figure 5.7), which contain the haemangioblasts and the 
VBI and head from stage 27 embryos (figure 5.8). Dissections were carried out as 
described in section 2.8.6. In each case 100 embryos were dissected and both the region 
of interest and the remainder of the embryo were collected, homogenised, freon 
extracted then analysed by Western blotting. Prior to protein separation by SDS-PAGE 


































Figure 5.6: Stage 15 Xenopus laevis anterior-ventral dissections.  
The anterior-ventral regions were dissected from stage 15 Xenopus laevis embryos 
using Dumont No 5 forceps. Parallel left-right incisions were made immediately 
posterior to the forming cement gland and half way down the embryo. Incisions joining 
the previous ones were made one-third the way up the dorsal-ventral axis and the 
anterior ventral region was removed. (A) Remainder of embryo once dissected. (B) 
Dissected anterior-ventral region. Western blots were then carried out using protein 




































Figure 5.7: Stage 18 Xenopus laevis anterior-ventral dissections.  
The anterior-ventral regions were dissected from stage 18 Xenopus laevis embryos 
using Dumont No 5 forceps. Parallel left-right incisions were made immediately 
posterior to the forming cement gland and half way down the embryo. Incisions joining 
the previous ones were made one-third the way up the dorsal-ventral axis and the 
anterior ventral region was removed. (A) Remainder of embryo once dissected. (B) 
Dissected anterior-ventral region. Western blots were then carried out using protein 






























Figure 5.8: Stage 27 Xenopus laevis head and VBI region dissections.  
The head and VBI region were dissected from stage 27 Xenopus laevis embryos using 
Dumont No 5 forceps. The head was removed by a cut immediately posterior to the 
branchial arches and a cut was made from the base of the ventral fin one-third to one-
half way toward the dorsal side of the embryo. The final cut was made parallel to the 
ventral to remove the region containing the VBI (A). Remainder of embryo once 
dissected. (B). Dissected head region. (C). Dissected VBI region. Western blots were 













spectrophotometery so that the samples could be normalised for total protein. The 
protein loadings were checked by SDS-PAGE and staining the gel with Coommassie 
blue (figure 5.9a).  
 
The Western blot results (figure 5.9b) reveal that Hex expression levels are greatest in 
the remainder of the embryo at stage 15, stage 18 and stage 27. However, Hex 
expression is detectable in the anterior-ventral regions of stage 15 and stage 18 
embryos. Figure 5.10 shows that hex mRNA is expressed in the anterior-ventral region 
and in the neural plate at stages 15 and 16. hex mRNA and protein expression therefore 
appear to be coincident although hex mRNA expression appears to be slightly more 
intense in the anterior-ventral region than in the neural plate so it is unexpected that Hex 
protein expression in the anterior-ventral region is less intense than in the remainder of 
the embryo. By stage 27 Hex expression levels have increased in the remainder of the 
embryo. Expression levels in the head and VBI are very similar and are greater than that 
of the anterior-ventral regions of stage 15 and stage 18 embryos. Figure 5.11 shows that 
at stage 27 hex mRNA is expressed in the head of the embryo, in the DLP, in the ventral 
region (it is unclear whether the staining is in the VBI, the vitelline veins or in both) and 
in the developing liver.  
 
5.5 Sub-cellular localisation of Hex 
The cells of a eukaryotic organism are subdivided into different membrane bound 
compartments. It is important to not only look at the tissue type within which a protein 
is expressed but also the sub-cellular localisation of a protein since this can provide 
information about the particular function of that protein. For instance, transcription 
factors can only be transcriptionally active if they are located in the nucleus of the cell 
as this is where the cell’s DNA is stored. Keeping a transcription factor out of the 
nucleus is one form of transcription regulation (reviewed in Vandrome et al., 1996).  
 
If Hex IHC experiments had of been successful this would have revealed the sub-
cellular localisation of Hex in the anterior-ventral regions and VBI. However, since they 
were not successful, the next set of experiments described focuses on the unexpected 
result that Hex protein is expressed throughout oogenesis and early development. This 
raises the following question: “is Hex transcriptionally active during oogengenis and 



































Figure 5.9: Western blot analysis of protein extracts from dissected stage 15, stage 
18 and stage 27 Xenopus laevis embryos using purified Hex antibody.  
The anterior-ventral region of 100 stage 15 and 100 stage 18 Xenopus laevis embryos 
and the head and VBI region of 100 stage 27 Xenopus laevis embryos were dissected.  
The dissected regions and the remainder of the embryos were then homogenised and 
Freon-extracted. (A) Approximately 50 µg of each protein extract was separated 
alongside BenchMark™ Protein Ladder (Invitrogen) (M) by SDS-PAGE. The gel was 
then stained with Coomassie blue in order to check that the amount of protein loaded 
from each extract was similar. (B) Approximately 75 µg of each protein extract was 
separated alongside SeeBlue® Plus2 Pre-Stained protein ladder (Invitrogen) by SDS-
PAGE then analysed by Western blotting. In each figure: Lane 1 is the remainder of 
stage 15 embryos; Lane 2 is the anterior-ventral region of stage 15 embryos; Lane 3 is 
the remainder of stage 18 embryos; Lane 4 is the anterior-ventral region of stage 18 
embryos; Lane 5 is the remainder of stage 27 embryos; Lane 6 is the head from stage 27 
embryos; and lane 7 is the VBI region from stage 27 embryos. 
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Figure 5.10: Wholemount Xenopus laevis embryo in situ hybridisation analysis of 
hex expression.  
(A) Anterior-ventral view of a stage 15 embryo. (B) Anterior-ventral view of a stage 16 
embryo. Staining can be seen in the anterior-ventral region and in the neural plate of 
stage 15 and stage 16 Xenopus laevis embryos (blue arrows indicate the anterior-ventral 
regions and yellow arrows indicate the neural plate) (images taken from XenMARK, 












































Figure 5.11: Wholemount stage 27 Xenopus laevis embryo in situ hybridisation 
analysis of hex expression.  
(A) lateral view of a stage 27 embryo. (B) Lateral view of a stage 27 embryo in 
Murray’s clear. Staining can be seen in the ventral region of the embryo (blue arrow), in 







In order to analyse the sub-cellular location of Hex during oogenesis the germinal 
vesicles (nucleus equivalent in oocytes) of 20 stage VI oocytes were carefully removed 
and separated from the cytoplasm as described in section 2.9.  Both the germinal vesicle 
and cytoplasm compartments were then homogenised and freon extracted. Western 
blots were carried out using whole stage VI oocyte extract, stage VI cytoplasm extract 
and stage VI germinal vesicle extract. As controls the blots were probed with either an 
antibody against ILF3 or the histone H3. The majority of ILF3 is known to be expressed 
in the germinal vesicle compartment during oogenesis but some protein is also 
expressed in the cytoplasm (Orford et al., 1998) and the histone H3 is found in the 
nucleus where it makes up part of the nucleosome (Widom, 1998), however maternal 
stores of H3 are also observed in the cytoplasm. Western blot results (figure 5.12) show 
that both ILF3 and the histone H3 can be detected in whole oocyte extract, in the 
cytoplasm and in the germinal vesicle as expected confirming that the germinal vesicle 
extractions were successful. Western blots could then be carried out on the extracts 
using Hex antibody. Results show that Hex expression is only observed in whole oocyte 
extract and in the cytoplasm of stage VI oocytes (figure 5.12c), indicating that although 
Hex is expressed during oogenesis it is not active as a transcription factor.  
 
Next, to analyse whether Hex is located in the cytoplasm or in the nucleus of cells of the 
pre-MBT embryo, cytosol/nuclear extracts were performed. The cytosol/nuclear 
extracts were carried out using 100 stage 7 Xenopus laevis embryos. Western blots were 
performed using the protein from whole stage 7 embryos, the cytosol fraction and the 
nuclear fraction and were then probed with an antibody against either ILF3 or the 
histone H3. At stage 7 ILF3 is only found in the cytoplasm of cells and not in the 
nucleus (Orford et al., 1998) whereas the histone H3 is found in the nucleus. Although 
results show that ILF3 is not present in the nuclear fraction they also show that the 
histone H3 cannot be detected in the nuclear fraction (data not shown). These results 
show that the cytosol/nuclear extracts were unsuccessful so could not be used for the 
analysis of Hex sub-cellular localisation. The same was true for cytosol/nuclear extracts 
made from stage 18 embryos for analysis of zygotic Hex.  
 
5.6 Analysis of Hex-containing complexes 
Transcription factors not only contain DNA-binding domains but many also contain 
































Figure 5.12: Stage VI Xenopus laevis oocyte cytosol/germinal vesicle extract 
Western blots.  
The germinal vesicles were removed from 20 stage VI Xenopus oocytes. Cytosol and 
germinal vesicles were placed in separate microcentrifuge tubes, homogenised and 
Freon-extracted. Western blots were then carried using whole stage VI oocyte extract 
(W), cytosol extract (C) and germinal vesicle extract (GV). The Western blots were 
either probed with (A) a 1:1000 dilution of histone H3 antibody (Abcam: ab1791), (B) a 
1:4000 dilution of ILF3 antibody or (C) approximately 750 ng/ml of purified Hex 
antibody. The histone H3 and ILF3 are present in whole oocyte extract, the cytosol and 
in the germinal vesicle. Hex is only present in the whole oocyte and cytosol extract and 
is absent from the germinal vesicle. 
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complexes can be formed between two or more of the same proteins (homocomplexes) 
or between different proteins, such as two or more different transcription factors or a 
transcription factor and RNA polymerase (heterocomplexes). The particular function of 
a protein can be dependent upon the complex of which it is a part. For example, whether 
a transcription factor is active as an activator or repressor of specific gene transcription. 
Gata1 is known to control haematopoietic development by activating and repressing 
gene transcription. Tripic et al., (2009) examined the composition of Gata1-associated 
protein complexes in a conditional erythroid rescue system and also used tiling arrays to 
show that a complex consisting of Tal1, Lmo2, Ldb1 and E2A was present at all 
positively acting Gata1-bound elements examined. This Tal1 protein complex is absent 
from sites where Gata1 has a negative affect demonstrating how the function of a 
transcription factor can change depending upon the complex that it is a part of.  
 
5.6.1 Maternal and zygotic Hex complex analysis 
One question that has arisen from the finding that Hex is expressed in embryos prior to 
the MBT is whether maternal and zygotic Hex are found in different protein complexes, 
therefore perhaps altering the function of Hex or its control mechanisms pre- and post-
MBT. One way in which to test whether Hex is in different complexes is to analyse the 
size of different Hex-containing complexes. This has been investigated by size 
exclusion chromatography (SEC), which is a technique used to separate proteins in 
solution according to their size differences. The agarose-based medium inside the 
column contains pores that are comparable in size to the proteins being passed through 
the column. Relatively small proteins get trapped inside the pores slowing down the rate 
at which they pass through the column whereas relatively large proteins are prevented 
from being trapped in the pores to the same degree, increasing the speed at which they 
pass through the column. Proteins that are sufficiently large are completely unable to 
enter the pores and pass straight through the column in what is referred to as the void 
volume.  
 
In order to determine the approximate size of any Hex-containing complexes the 
column was firstly calibrated. This was carried out by passing four marker proteins of 
known molecular mass through the column as described in section 2.6.7. The volume at 
which each of the proteins was eluted from the column was recorded. The table in 
figure 5.13a shows the name of each of the four marker proteins, their molecular weight 












Figure 5.13: Superose 6 10/300 GL column calibration.  
The Superose 6 10/300 GL column (GE Healthcare) was calibrated by passing four 
known standard proteins through the column and recording at what volume each of the 
proteins was eluted. (A) The table shows the name of each of the four protein standards, 
their molecular mass, log10 of their molecular mass and the volume at which each of the 
proteins was eluted. (B) The elution volume of each protein was plotted against log10 of 
its molecular mass. The line of best fit added to the graph gives an equation, which 
makes it possible to calculate the molecular mass of a protein from the volume at which 
it was eluted from the column.  
























Ferritin 440 2.64 12.71 
Catalase 232 2.37 13.95 
Aldolase 158 2.2 14.56 





graph was then constructed by plotting log10 molecular mass of the known marker 
proteins against the volumes at which they were eluted (figure 5.13b). The addition of a 
line of best fit to the graph gives an equation making it possible to calculate the 
molecular mass of a protein from the volume at which it was eluted from the column.  
 
Any calculated molecular mass of a protein or protein complex is only a rough 
estimation since the shape of a protein or protein complex can also affect the rate at 
which it passes through the column but it does allow a direct comparison at different 
stages of development. 
 
Following calibration of the Superose 6 10/300 GL column, protein extract from 150 
stage 5 Xenopus laevis embryos was prepared and separated as described in sections 
2.8.5 and 2.6.7. The protein was eluted from the column in 0.5 mL fractions. The graph 
showing the absorbance at 280 nm of the total protein eluted from the column against 
volume (mL) (figure 5.14a) indicates that total protein was eluted between 6.5 mL (B1) 
and 23.5 mL (D10). Adjacent fractions from B1 to D10 were pooled to form 1 ml 
protein samples. Protein was then precipitated from the samples using TCA as 
described in section 2.6.8. SDS-PAGE was used to separate 25 % of each protein 
sample between fractions B1 and D10. Western blot analysis of the protein samples was 
then carried out using purified Hex anti-serum (figure 5.14b). Results show that Hex 
protein was eluted from the column in fractions C5 and C6 (15 ml), C7 and C8 (16 ml) 
and C9 and C10 (17 ml). Fractions C5 and C6 correspond to a protein complex of 
approximately 121.1 kDa in which case Hex could either be in a complex with one or 
more different proteins or it could be in a tetramer Hex complex. Fractions C7 and C8 
correspond to a protein complex of approximately 67.8 kDa. The majority of Hex 
protein was eluted in these two fractions (figure 5.14). Again Hex could be bound to 
one or more different proteins or it could be present as a Hex dimmer complex. 
Fractions C9 and C10 correspond to a protein of approximately 37.9 kDa suggesting 
that Hex is present as a monomer in these two fractions (Table 5.1). The Western blot 
(figure 5.14b) also reveals a slightly larger protein than Hex detected by the anti-serum 
in fractions C9 and C10 thought to be a modified form of Hex since the anti-serum is 



















Figure 5.14: Stage 5 whole Xenopus laevis extract separated by size exclusion 
chromatography and analysed by Western blotting using purified Hex antibody. 
Protein from 150 stage 5 Xenopus laevis embryos was separated using a Superose 6 
10/300 GL (GE Healthcare). Protein was eluted from the column in 0.5 mL fractions. 
Adjacent fractions from B1 (6.5 mL) to D10 (23.5 mL) were pooled to form 1 mL 
protein samples. (A) The graph shows the absorbance at 280 nm of the total protein 
eluted from the column against volume (mL). Hex protein eluted between 14.5 mL and 
17.5 mL (*). (B) Fractions B1 to D10 were separated alongside SeeBlue® Plus2 Pre-
Stained protein ladder (Invitrogen) using SDS-PAGE then analysed by Western blotting 
using purified Hex anti-serum. The blot shows that fractions C5 and C6 (15 mL), C7 
and C8 (16 mL) and C9 and C10 (17 mL) contain Hex protein. Hex protein was not 
present in other fractions. (C) Fractions C5 and C6 (15 mL), C7 and C8 (16 mL) and C9 
and C10 (17 mL) were separated alongside BenchMark™ Protein Ladder (Invitrogen) 
(M) by SDS-PAGE then stained with Coomassie blue. 
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The same procedure was then carried out using protein extract from 150 stage 18 
Xenopus laevis embryos containing zygotic Hex and possibly maternal Hex protein. 
Total embryo protein (except protein eluted in the void volume) was again eluted 
between 6.5 mL (B1) and 23.5 mL (D10) (figure 5.15a). Protein samples were treated as 
previously described for stage 5 Xenopus laevis embryo extract. Western blots were 
carried using all protein samples between fractions B1 and D10 (figure 5.15b). Results 
reveal that Hex is eluted between fractions C5 and C10, the same fractions, which it 
was eluted when carrying out the same experiment for stage 5 Xenopus laevis embryo 
extract. There were no obvious differences between the stage 18 (potentially a mixture 
of maternal and zygotic protein) Hex containing protein complexes from the stage 5 
(maternal protein only) Hex containing protein complexes.  
 
5.6.2 Analysis of Hex-containg complexes in the haemangioblast-containing region 
In order to test whether any of the Hex-containing complexes were specific for the 
haemangioblast-containing region, size exclusion chromatography was performed using 
protein extract from the anterior-ventral region of 300 stage 18 Xenopus laevis embryos, 
and also using the remainder of the embryos. Western blotting reveals that fractions C5-
C10 contain Hex protein in the remainder of the embryo (figure 5.16), however only 
fractions C5-C8 contain Hex in the anterior-ventral region. Hex is missing from 
fractions C9 and C10 in the anterior-ventral region (figure 5.17).  
 
5.7 Discussion  
5.7.1 Hex is expressed throughout oogenesis and early development 
The initial aim of the results described in chapter 5 was to determine at which stages of 
Xenopus laevis early development Hex protein is expressed. It was found that Hex is 
expressed as early on as 2-cell stage (figure 5.2). This was an unexpected result because 
previous research suggests that hex mRNA transcripts are present in the Xenopus laevis 
embryo no earlier than stage 8 (Newman, et al., 1997; Jones, et al., 1999; Zorn et al., 
1999). This result prompted a further two experiments to be performed. 
 
Firstly, RT-PCR of a developmental stage series in order to check the current hex 
mRNA data. The developmental stage series included stage VI oocytes and unfertilised 


















Figure 5.15: Stage 18 whole Xenopus laevis extract separated by size exclusion 
chromatography and analysed by Western blotting using purified Hex antibody.  
Protein from 150 stage 5 Xenopus laevis embryos was separated using a Superose 6 
10/300 GL (GE Healthcare). Protein was eluted from the column in 0.5 mL fractions. 
Adjacent fractions from B1 (6.5 mL) to D10 (23.5 mL) were pooled to form 1 mL 
protein samples. (A) The graph shows the absorbance at 280 nm of the total protein 
eluted from the column against volume (mL). Hex protein was eluted between 14.5 mL 
and 17.5 mL (*). (B) Fractions B1 to D10 were separated alongside SeeBlue® Plus2 
Pre-Stained protein ladder (Invitrogen) using SDS-PAGE then analysed by Western 
blotting using purified Hex anti-serum. The blot shows that fractions C5 and C6 (15 
mL), C7 and C8 (16 mL) and C9 and C10 (17 mL) contain Hex protein. Hex protein 
was not present in other fractions. (C) Fractions C5 and C6 (15 mL), C7 and C8 (16 
mL) and C9 and C10 (17 mL) were separated alongside BenchMark™ Protein Ladder 
(Invitrogen) (M) by SDS-PAGE then stained with Coomassie blue. 












































Figure 5.16: Stage 18 Xenopus laevis remainder embryo extract separated by size 
exclusion chromatography and analysed by Western blotting using purified Hex 
antibody.  
The anterior-ventral region of 300 stage 18 Xenopus laevis embryos was dissected out. 
Protein extract from the remainder of the embryos was separated using a Superose 6 
10/300 GL (GE Healthcare). Protein was eluted from the column in 0.5 mL fractions. 
Adjacent fractions from B1 (6.5 mL) to D10 (23.5 mL) were pooled to form 1 mL 
protein samples. (A) The graph shows the absorbance at 280 nm of the total protein 
eluted from the column against volume (mL). Hex protein was eluted between 14.5 mL 
and 17.5 mL (*). (B) Fractions B1 to D10 were separated alongside SeeBlue® Plus2 
Pre-Stained protein ladder (Invitrogen) using SDS-PAGE then analysed by Western 
blotting using purified Hex anti-serum. The blot shows that fractions C5 and C6 (15 











































Figure 5.17: Stage 18 Xenopus laevis anterior-ventral region embryo extract 
separated by size exclusion chromatography and analysed by Western blotting 
using purified Hex antibody.  
The anterior-ventral region of 300 stage 18 Xenopus laevis embryos was dissected out. 
Protein extract from the anterior-ventral region of the embryos was separated using a 
Superose 6 10/300 GL (GE Healthcare). Protein was eluted from the column in 0.5 mL 
fractions. Adjacent fractions from B1 (6.5 mL) to D10 (23.5 mL) were pooled to form 1 
mL protein samples. (A) The graph shows the absorbance at 280 nm of the total protein 
eluted from the column against volume (mL). Hex protein was eluted between 14.5 mL 
and 16.5 mL (*). (B) Fractions B1 to D10 were separated alongside SeeBlue® Plus2 
Pre-Stained protein ladder (Invitrogen) using SDS-PAGE then analysed by Western 
blotting using purified Hex anti-serum. The blot shows that fractions C5 and C6 (15 
mL) and fractions C7 and C8 (16 mL) contain Hex protein. Hex is missing from 
fractions C9 and C10 (17 mL) in which it is present in the remainder of the embryo 
(figure 5.16). 


















degraded. Previous analysis of hex mRNA expression in the oocyte is unknown. hex 
mRNA was found to be present in stage VI oocytes, unfertilised eggs and in each of the 
developmental stages analysed (figure 5.5) indicating that hex mRNA is maternal and 
remains in the embryo following fertilisation which in turn suggests that Hex protein is 
continuously translated throughout early development. This would explain why it was 
possible knock-down expression of Hex protein using AMO in stage 7 Xenopus laevis 
embryos (figure 4.7). 
 
RNase protection assays carried out by Jones, et al., (1999) only detected hex mRNA 
from stage 9, however the authors used a probe for odc on the same samples as a control 
and no odc was detected in the stage 8 sample suggesting that there could be a problem 
with the stage 8 sample. Zorn et al., 1999 carried out RT-PCR using hex primers and 
show that hex mRNA is not expressed in stage 8 embryos but is expressed in stage 10.5 
embryos. This result is inconsistent with the RT-PCR results shown in figure 5.5 since 
the hex expression levels in this experiment appear to be very similar at stages 8 and 10. 
Assuming that Zorn et al., used the same stage 8 cDNA for performing RT-PCR for 
each of the genes they analysed then the stage 8 cDNA sample should not be the 
problem because Ef-1α mRNA was detected at stage 8. The earliest known reports of 
hex mRNA detection by in situ hybridisation are at stage 8 (Jones, et al., 1999). 
However, in situ hybridisation is not as sensitive as RT-PCR at detecting mRNA 
transcripts so this could explain why hex mRNA has not been detected prior to stage 8 
using this technique. 
 
Since Hex protein was expressed as early on as 2-cell stage this suggested that it could 
also be expressed during oogenesis. Western blots were carried out using protein extract 
from all six stages of oocyte development showing that Hex protein is expressed 
throughout oogenesis with expression levels increasing with advancing oocyte 
development (figure 5.3). This is reminiscent of another embryonic HTF, Gata2. 
Partington et al., (1997) showed that Xenopus oocytes and embryos prior to the MBT 
contain Gata2 protein, Zon et al., (1991) were able to detect gata2 mRNA by RT-PCR 
before stage 10. Partington et al., (1997) used oocyte extract prepared from isolated 
germinal vesicles to carry out their experiments, showing that maternal Gata2 protein is 
stored in the nuclei but were unable to assign a function to it. The results in this thesis 
show that Hex protein can only be detected in the cytoplasm of stage VI oocytes (figure 
5.12), indicating that Hex is not regulating transcription in oocytes. The majority of 
 153 
Gata2 was shown to be complexed but not chromatin bound, some Gata2 was available 
to function transcriptionally. Therefore, although Gata2 and Hex are both HTFs 
expressed in oocytes they appear to be carrying out different functions during 
oogenesis. The potential cytoplasmic roles of Hex are discussed in section 5.7.3. 
 
5.7.2 Hex protein is expressed in the regions containing the sites of embryonic and 
adult blood development  
In order to analyse the spatial expression pattern of Hex protein, wholemount IHC 
experiments were performed. However, these experiments were unsuccessful. No 
difference was observed between embryos probed with either Hex anti-serum or 
embryos probed with pre-immune serum. An example of the non-specific staining 
patterns observed can be seen in appendix VI. Various IHC protocols and fixatives were 
tested with no success. Furthermore, no staining was observed when probing MEMFA 
fixed wax-embedded sections.  
 
There are several possible reasons why Hex IHC experiments were unsuccessful, 
including: the antigen site recognised by the Hex antibody is folded within the native 
protein or the antigen site is hidden by another protein in a complex with Hex. 
Subsequent experiments described in section 5.6.1 reveal that the majority of Hex 
protein in the embryo is contained within a complex so this is one possible explanation 
for why IHC were unsuccessful. It is also possible that the Hex antigen-binding site is 
made inaccessible to the antibody by the crosslinks formed when using formaldyhyde 
based fixatives such as MEMFA. During the fixation process using formaldehyde based 
fixatives a profound change in the conformation of proteins occurs, meaning that their 
tertiary and quaternary structure is altered. Since some antibodies not only recognise the 
primary amino acid sequence but also the structure of their antigens, fixation can result 
in an antibody being unable to recognise its antigen (Mason and O’Leary, 1991). There 
are antigen retrieval (AR) techniques available for IHC carried out on sections that have 
been fixed using formaldehyde based fixatives. These include AR with enzymes, 
protease-induced epitope retrieval (Huang, 1975 and Huang et al., 1976) and heat-
induced epitope retrieval (Shi et al., 1991). Some alternative methods for producing 
sections to be subjected to IHC include; cryosections, which eliminate the problems 
caused by formaldehyde based fixatives or as suggested by Britten et al., (1993) 
fixation of small samples in acetone at -20 oC with protease inhibitors followed by 
embedding the sample in glycol methacrylate (GMA). Embedding in GMA is said to 
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also eliminate the problems caused by formaldehyde based fixatives and produces a 
superior morphology to that produced by frozen sections.  
 
Since Hex IHC experiments were unsuccessful it was necessary to carry out Western 
blots using protein extract from the following regions: the anterior-ventral region, which 
contains the haemangioblasts and the remainder of stage 15 and stage 18 embryos 
(figure 5.6 and figure 5.7); and the VBI, the head and the remainder of stage 27 
embryos (figure 5.8). Between stages 15 and 18 hex mRNA is expressed in the anterior-
ventral region and in the neural plate (figure 5.10). Western blot results show that Hex 
protein is expressed in the remainder of stage 15 and stage 18 embryos (figure 5.9). The 
remainder of the embryo contains the mRNA expressed in the neural plate suggesting 
that hex mRNA and Hex protein expression are coincident in this region. Hex protein is 
also expressed in the anterior-ventral region but to a much lesser extent than in the 
remainder of the embryo (figure 5.9). This result is surprising since hex mRNA 
expression in the anterior-ventral region appears to be slightly stronger than in the 
neural plate (figure 5.10). 
 
Therefore, although the data suggest that translation of zygotic hex mRNA transcripts, 
is occurring in the anterior-ventral region there could also be some form of negative 
post-transcriptional regulation controlling the amount of Hex protein being expressed. 
One other possibility is that the observed protein expression is not translated from the 
zygotic hex mRNA detected by in situ hybridisation at stages 15 and 16 (figure 5.10) 
but is the result of a persistent maternal contribution that is widely distributed 
throughout the embryo. This has been shown for both ILF3 and NAP1 during early 
Xenopus development (Orford, 1998; Steer, 2003). 
 
These data confirm that Hex is not absent from the anterior-ventral region of stage 15 
and stage 18 embryos. However, the limitation of the experiment is that the data do not 
confirm that Hex is expressed in the haemangioblasts, only that Hex protein is present 
in the dissected region containing the haemangioblasts. 
 
By stage 27, hex mRNA is expressed in the DLP, in the head of the embryo and in the 
liver. Weak expression is also detected in the ventral region but it is unclear whether the 
staining is in the VBI, the vitelline veins or in both (figure 5.11). Western blotting 
shows that at stage 27, Hex protein expression is strongest in the remainder of the 
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embryo, the region of the embryo containing hex mRNA expressed in the DLP. This 
result is consistent with hex mRNA and Hex protein expression being coincident in the 
DLP. The same limitations apply to the stage 27 dissection experiment as for the stage 
15 and stage 18 dissections, the data only confirm that Hex is not absent from the 
remainder of the embryo. Hex protein is also expressed in the ventral region and in the 
head of the embryo. Expression levels are very similar between these two regions 
(figure 5.9). The way in which the embryos were dissected means that the region of the 
embryo containing the mRNA for liver development was split between the ventral 
region and the head of the embryo (figure 5.11). Therefore, it is not possible to 
determine whether the protein expression observed in the ventral region is from mRNA 
transcripts located in the VBI/vitelline veins or in the liver or both. The same is true for 
Hex protein expression in the head. It is not possible to determine whether it is the 
mRNA transcripts in the head or in the liver or both that are being translated. However, 
there is no apparent evidence for negative Hex post-transcriptional regulation occurring 
at late tail bud stages. 
 
5.7.3 Sub-cellular localisation of Hex 
It was also necessary to analyse the sub-cellular localisation of Hex since this can give 
clues to the function or control of a protein. As stated earlier in this discussion Hex 
protein expression in stage VI oocytes is localised within the cytoplasm (figure 5.12). 
Previous studies by Ghosh et al. (2000) suggest that compartmentalisation of Hex 
protein plays an important role in its function during mouse development. In the 
developing mouse embryo, at E7.5 Hex expression in the definitive endoderm is 
predominantly cytoplasmic whereas expression in the developing VBI is confined to the 
nuclei of cells. Moreover, at E8.5 expression of Hex in the posterior region of foregut 
endodermal cells is predominantly cytoplasmic whereas staining in the anterior region 
is mostly nuclear. The authors suggest that the differential localisation of Hex is likely 
to be a mechanism for regulating its transcription regulation activity. However, the 
localisation of Hex to the cytoplasm of oocytes may also indicate that Hex is in fact 
carrying out a second function rather than just its transcription regulation activity being 
controlled.  
 
Hex is also known to play a role in inhibiting the transport of specific mRNAs required 
for cell proliferation and therefore inhibiting translation of these mRNAs. Hex carries 
out this function by regulating the activity of the eukaryotic translation initiation factor 
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4E (eIF-4E). One function of eIF-4E, which is carried out in the nucleus, is to mediate 
the nucleocytoplasmic transport of mRNA transcripts that are essential for cellular 
growth (Rousseau et al., 1996). Hex is known to interact with eIF-4E through a 
conserved binding site and inhibits this activity in myeloid cells (Topisirovic et al., 
2003; Topisirovic et al., 2005). Although in order for Hex to function as an inhibitor of 
nucleocytoplasmic mRNA transport it would have to be localised to the nucleus, it may 
be possible that a maternal store of Hex is built up in the cytoplasm during oogenesis 
and is then re-localised to the nucleus later in development when required. Hex has also 
been shown to interact with eIF-4E in the cytoplasm of U937 cells as well the nucleus 
by Co-IP suggesting that Hex may play another role in the cytoplasm of cells 
(Topisirovic et al., 2003). 
 
The localisation of eIF-4E changes during Xenopus development. In stage I and II 
oocytes eIF-4E is found in the cytoplasm but by embryonic stage 4 it has re-localised to 
the nucleus. In gastrula stages eIF-4E is mainly present in nuclear bodies (Strudwick 
and Borden, 2002) and Hex has been found in similar structures (Soufi et al., 2006). 
Topisirovic et al., (2003) suggest that the regulation of eIF-4E through interactions with 
tissue-specific regulators such as Hex may play an important role in differentiation and 
development. 
 
Attempts to analyse the sub-cellular localisation of Hex in stage 7 and stage 18 embryos 
were unsuccessful.  
 
5.7.4 Analysis of Hex-containing complexes  
The final experiments discussed in this chapter aimed to analyse whether maternal and 
zygotic Hex are in different protein complexes, since the function or control 
mechanisms of a protein can alter depending on the complex it is in. For example it is 
possible maternal and zygotic Hex are in different complexes and therefore performing 
different functions during development. The ideal experiment to investigate Hex-
containing complexes would be a protein complex immunoprecipitation (Co-IP). This 
would allow the identification of other proteins bound to Hex, however since single 
protein immunoprecipitaions were unsuccessful for Hex (figure 4.17) it was unlikely 
that a Co-IP would be successful. For this reason size exclusion chromatography was 
used to separate the protein from stage 5 and stage 18 Xenopus laevis embryos. Western 
blot analysis of the different protein fractions eluted from the column show no 
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difference in the size of Hex containing complexes in stage 5 and stage 18 embryos, 
suggesting that either there is no obvious difference between maternal and zygotic Hex 
complexes, that zygotic Hex has not yet been translated by stage 18 (figure 5.14 and 
5.15) or that the distinct complexes are unstable during chromatography. At both stage 
5 and stage 18, Hex was eluted in fractions that correspond to Hex being present as a 
monomer and up to a tetramer, although these complexes could also represent Hex 
hetero-complexes. For example, Hex has been shown to physically interact with the 
Gata family of proteins, which is associated with reduced Gata binding and 
transcriptional activity (Minami et al., 2004). 
 
Previous research by Soufi et al. (2006) has shown that Hex is capable of 
oligomerisation both in vitro and in vivo. COS-7 cells were infected with a recombinant 
adenovirus that over-expresses Myc-tagged Hex. Following separation of whole cell 
extract produced from the infected COS-7 cells by SDS-PAGE and Western blotting 
using an antibody against the Myc-tag, the blots showed that the cells contain a protein 
of the correct molecular mass to be Myc-Hex. In comparison, when the proteins in the 
infected cells were cross-linked by treatment with glutaraldehyde, Western blotting 
showed a ladder of bands corresponding to the apparent molecular masses of Hex 
monomers, dimers, trimers, tetramers and larger undistinguishable oligomers. When the 
cross-linking experiment was repeated using purified recombinant Hex protein in 
solution, again separation by SDS-PAGE and Western blotting reveals that Hex is 
present as monomers, dimers, trimers, tetramers and a larger discrete complex. These 
data are partially consistent with the results shown in figures 5.14 and 5.15 (section 
5.6). Hex protein from whole stage 5 and stage 18 Xenopus laevis extract was present in 
complexes that correspond to molecular masses of Hex monomers, dimers and 
tetramers, although these could also represent Hex hetero-complexes. However, unlike 
the results described by Soufi et al. (2006) Hex was not found to be in any complexes 
larger than approximately 121 kDa (section 5.6). Soufi et al. (2006) used analytical 
ultracentrifugation (AUC) and gel filtration experiments to show that purified Hex 
appears to from octamers and even larger oligomers.  
 
More recently, Soufi et al. (2010) have shown that these large Hex oligomers are able to 
compact DNA by binding to arrays of Hex binding sites within long DNA fragments 
and self-associating to form protein-DNA fibres. This method of compacting DNA is 
thought to contribute to the repression of gene expression by steric hinderance and is 
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similar to that used by some DNA binding proteins found in bacteria and archea such as 
the Lrp/AsnC family of proteins, which form octamers and hexadecamers and are 
involved in both gene-specific transcriptional regulation and the global control of the 
genome architecture (Thaw et al., 2006; de los Rios and Perona, 2007). 
 
The data described above (Soufi et al., 2006; Soufi et al., 2010) suggest that Hex-
containing complexes of at least 240 kDa would be observed following SEC, however 
the largest Hex-containing complex observed was approximaeteluy 121 kDa. There are 
several possible reasons why no larger Hex-containing complexes were observed. 
Firstly, the embryo extract used to carry out the SEC was not cross-linked and it is 
possible that any larger complexes are unstable during chromatography. One way in 
which to test this would be to cross-link the protein in embryos, prepare extract, 
separate the extract by SDS-PAGE then perform a Western blot using purified Hex 
antibody. One other possibility to consider is that the experiments carried out by Soufi 
et al. (2006) were performed using either over-expressed Hex protein in COS-7 cells or 
purified recombinant Hex protein in solution. Therefore, the concentration of Hex 
would be higher than that found naturally in cells and Hex was not in its normal 
physiological environment. Both of these factors could affect the way in which Hex 
oligomerises. Furthermore, it is possible that whatever function Hex is performing as an 
octamer or larger is not required during early Xenopus laevis development, hence no 
large hex oligomers were observed following SEC. 
 
Interestingly, in both stages 5 and 18 a double band is observed in the fraction where 
Hex is eluted as a monomer (fractions C9 and C10/17 mL) (figures 5.14 and 5.15). The 
second protein is approximately 10 kDa larger than Hex and is likely to be a modified 
form of Hex. One possibility is that Hex has been ubiquitinated because Ubiquitin is an 
8.5 kDa protein (Hochstrasser, 2009). Previous research reporting Hex ubiquitination is 
unknown, however UbPred (predictor of protein ubiquitination sites) predicts that Hex 
has four possible ubiquitin binding sites with medium confidence and two with high 
confidence so it does appear possible that ubiquitination of Hex can occur. There is 
evidence for Hex phosphorylation, Soufi et al. (2009) report that phosphorylation of 
Hex by CK2 inhibits its DNA binding activity and as discussed later in this thesis 
(section 7.2) there is evidence that phosphorylation can reduce the migration rate of a 
protein during SDS-PAGE. 
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Since no difference was observed between maternal and zygotic Hex containing 
complexes, whether there is a difference between Hex containing complexes in the 
region containing the haemangioblasts and the remainder of the embryo at stage 18 was 
tested. Western blot results (figures 5.16 and 5.17) show that Hex is absent from 
fractions C9 and C10 in the anterior-ventral region. Hex eluted in these fractions is 
present as a monomer showing that in the region containing the haemangioblasts all 
Hex protein is complexed with either other Hex molecules or other proteins. This may 
reflect the possibility that Hex is mainly in active complexes in the cells where 




Friend Leukemia Virus Integration 1 
 
6.1 Introduction  
The results discussed in chapter 4 demonstrate that antibodies have successfully been 
raised against Xenopus fli1. When probing Western blot membranes containing 
separated protein from stage 7, stage 18 and stage 27 whole Xenopus extract with fli1 
anti-serum a strong band corresponding to a protein of approximately 50 kDa is 
observed in all three stages of development. The expected size of fli1 is 50.885 kDa 
(NCBI). This band is not observed when probing with pre-immune serum suggesting 
that the protein detected is fli1. The protein was confirmed as being fli1 by showing that 
fli1 anti-serum is capable of detecting fli1 protein produced by in vitro translation and 
following over-expression of fli1 protein in Xenopus laevis embryos. However, as well 
as the 50 kDa protein confirmed as being fli1 the anti-serum also detects a second 
protein of approximately 36 kDa that is not present when probing with pre-immune 
serum. This 36 kDa protein is observed in stage 18 and stage 27 embryos but not stage 7 
so its presence is developmentally regulated. It is unknown whether fli1 anti-serum is 
cross-reacting with another protein, possibly an ets domain related protein, although the 
antigen sequence does not include the fli1 ets domain or if the protein is an isoform of 
fli1 generated by alternative splicing. 
 
The first set of experiments discussed in this chapter aimed to determine whether the 
observed 36 kDa band is due to the fli1 anti-serum cross-reacting with another protein 
or if it is the protein product of an alternatively spliced fli1 transcript. The second set of 
experiments aimed to use the fli1 anti-serum to analyse the spatial and temporal 
expression patterns of fli1 protein throughout early development. All subsequent fli1 
experiments have been carried out using Xenopus laevis embryos. 
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6.2 What is the 36 kDa protein detected by fli1 anti-serum? 
6.2.1 Bio-informatic research 
Fli1 bio-informatic research revealed another protein named Friend leukemia virus 
integration 1 (Xenopus laevis) (accession number: NP_001091213) on the NCBI web 
database. This protein has a calculated molecular mass of 32 kDa (NCBI) and was 
therefore a candidate for the unknown 36 kDa protein detected by fli1 anti-serum. 
BLAST was used to align the whole amino acid sequence of the 32 kDa protein named 
fli1 against translated reference mRNA sequences from all species. Results showed that 
fli1 proteins were the most similar to the 32 kDa protein, however there was only 53% 
identity between the 32 kDa protein and the Xenopus laevis 51 kDa fli1 protein. Further 
research and the construction of a cladogram (mobyle@pasteur) using the ets domain 
amino acid sequences (appendix V) of several different ETS domain proteins including 
fli1, c-ets-1, c-ets-2, erg and spib from human, mouse, chicken and Xenopus laevis 
including the unknown 32 kDa Xenopus laevis protein named fli1 revealed that the 
unknown protein is in fact three ancestral nodes away from the full length fli1 protein 
(figure 6.1). The Xenopus laevis 51 kDa fli1 protein is within the same ancestral node as 
human, mouse and chicken fli1 proteins confirming that this protein is correctly named 
as fli1. The bio-informatic evidence suggests that the 32 kDa Xenopus laevis protein has 
no apparent orthologues in any other species including Xenopus tropicalis and is 
therefore a Xenopus laevis specific fli1 paralogue, however the fli1 anti-serum also 
detects the 36 kDa protein in Xenopus tropicalis embryo extract.  
 
To determine how likely it is that the fli1 anti-serum is cross-reacting with the 32 kDa 
protein a BLAST alignment was carried out between the fli1 antigen amino acid 
sequence and translated reference mRNA sequences from Xenopus. Results showed that 
there is only 41% identity between the antigen sequence and the 32 kDa protein 
sequence compared to a 96% identity between the antigen sequence and fli1 protein 
sequence (figure 6.2). Furthermore, there are no more than three consecutive matching 
amino acids between the two sequences. It is therefore unlikely that the fli1 anti-serum 
is cross-reacting with the 32 kDa protein since antibodies typically recognise epitopes 
that are between 6-8 amino acids long. Moreover, the fli1 antigen sequence shares no 











































Figure 6.1: Cladogram of ETS domain proteins.  
The website Mobyle@pasteur was used to construct a cladogram from the ets domain 
amino acid sequences of several ETS domain proteins including fli1, c-ets-1, c-ets-2, 
erg and spib from human, mouse, chicken and Xenopus laevis in order to try and 
identify an unknown Xenopus laevis ets domain protein (∗). Although the unknown 
protein is named as fli1 on the NCBI web database the cladogram shows that the 
unknown protein is three ancestral nodes away from Xenopus laevis fli1 (∗) suggesting 






































Query  1    SHLNYLRDSSSSLGYNTQAHTDQSPRLTAKEDPSYEAVRRSGWGNSLSSPVTKSPP  56 
            SHLNYLRDSSSSLGYNTQAHTDQS RLTAKEDPSYEAVRRSGWGNS+SSPVTKSPP 









Query  1    SHLNYLRDSSSSLGYNTQ----AHTDQSPRLTAKEDPSYEAVRRSGWGNSLSSPVTKSPP  56 
            SHL YLR +S +  Y+      AH   +PR   K +P YE VRR  W +S  S    SPP 








Figure 6.2: BLAST alignment between the fli1 antigen amino acid sequence and 
Xenopus laevis fli1 protein and the unknown Xenopus laevis 32.2 kDa protein.  
(A) Blast alignment between the fli1 antigen amino acid sequence and Xenopus laevis 
fli1 protein sequence. The two sequences share 96% identity. (B) BLAST alignment 
between the fli1 antigen amino acid sequence and the unknown Xenopus laevis 32.2 
kDa protein sequence. The two sequences only share 41% identity suggesting that fli1 




Since it appears unlikely that the fli1 anti-serum is cross-reacting with another protein, 
ENSEMBL was used to investigate the possibility of the smaller protein detected by fli1 
anti-serum being an isoform of the full-length fli1 protein. There was no documented 
evidence of fli1 alternative splicing in Xenopus tropicalis and the same was true for 
mouse and chicken, however in humans there is a 43 kDa fli1 protein (protein ID: 
ENSP00000281428) as well as two 51 kDa fli1 proteins (protein ID: 
ENSP00000339627 and ENSP00000399985) and zebrafish contain three different 
isoforms of fli1 protein including a 30 kDa protein (protein ID: 
ENSDARP0000041353). The fli1 antigen sequence is present in the small human and 
zebrafish fli1 isoforms so it does appear possible that Xenopus contain a smaller 
isoform of fli1 protein. However, the documented zebrafish 30 kDa protein could be 
due to a sequencing error since the sequence that matches the full length protein stops 
part way through an exon rather than at an exon boundary. No conclusions can be made 
from the bio-informatic research about whether the fli1 anti-serum is cross-reacting 
with another protein or if it is the protein product of an alternatively spliced fli1 
transcript. 
 
6.2.2 Fli1 immunoprecipitaion  
In an attempt to try and isolate the 36 kDa protein detected by fli1 anti-serum an IP was 
carried out using the protein from 100 stage 27 Xenopus laevis embryos and 
approximately 10 µg of fli1 caprylic acid purified fli1 anti-serum as described in section 
2.6.9. Isolation of the 36 kDa protein would allow the protein to be sent off for mass 
spectrometry and identified. However, although Western blot analysis of the IP does 
show that the experiment was successful (figure 6.3), the 36 kDa protein was not 
detectable by Coomassie blue staining. Therefore, the protein could not be excised from 
the gel and sent off for mass spectrometry analysis. Attempts to scale up the experiment 
were also unsuccessful. 
 
6.2.3 Fli1 Northern blot 
Northern blotting (Alwine et al., 1977) is a technique used for the analysis of mRNA 
expression. It not only allows the quantification of mRNA expression levels but is also 
used for determining the size of transcripts and for detecting alternatively spliced 































Figure 6.3: Western blot analysis of fli1 immunoprecipitation.  
One hundred stage 27 Xenopus laevis embryos were homogenised in RIPA buffer then 
Freon extracted. Following a blocking step to remove any proteins that bind to the 
Protein G SepharoseTM, the embryo extract was incubated overnight with approximately 
10 µg of caprylic acid purified fli1 anti-serum. Following centrifugation the embryo 
extract/antibody mixture was incubated with 0.02 g of Protein G SepharoseTM (GE 
Healthcare) per 200 µL of extract for 2.5 hours. Several centrifugation steps and RIPA 
buffer washes were then carried out to remove any unbound protein. The Protein G 
SepharoseTM, antibody and bound protein were then resuspended in 50 µL RIPA buffer 
and 3 x SDS loading dye was added. A control IP was also carried out using pre-
immune serum. Western blotting was then used to compare the starting protein content 
(1), protein content following the blocking step (2) unbound protein content (3) and 
immune (4) and pre-immune (5) IPs. The protein samples were separated alongside 
SeeBlue® Plus2 Pre-Stained protein ladder (Invitrogen) by SDS-PAGE. The Western 
blot shows that fli1 (*) and the 36 kDa protein (**) are present in the starting protein 
content. The 36 kDa protein is present in the unbound fraction, however some protein 
has bound to the antibody during the IP.  














Ten oocytes at stage VI and ten embryos at each of the following stages; 2-cell stage, 
stage 6, stage 10, stage 14, stage 18, stage 24, stage 28, stage 32 and stage 38 were 
collected and the RNA isolated as described in section 2.8.4. This developmental time 
course would allow the analysis of RNA from several pre and post MBT stages. The 
RNA was separated by denaturing gel electrophoresis, visualised under UV illumination 
and was then transferred to a piece of nylon membrane via upward capillary transfer as 
described in section 2.4.17. Once the RNA was cross-linked to the membrane the blot 
was pre-hybridised to block all non-specific sites. The blot was then probed with an [α-
32P]-dCTP labeled fli1 probe. 
 
Following the removal of excess probe the image of radio labelled probe hybridised to 
RNA was transferred over a two-week period onto an imaging plate (Fujifilm). The 
image on the plate was then visualised using a Fujifilm FLA-5000. The results of the 
fli1 northern blot (data not shown) show that the fli1 probe had only hybridized non-
specifically to the ribosomal RNA meaning that the amount of fli1 mRNA present in 
embryos is below the level of detection by northern blot analysis. Due to limited time 
the fli1 northern blot experiment was not repeated however, if it were to be repeated 
then isolated poly(A)+ RNA would be used instead of total RNA. 
 
No conclusions can be drawn from the bio-informatic research, the fli1 IP or the fli1 
northern blot about whether the observed 36 kDa band is due to the fli1 anti-serum 
cross-reacting with another protein or if it is the protein product of an alternatively 
spliced fli1 transcript. 
 
6.3 Fli1 expression during early embryonic development 
Attempts were made to affinity purify the fli1 anti-serum but these were unsuccessful. 
Therefore, all subsequent experiments have been carried using caprylic acid purified 
fli1 anti-serum. 
 
In order to determine at which stages of Xenopus laevis early development fli1 protein 
is expressed, Western blotting of a developmental stage series was carried out using the 
same protein samples as described in section 5.3. Previous results obtained from 
characterising the fli1 anti-serum had shown fli1 protein to be expressed in stage 6, 
stage 18 and stage 27 embryos (figure 4.2). The result of the developmental time course 
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shows that fli1 is expressed throughout early development, from the two-cell stage until 
at least stage 40 (figure 6.4). The expression levels of fli1 appear to be fairly constant, 
increasing slightly as development proceeds. The expression of fli1 protein from two-
cell stage is an unexpected result since Meyer et al., 1993 and Meyer et al., 1995 report 
that fli1 transcripts are only detectable in Xenopus by in situ hybridisation from early 
neurula stages. Previous research reporting earlier expression of fli1 mRNA in Xenopus 
is unknown. 
 
There appears to be a strong peak in fli1 expression at stage 28, a small peak in Hex 
expression was also observed at this stage. This appears to be a genuine result rather 
that a problem with the stage 28 protein sample because the band produced by non-
specific binding of the fli1 anti-serum is no stronger in stage 28 than in any of the other 
stages. If the stage 28-protein sample had a higher overall total protein concentration 
then the intensity of the non-specific band would also be increased. In order to confirm 
this result a developmental time course was collected by incubating embryos at 23 oC 
then collecting 10 embryos at approximately 1.5-hour intervals between stage 24 and 
stage 31. The embryos were then homogenised, freon-extracted and Western blotting 
carried out using fli1 ant-serum. The result of this developmental time course (figure 
6.5) reveals that fli1 expression levels are not consistent between stages 24 and 31. 
There does still appear to be a peak in expression at around about stage 28 
(approximately 4.5 hours after the start point) although the peak is not as intense as the 
peak observed in figure 6.4. Furthermore, fli1 expression is almost completely lost 
between 1.5 and 3 hours after the start point. Again this appears to be a genuine result 
since the non-specific band is not reduced in intensity but in fact appears to be slightly 
stronger. The whole experiment was repeated in order to confirm the result. Figure 6.5b 
shows that the experiment was repeatable. There is a slight peak in fli1 expression 
approximately 4.5 hours after the start point and fli1 expression is lost between 1.5 and 
3 hours after the start point.  
 
6.3.1 Fli1 in situ hybridisation 
Whilst repeating the developmental time course between stages 24 and 31 embryos 
were also fixed in MEMFA (section 2.8.10) at the same time points as embryos were 
collected for protein analysis. The fixed embryos were to be used for fli1 in situ 
hybridisations to analyse whether there are any changes in fli1 mRNA expression at the 



























Figure 6.4: Western blots using fli1 anti-serum on whole Xenopus laevis embryo 
extract.  
(A) Protein from whole embryos (approximately two embryo equivalents) was 
separated alongside SeeBlue® Plus2 Pre-Stained protein ladder (Invitrogen) using SDS-
PAGE and transferred to a nitrocellulose membrane. The numbers above each lane 
indicate the stage of embryonic development. The Western blot was probed with 
approximately 5 µg/ml of caprylic acid purified fli1 anti-serum. Following removal of 
the primary antibody the blot was probed with a 1/5000 dilution of donkey anti-sheep 
secondary antibody conjugated to HRP. The blot was developed using ECL (GE 
Healthcare). The blot shows that fli1 (∗) is expressed throughout early development. 
The expression levels of fli1 appear to increase very slightly as development proceeds. 
At stage 28 a large peak in expression is observed which has decreased by stage 32. (B) 
The Western blot was repeated using the same protein samples as previously used. A 
peak in fli1 expression levels is again observed at stage 28.  
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Figure 6.5: Western blots using fli1 and Hex anti-serum on whole Xenopus laevis 
embryo extract between stage 24/25 and stage 31.  
(A) Xenopus laevis embryos were incubated at 23 oC then 10 embryos were collected at 
approximately 1.5-hour intervals between stage 24 (1) and stage 31 (7). Numbers 2-6 
represent 1.5-hour intervals between the start and end point of collection. The embryos 
were then homogenised, Freon-extracted and Western blotting was carried out by 
separating the protein samples alongside SeeBlue® Plus2 Pre-Stained protein ladder 
(Invitrogen) by SDS-PAGE, transferring the protein to nitrocellulose membrane then 
probing the Western blot with fli1 anti-serum. Fli1 protein is present in lanes 1, 4, 5, 6 
and 7. Fli1 protein is absent from lanes 2 and 3. A slight peak in fli1 expression is 
observed in lane 4. (B) Repeat of the previously described experiment. (C) The protein 
samples from the experiment in B were probed with Hex anti-serum as a control. Hex 
protein is present in lanes 1-7. 
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described in section 2.8.13. The results shown in figure 6.6 reveal that fli1 mRNA is 
expressed in the head of the embryo, the DLP and in the vitelline veins surrounding the 
VBI. There appears to be no loss of fli1 mRNA expression at the time points when fli1 
protein expression is absent (1.5-3 hours after the start point at stage 24). This suggests 
not only that the fli1 protein present in the embryo at stage 24 is being degraded but 
also that some form of negative fli1 post-transcriptional regulation is occurring.  
 
6.3.2 Fli1 expression in oocytes 
Using the same oocyte protein samples as described in section 5.3.2 Western blotting 
was carried in order to analyse whether fli1 protein is detectable during oogenesis. The 
result was similar to that observed with Hex (figure 5.3). Fli1 protein is expressed 
throughout oogenesis with expression levels increasing with advancing oocyte 
development (figure 6.7). 
 
6.3.3 Fli1 mRNA expression during early development 
In order to check the current fli1 mRNA data, RT-PCR was carried out using the same 
cDNA samples as described in section 5.3.2. RT-PCR was performed by Dr Colin 
Sharpe. Figure 6.8 shows that a cDNA fragment of just over 500 base pairs is present in 
stage VI oocytes, unfertilised eggs, stage 12.5, stage 18, stage 24, and stage 32 
embryos. The expected size of the fli1 cDNA fragment is 514 base pairs. The fli1 cDNA 
fragment is absent from 2-cell stage embryos and stage 5, stage 8 and stage 10 embryos. 
It is also absent from both negative controls (see figure 5.5a for odc control). This result 
suggests that fli1 protein is synthesised during oogenesis then the mRNA gets degraded 
following fertilisation. fli1 mRNA expression appears to dramatically increase between 
stage 12.5 and stage 32. Figure 6.8 also shows that larger than expected cDNA 
fragments are present in stage VI oocytes (*) and in stage 24 and 32 embryos (**).  
 
6.3.4 Fli1 immunohistochemistry 
IHC experiments carried out for fli1 were unsuccessful. MEMFA, DENTs and Bouins 
fixatives were tested but no specific staining was observed (an example of the non-
specific staining observed in MEMFA fixed embryos can be seen in appendix VI). IHC 











































Figure 6.6: Wholemount in situ hybridization showing fli1 mRNA expression 
between stage 24 and stage 31 of Xenopus development.  
Xenopus laevis embryos incubated at 23 oC were collected at 1.5-hour intervals between 
stage 24 and stage 31 then fixed in MEMFA. Wholemount in situ hybridisations were 
carried using a fli1 probe. The numbers in the top left hand corner of each image 
indicate the length of time after the start point (stage 24) that the embryos were 
collected. Fli1 mRNA is expressed in the head of the embryo, the DLP and in the 


































Figure 6.7: Western blot using fli11 anti-serum on Xenopus laevis oocyte extract.   
Protein from whole oocytes (approximately three oocyte equivalents) was separated 
alongside SeeBlue® Plus2 Pre-Stained protein ladder (Invitrogen) using SDS-PAGE 
and transferred to a nitrocellulose membrane. The Roman numerals above each lane 
indicate the stage of oocyte development. The Western blot was probed with 
approximately 100 µg/ml of caprylic acid purified fli1 anti-serum. Following removal 
of the primary antibody the blot was probed with a 1/5000 dilution of donkey anti-sheep 
secondary antibody conjugated to HRP. The blot was developed using ECL (GE 
Healthcare). The blot shows that fli1 protein is expressed in oocytes. Its expression 
levels although low are detectable in stages I and II of oocyte development. Fli1 
expression levels then increase throughout oocyte development. 
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Figure 6.8: Reverse Transcription-Polymerase Chain Reaction carried out on a 
Xenopus laevis developmental stage series using primers for fli1, analysed by 
agarose gel electrophoresis and visualised by ethidium bromide staining.  
cDNA was prepared from 10 different stages of Xenopus laevis development including; 
stage VI oocytes, unfertilised eggs, 2-cell stage, stage 5, stage 8, stage 10, stage 12.5, 
stage 18, stage 24 and stage 32. Two minus reverse transcription controls were also 
prepared using stage VI oocyte RNA extract and stage 24 RNA extract. RT-PCR was 
carried out on each of the cDNA samples using primers for fli1 (see figure 5.5 for odc 
control). RNA equivalent to 0.1 of an embryo was analysed by agarose gel 
electrophoresis alongside 100 bp ladder (M). The expected size of the fli1 cDNA 
fragment was 514 bp and a band just above the 500 bp mark was observed on the gel. 
Fli1 expression is observed in stage VI oocytes and in unfertilised eggs then disappears 
by 2-cell stage and reappears by stage 12.5. Larger than expected cDNA fragments are 
observed in stage VI oocytes (*) and in stage 24 and 32 embryos (**). Fli1 cDNA is 
absent from the negative controls. 
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6.4 Fli1 expression in the haemangioblasts and ventral blood islands 
Since IHC experiments were also unsuccessful for fli1 as with Hex, the expression of 
fli1 in the haemangioblasts and the VBI was analysed by carrying out Western blots 
using the same protein samples from dissected embryos as described in section 5.4 
(figures 5.6-5.8). Western blotting reveals that fli1 is expressed in the region containing 
the haemangioblasts at stage 15 and at stage 18 as well as in the remainder of the 
embryo. At stage 27 fli1 is expressed in the ventral region, the head and the remainder 
of the embryo (figure 6.9).  
 
Wholemount in situ hybridisation experiments performed using a fli1 probe (XenMark, 
submitted by Prof. Roger Patient lab) show that fli1 mRNA is only expressed in the 
anterior-ventral region and in the neural plate of stage 15 and stage 17 Xenopus laevis 
embryos (figure 6.10), suggesting that fli1 mRNA and fli1 protein expression are 
coincident in both the anterior-ventral region and the remainder of the embryo. Figures 
1.7a and 6.6 both show that between stages 26 and 28 fli1 mRNA is expressed in the 
head of the embryo, in the DLP and in the viteline veins which surround the VBI, again 
suggesting that fli1 mRNA and fli1 protein expression are coincident since fli1 protein 
is present in the head, the remainder of the embryo and in the ventral region.  
 
6.5 Sub-cellular localisation of fli1 
The sub-cellular localisation of fli1 in oocytes was analysed by carrying out Western 
blots using cytosol extract and germinal vesicle extract of stage VI oocytes (section 
2.?). Results showed that the majority of fli1 protein is localised to the cytoplasm but 
some fli1 protein was present in the germinal vesicle (figure 6.11). The controls for this 
experiment are described in section 5.5 (figure 5.12). Attempts to analyse the sub-
cellular localisation of fli1 in stage 7 and stage 18 embryos were unsuccessful. 
 
6.6 Fli1 complex analysis 
6.6.1 Maternal and zygotic fli1 complex analysis 
Since fli1 has been shown to be present as a maternal protein during embryonic 





































Figure 6.9: Western blot analysis of protein extracts from dissected stage 15, stage 
18 and stage 27 Xenopus laevis embryos using caprylic acid purified fli1 antibody. 
The anterior-ventral region of 100 stage 15 and 100 stage 18 Xenopus laevis embryos 
and the head and VBI region of 100 stage 27 Xenopus laevis embryos were dissected.  
The dissected regions and the remainder of the embryos were then homogenised and 
Freon-extracted. (A) Approximately 50 µg of each protein extract was separated 
alongside BenchMark™ Protein Ladder (Invitrogen) (M) by SDS-PAGE. The gel was 
then stained with Coomassie blue in order to check that the amount of protein loaded 
from each extract was similar. (B) Approximately 75 µg of each protein extract was 
separated alongside SeeBlue® Plus2 Pre-Stained protein ladder (Invitrogen) by SDS-
PAGE then analysed by Western blotting. In each figure: Lane 1 is the remainder of 
stage 15 embryos; lane 2 is the anterior-ventral region of stage 15 embryos; lane 3 is the 
remainder of stage 18 embryos; lane 4 is the anterior-ventral region of stage 18 
embryos; lane 5 is the remainder of stage 27 embryos; lane 6 is the head from stage 27 
embryos; and lane 7 is the VBI region from stage 27 embryos. 
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Figure 6.10: Wholemount Xenopus laevis embryo in situ hybridisation analysis of  
fli1 expression.  
(A) Anterior-ventral view of a stage 15 embryo. (B) Anterior-ventral view of a stage 17 
embryo. Staining can be seen in the anterior-ventral region and in the neural plate of 
stage 15 and stage 17 Xenopus laevis embryos (blue arrows indicate the anterior-ventral 
regions and green arrows indicate the neural plate) (images taken from XenMARK, 


































Figure 6.11: Stage VI Xenopus laevis oocyte cytosol/germinal vesicle extract 
Western blot probed with fli1 anti-serum.  
The germinal vesicles were removed from 20 stage VI Xenopus laevis oocytes. Cytosol 
and germinal vesicles were placed in separate microcentrifuge tubes, homogenised and 
Freon-extracted. The Western blot was then carried using cytosol extract (C) and 
germinal vesicle extract (GV). The Western blot was probed with fli1 anti-serum. The 
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allow the protein to carry out different functions or have distinct control mechanisms 
before and after the MBT. In order to analyse this, the same protein samples that were 
used for the analysis of different sized Hex-containing complexes in stage 5 and stage 
18 Xenopus laevis embryos (section 5.6.1) were used in Western blot experiments for 
fli1. The results shown in figures 6.12 and 6.13 reveal that fli1 was eluted from the 
Superose 6 10/300 GL column between 14.5 mL and 17.5 mL (fractions C5-C10) for 
both stage 5 and stage 18 Xenopus laevis embryo extract, the same volume that Hex was 
eluted from the column for both stages. As previously described for Hex in section 5.6 
fractions C5-C6 (15 mL) correspond to a protein complex of approximately 121.1 kDa, 
therefore fli1 could either be in a complex with one or more different proteins or it 
could be in a tetramer fli1 complex. Fractions C7 and C8 (16 mL) correspond to a 
protein complex of approximately 67.8 kDa. The majority of fli1 protein was eluted in 
these two fractions. Again fli1 could be bound to one or more different proteins or it 
could be present as a fli1 dimmer complex. A small amount of fli1 was present in 
fractions C9 and C10 (17 mL), which correspond to a protein of approximately 37.9 
kDa suggesting that fli1 is also present as a monomer in both stage 5 and stage 18 
embryos (Table 5.1). Although no other bands of the correct size to be fli1 are present 
in other fractions the anti-serum does detect other proteins. Since the fli1 anti-serum is 
not purified it is not possible to interpret whether these are all non-specific bands or if 
there are also modified forms of fli1 present in other fractions.  
 
6.6.2 Analysis of fli1 complexes in the haemangioblast-containing region 
In order to test whether any of the fli1-containing complexes were specific for blood 
development, the same protein samples that were used for analysis of Hex-containing 
complexes in blood development (section 5.6.2) were used to carry out fli1 Western 
blots. Figure 6.14 shows that fli1 protein from the remainder of stage 18 embryos was 
eluted in fractions C5-C10 (14.5 mL-17.5 mL), the same fractions that fli1 was eluted 
when separating the protein from whole stage 5 and stage 18 embryos. There also 
appears to be a small amount of fli1 in fractions C3-C4 and fractions C11-C12. The 
majority of fli1 was eluted in fractions C7-C8 (16 mL). Fli1 protein from the anterior-
ventral region of stage 18 embryos was also eluted in fractions C5-C10. However, 
although the amount of fli1 protein present in fractions C5-C6 (15 mL) appears to be 
















Figure 6.12: Stage 5 whole Xenopus laevis extract separated by size exclusion 
chromatography and analysed by Western blotting using fli1 anti-serum.  
Protein from 150 stage 5 Xenopus laevis embryos was separated using a Superose 6 
10/300 GL (GE Healthcare). Protein was eluted from the column in 0.5 mL fractions. 
Adjacent fractions from B1 (6.5 mL) to D10 (23.5 mL) were pooled to form 1 mL 
protein samples. (A) The graph shows the absorbance at 280 nm of the total protein 
eluted from the column against volume (mL). Fli1 protein was eluted between 14.5 ml 
and 17.5 mL (*). (B) Fractions B1 to D10 were separated alongside SeeBlue® Plus2 
Pre-Stained protein ladder (Invitrogen) using SDS-PAGE then analysed by Western 
blotting using fli1 anti-serum. The blot shows that fractions C5 and C6 (15 mL), C7 and 
C8 (16 mL) and C9 and C10 (17 mL) contain fli1 protein. Protein of the correct size to 
be fli1 was not present in any other fractions.  



































Figure 6.13: Stage 18 whole Xenopus laevis extract separated by size exclusion 
chromatography and analysed by Western blotting using fli1 anti-serum.  
Protein from 150 stage 18 Xenopus laevis embryos was separated using a Superose 6 
10/300 GL (GE Healthcare). Protein was eluted from the column in 0.5 mL fractions. 
Adjacent fractions from B1 (6.5 mL) to D10 (23.5 mL) were pooled to form 1 mL 
protein samples. (A) The graph shows the absorbance at 280 nm of the total protein 
eluted from the column against volume (mL). Fli1 protein was eluted between 14.5 mL 
and 17.5 mL (*). (B) Fractions B1 to D10 were separated alongside SeeBlue® Plus2 
Pre-Stained protein ladder (Invitrogen) using SDS-PAGE then analysed by Western 
blotting using fli1 anti-serum. The blot shows that fractions C5 and C6 (15 mL), C7 and 
C8 (16 mL) and C9 and C10 (17 mL) contain fli1 protein. Protein of the correct size to 
be fli1 was not present in any other fractions. 
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Figure 6.14: Stage 18 Xenopus laevis remainder embryo extract separated by size 
exclusion chromatography and analysed by Western blotting using fli1 anti-serum.  
The anterior-ventral region of 300 stage 18 Xenopus laevis embryos was dissected out. 
Protein extract from the remainder of the embryos was separated using a Superose 6 
10/300 GL (GE Healthcare). Protein was eluted from the column in 0.5 mL fractions. 
Adjacent fractions from B1 (6.5 mL) to D10 (23.5 mL) were pooled to form 1 mL 
protein samples. (A) The graph shows the absorbance at 280 nm of the total protein 
eluted from the column against volume (mL). Fli1 protein was eluted between 14.5 mL 
and 17.5 mL (*). (B) Fractions B1 to D10 were separated alongside SeeBlue® Plus2 
Pre-Stained protein ladder (Invitrogen) using SDS-PAGE then analysed by Western 
blotting using fli1 anti-serum. The blot shows that fractions C5 and C6 (15 mL), C7 and 
C8 (16 mL) and C9 and C10 (17 mL) contain fli1 protein.  
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C8 (16 mL) is greatly reduced in the anterior-ventral region and fli1 is barely detectable 
in fractions C9-C10 (17 mL) in the anterior-ventral region (figure 6.15). 
 
6.7 Discussion  
6.7.1 Fli1 is expressed throughout oogenesis and early development 
As was observed for Hex, fli1 protein is expressed during oogenesis and early 
embryonic development (figures 6.4 and 6.7). Again this was an unexpected result since 
Meyer et al., 1993 and Meyer et al., 1995 report that fli1 transcripts are only detectable 
in Xenopus by in situ hybridisation from early neurula stages. However, Meyer et al., 
1993 originally identified the Xenopus fli1 homolouge from a cDNA library prepared 
from unfertlised eggs suggesting that fli1 mRNA is expressed during oogenesis. Since 
RT-PCR is a more sensitive technique at detecting mRNA transcripts than in situ 
hybridisation, RT-PCR on a developmental stage series was carried out. The 
developmental stage series included stage VI oocytes and unfertilised eggs in case fli1 
protein is synthesised during oogenesis and the mRNA then gets degraded. The results 
shown in figure 6.8 show that indeed it does appear to be the case that fli1 protein is 
translated during oogenesis from fli1 mRNA transcripts present in oocytes. The fli1 
mRNA transcripts degrade following fertilisation whereas the fli1 protein is stable and 
persists in the embryo through early development (figure 6.4). Zygotic fli1 mRNA is 
transcribed by stage 12.5 (figure 6.8). These data are consistent with results produced 
by Meyer et al., 1993 and Meyer et al., 1995. These data are also consistent with fli1 
knock-down results described in section 4.4.2. It was not possible to decrease fli1 
protein expression in stage 7 and stage 17 embryos using AMO because it appears that a 
stable form of fli1 protein already exists in the embryo. The results shown in figure 6.8 
show that larger than expected cDNA fragments are also observed in stage VI oocytes 
(*) and in stage 24 and 32 embryos (**) suggesting the possibility of larger fli1 splice 
variants. Although it is also possible that the larger DNA fragment observed in stage VI 
oocytes is fli1 pre-mRNA. 
 
Interestingly, there appeared to be a peak in fli1 protein expression at stage 28 (figure 
6.4). This result was checked by carrying out an intensively sampled developmental 
time-course between stages 24 and 31 (figure 6.5). There is a slight peak in fli1 
expression at stage 28 but even more interesting was the absence of fli1 expression 

















Figure 6.15: Stage 18 Xenopus laevis anterior-ventral region embryo extract 
separated by size exclusion chromatography and analysed by Western blotting 
using fli1 anti-serum.  
The anterior-ventral region of 300 stage 18 Xenopus laevis embryos was dissected out. 
Protein extract from the anterior-ventral region of the embryos was separated using a 
Superose 6 10/300 GL (GE Healthcare). Protein was eluted from the column in 0.5 mL 
fractions. Adjacent fractions from B1 (6.5 mL) to D10 (23.5 mL) were pooled to form 1 
mL protein samples. (A) The graph shows the absorbance at 280 nm of the total protein 
eluted from the column against volume (mL). Fli1 protein was eluted between 14.5 mL 
and 16.5 mL (*). (B) Fractions B1 to D10 were separated alongside SeeBlue® Plus2 
Pre-Stained protein ladder (Invitrogen) using SDS-PAGE then analysed by Western 
blotting using fli1 anti-serum. The blot shows that fractions C5 and C6 (15 mL) and 
fractions C7 and C8 (16 mL) contain fli1 protein. A small amount of fli1 can be 
























the same stages confirm that the loss of fli1 protein expression is not due to loss of fli1 
mRNA expression (figure 6.6) and that some form of negative fli1 post-transcriptional 
regulation must be occurring to stop translation of fli1 and/or the existing, stable fli1 
protein must be degraded by some mechanism. Previous research reporting this effect 
for any other protein during development is unknown and the reason for down-
regulating fli1 expression for such a short period of time is unknown.  One possibility is 
that the embryo is disposing of all maternal fli1 protein, or perhaps the first function of 
fli1 (maternal or zygotic) is required for the development of the haemangioblasts in the 
anterior-ventral region of the embryo then all fli1 protein is cleared before it is needed 
for endothelial development in the ventral region and blood development in the DLP. 
The possible mechanisms for negative control over fli1 translation and degradation of 
fli1 protein are discussed in section 8.2. 
 
6.7.2 fli1 protein is expressed in the regions containing the sites of embryonic and 
adult blood development 
IHC experiments were also unsuccessful for fli1 (appendix VI). Therefore in order to 
analyse whether fli1 protein is expressed in the regions of the embryo containing the 
sites for embryonic and adult blood development, Western blots were carried out using 
the anterior-ventral region and the remainder of stage 15 and stage 18 embryos (figure 
5.6 and figure 5.7); and the VBI, the head and the remainder of stage 27 embryos 
(figure 5.8). Between stages 15 and 18 the fli1 mRNA expression pattern is very similar 
to that of hex. Fli1 mRNA is expressed in the anterior-ventral region and in the neural 
plate (figure 6.10). Western blot results show that fli1 protein is expressed in the 
remainder of stage 15 and stage 18 embryos and in the anterior-ventral region. Fli1 
expression levels in these two regions appear to be very similar (figure 6.9). These data 
confirm that fli1 protein is not absent from the region containing the haemangioblasts or 
the remainder of the embryo. Therefore, it is possible that fli1 mRNA expression and 
fli1 protein expression are coincident, in which case no post-transcriptional control over 
fli1 expression is occurring at neurular stages.  However, the possibility that the fli1 
protein being detected is from a persistent maternal contribution that is widely 
distributed throughout the embryo cannot be excluded. 
 
At stage 27, fli1 and hex mRNA expression patterns are again very similar. Fli1 is 
expressed in the DLP, in the head of the embryo and in the vitelline veins. Fli1 mRNA 
expression is however absent from the developing liver but is stronger than hex in the 
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viteline veins (figures 1.7a and 6.6). Western blotting shows that at stage 27 fli1 protein 
expression levels are very similar in the remainder of the embryo, which contains fli1 
mRNA expressed in the DLP, in the head of the embryo and in the ventral region, 
which contains fli1 mRNA expressed in the viteline veins. Again these data only 
confirm that fli1 protein is not absent from these regions but would suggest that fli1 
mRNA expression and fli1 protein expression are coincident at stage 27. There is no 
apparent evidence for fli1 post-transcriptional regulation occurring at this stage although 
the results discussed in sections 6.3 and 6.7.1) provide evidence that fli1 post-
transcriptional control is occurring at early tail-bud stages. 
 
6.7.3 Sub-cellular localisation of fli1 
It was also necessary to analyse the sub-cellular localisation of fli1 as this may give 
some indication of the function/control of fli1 during development. Fli1 protein was 
shown to be expressed throughout oogenesis (figure 6.7). Western blots carried out 
using cytosol extract and germinal vesicle extract of stage VI oocytes show that the 
majority of fli1 protein is located in the cytoplasm but there is some fli1 present in the 
germinal vesicle (figure 6.11). This is not due to contamination since Hex was 
completely absent from the same extract. It is therefore possible that some fli1 protein is 
available to function transcriptionally during oogenesis. One way in which to test this 
would be to carry out a promoter activity assay. Briefly, this experiment would involve 
cloning the cognate fli1 DNA binding sequence in front of the firefly luciferase gene 
(reporter gene), injecting the DNA construct into oocytes together with a ubiquitous 
control, lysing an appropriate number of oocytes, starting the luminescence reaction and 
measuring the amount of activity using a luminometer. Luminescence will only be 
detected if fli1 protein is transcriptionally active since the reporter gene can only be 
switched on by fli1.  
 
The fli1 protein localised to the cytoplasm in oocytes could be a mechanism for 
controlling the amount of fli1 protein available in the nucleus to function as a regulator 
of transcription, or could possibly be a store of fli1 for use later in development. It is 
also possible that fli1 has an alternative function to acting as a transcription factor, and 
that, that function requires fli1 to be located in the cytoplasm of cells. 
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6.7.4 Analysis of fli1-containing complexes  
The difference between maternal and zygotic fli1-containing complexes was analysed 
as was done for Hex (section 5.6) using SEC because the function or control 
mechanisms of fli1 could alter depending on the complex it is part of and this may be 
the factor distinguishing between maternal and zygotic fli1 activity. Western blot results 
showed that there was no obvious difference between maternal and zygotic fli1 
containing complexes (figures 6.12 and 6.13). For both stage 5 and stage 18 embryo 
extract, fli1 was eluted from the SEC column in volumes that correspond approximately 
to fli1 being present as a monomer and up to a tetramer, although these complexes 
could also represent fli1 hetero-complexes. Examples of previously reported fli1 hetero-
complexes include; fli1 and Gata1 interactions which are thought to activate the 
expression of megakaryocyte-specific genes (Eisbacher et al., 2003) and fli1 and Runx1 
interactions which are thought to be important for normal megakaryocyte development 
(Huang et al., 2009). Also the SUMO E3 ligase, PIASxα/ARIP3 has been shown to 
physically interact with fli1 and repress its transcription activity by re-localising fli1 
into PIASxα nuclear bodies (van den Akker et al., 2005). As previously mentioned for 
Hex, the reasons for observing no difference between the two stages could be that either 
there is no obvious difference between maternal and zygotic fli1 complexes, that 
zygotic fli1 has not yet been translated by stage 18 or that the distinct complexes are 
unstable during chromatography.  
 
Since no difference was observed between maternal and zygotic fli1 containing 
complexes, whether there is a difference between fli1 containing complexes in the 
region containing the haemangioblasts and the remainder of the embryo at stage 18 was 
tested. Western blot results (figures 6.14 and 6.15) show that fli1 from the remainder of 
the embryo was eluted from the column between fractions C5-C10 as previously 
observed using whole embryo extract but the amount of fli1 eluted from the column 
from the anterior-ventral region was greatly reduced in fractions C7-C8 and was barely 
detectable in fractions C9-C10. Therefore, a difference was observed between fli1-
containing complexes in the remainder of the embryo and in the anterior-ventral region, 
which as previously stated for Hex may reflect the possibility that fli1 is mainly in 
active complexes in the cells where transcriptional regulation of several of its 
endothelial and haematopoietic target genes occurs. 
 
 187 
It is noteworthy that fli1 and Hex were eluted from the SEC column in the same 
fractions and that both proteins were absent or the amount greatly reduced in the same 
fractions (C9-C10) when SEC was carried out using the anterior-ventral regions, This 
will be discussed in chapter 8.  
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Chapter 7 
The further characterisation of the Xenopus 
tropicalis protein recognised by the Tal1 antibody 
 
7.1 Introduction  
Initial Tal1 anti-serum characterisation results (as described in chapter 4) suggest that 
antibodies may have been raised against Xenopus tropicalis Tal1 since a strong band 
was produced on Western blots containing separated whole Xenopus tropicalis protein 
that had been probed with Tal1 anti-serum. This band was not present on blots probed 
with pre-immune serum (figure 4.6). However, the observed band corresponds to a 
protein with a Mr of just under 64 kDa and the expected size of Xenopus tropicalis Tal1 
is 42.9 kDa (NCBI). Western blots performed using Xenopus tropicalis Tal1 protein 
produced by in vitro translation confirmed that Tal1 anti-serum is capable of detecting 
Xenopus tropicalis Tal1 protein. The protein produced by in vitro translation is just over 
50 kDa. When Xenopus tropicalis tal1 mRNA is injected into one-cell stage Xenopus 
tropicalis embryos, Western blot analysis reveals that a protein of just over 50 kDa is 
detected in injected embryos that is not detected in uninjected control embryos. The 
endogenous 64 kDa anti-serum-specific band does not increase in intensity (figure 
4.15). Attempts to IP the larger unknown protein using caprylic acid purified Tal1 anti-
serum were unsuccessful. It is therefore unknown whether or not the observed 64 kDa 
protein in Xenopus tropicalis embryos is Tal1.  
 
There are several possible identities of the observed 64 kDa protein recognised by Tal1 
anti-serum in Xenopus tropicalis embryos. Firstly, the anti-serum could be cross-
reacting with another protein, so the observed band is not Tal1. In this case knowing 
that Tal1 anti-serum is capable of detecting Xenopus tropicalis Tal1 protein, either Tal1 
protein is not present in the stages of embryonic development tested (stages 7, 16 and 
27) or it is present at such low levels that the anti-serum is unable to detect it. The 
former seems unlikely since previous research carried out by Robb et al., 1995 and 
Shivdasani et al., 1995 show that Tal1 is essential in order for primitive haematopoiesis 
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to occur in mice. Mice homozygous for a tal1 mutation show no signs of 
haematopoiesis occurring and an absence of erythroid cells is observed. Moreover, 
ectopic expression of Tal1 in zebrafish has been shown to cause overproduction of 
blood (Gering et al., 1998). Therefore, the evidence suggests that Tal1 protein is 
essential for blood development and should be expressed in at least stage 27 embryos 
when the VBI are present. 
 
Secondly, the observed 64 kDa protein in embryos could either be a modified form of 
Tal1 or a larger splice variant of Tal1. The latter is unlikely to be true since basic 
bioinformatic research using ENSEMBL shows no documented evidence for Tal1 
alternative splicing in Xenopus. There is evidence for Tal1 alternative splicing in human 
and mouse, however the alternative isoforms are smaller, not larger than the expected 
size of Tal1 (ENSEMBL and GeneCards V3). Moreover, the web database Metazone 
was used to analyse expressed sequence tags (ESTs) in Xenopus tropicalis. In one EST 
there does appear to be an extra exon at the 3′ end of the gene (marked by * in figure 
7.1). However, when the sequence of this apparent extra exon was translated it had no 
open reading frame. It contained lots of stop codons and no start codons. There is also 
evidence for an extra exon within an intron (marked by ** in figure 7.1). The DNA 
sequence of this apparent extra exon is full of repeats so is unlikely to code for a 
protein. There are limitations to this analysis in that the ESTs only cover the 3′ end of 
the gene so it is unknown about exons in the 5′ end and furthermore the extra exon 
could be embryo specific. However, it seems unlikely that the observed 64 kDa protein 
in embryos is a larger splice variant of Tal1. 
 
This chapter discusses the results from several experiments that were devised in order to 
determine whether or not Tal1 anti-serum is cross-reacting with another protein or if the 
observed band in embryos is a modified form of Tal1. 
 
7.2 Possible Tal1 post-translational modifications 
The approximate size difference between the expected size of Tal1 and the size of the 
observed 64 kDa protein detected by Tal1 anti-serum when Western blotting is 22 kDa. 
Goldfarb et al., (1992) report an 8 kDa size difference between the expected size of 













Figure 7.1: Xenopus tropicalis tal1 expressed sequence tags.  
ESTs show evidence of an extra exon at the 3′ end of the tal1 gene (*) and within one of 




protein expressed in Cos-7 cells (42 kDa). Valge-Archer et al., (1994) report isolating 
Tal1 protein from mouse erythroleukemia cell lines by immunoprecipitation. SDS-
PAGE showed the isolated protein to have an approximate Mr of 46 kDa. The expected  
size of mouse Tal1 protein is 34.1 kDa (NCBI) so a 12 kDa size difference is observed.  
 
Goldfarb et al., (1992), Cheng et al., (1993) and Valge-Archer et al., (1994) all report 
that Tal1 is a phospho-protein. It is unknown whether the discrepancies between the 
expected and observed sizes of Tal1 are due to phosphorylation, other forms of post-
translational modification or just anomalous migration on SDS-PAGE as has been 
shown for C-myc (Hann et al., 1984). There are conflicting opinions about whether 
phosphorylation can increase the observed size at which a protein appears on an SDS-
PAG, however there are examples of phosphorylation slowing down the migration rate 
of proteins during SDS-PAGE, including the phosphorylation/dephosphorylation of the 
two subunits of M phase-promoting factor (MPF); Cdc2 and cyclin B. During the 
prophase/metaphase transition of starfish oocyte maturation the dephosphorylation of 
Cdc2 and phosphorylation of Cyclin B is required. Both the phosphorylated forms of 
these two subunits have a slower migration rate on SDS-PAGE. Phosophorylation was 
confirmed as the reason for an apparent increase in Mr by treating metaphase Cyclin B 
(phosphorylated) with different phosphatases and showing that dephosphorylated 
metaphase Cyclin B has the same electrophoretic mobility as prophase Cyclin B which 
is dephosphorylated (Borgne et al., 1999). Another example of phosphorylation slowing 
down the migration rate of a protein includes phosphorylation of CREB-binding protein 
(CBP). Again phosphatase experiments were performed to show that the slower 
migrating forms of CBP were generated by phosphorylation (Kovács et al., 2003). The 
exact size differences are not stated in either report. 
 
To test whether the 64 kDa band observed in Xenopus tropicalis is a phosphorylated 
form of Tal1, stage 27 Xenopus tropicalis embryo extract was treated with Antarctic 
phosphatase. A Western blot using Tal1 anti-serum was then carried out in order to 
compare the protein from untreated embryo extract and phosphatase treated extract. The 
aim was to test whether the observed 64 kDa band was absent from the treated extract 
and a band of the expected size of Tal1 was present. Results did show that the larger 
unknown protein was absent following phosphatase treatment, however other non-
specific bands had also disappeared and no new protein of the correct size to be Tal1 
was observed (results not shown), suggesting that the protein had been degraded rather 
 192 
than dephosphorylated. This experiment was also carried out in the presence of 
phosphatase inhibitors but the signal on the Western blot appeared as a smear. 
 
There is also evidence for Tal1 ubiquitination. Ubiquitin is an 8.5 kDa protein that binds 
to target proteins either as a monomer or as polyubquitin chains, typically marking them 
for degradation, one form of post-transcriptional regulation. However, this post-
translational modification is also used in other non-proteolytic regulatory mechanisms 
(Hochstrasser, 2009). Nie et al., (2007) showed that Notch regulates Tal1 degradation 
mediated by ubiquitination and proteasomes and more recently, Terme et al., (2009) 
have shown that TGF-β regulates Tal1 stability through polyubiquitination and 
proteasomal degradation. SUMO protein is an ubiquitin-like modifier but there is no 
known evidence of Tal1 sumoylation.  
 
Another Tal1 post-translational modification was reported by Huang et al., (2000) who 
show that Tal1 is acetylated by the co-activators p300 and p300/CBP-associated factor 
(P/CAF). Tal1 acetylation mediated by P/CAF enhances Tal1 DNA-binding activity 
whilst destabilising its interaction with the co-repressor mSin3A.  
 
There is documented evidence for various Tal1 post-translational modifications 
suggesting the possibility that the larger observed band when Western blotting with 
Tal1 anti-serum could be a modified form of Tal1 protein.  
 
7.3 Is Tal1 protein modified in oocytes? 
If the observed 64 kDa protein detected by Tal1 anti-serum is indeed Tal1 and if the 
difference between expected and observed protein size is due to Tal1 protein being 
heavily modified then it is possible that when Tal1 protein first appears it is unmodified. 
Furthermore, it would appear that the Tal1 modification would have to be oocyte 
specific since the larger observed band in embryos does not increase in intensity 
following injection of exogenous Tal1 mRNA (figure 4.15). To test this, Western blot 
analysis of all six stages of oocyte development was carried out. The aim of the 
experiment was to test whether at any point during oogenesis a band of the correct size 
to be Tal1 could be detected because perhaps there is a delay between Tal1 synthesis 
and Tal1 modification, if so it should be possible to detect both the unmodified and 
modified forms of Tal1. The experiment involved collecting 20 Xenopus tropicalis 
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oocytes of each developmental stage and as with previous oocyte experiments described 
in chapters 5 and 6, stages I and II were combined (10 stage I ooctyes and 10 stage II 
oocytes). Following homogenisation of the oocytes and freon-extraction, whole oocyte 
extract was separated using SDS-PAGE then analysed by Western blotting using Tal1 
anti-serum. 
 
The results from this experiment (figure 7.2) show that the 64 kDa protein observed in 
embryos is detected in oocyes. The band is first detected in stage III oocytes and 
increases in intensity up to stage VI. There is also a very faint band just under 50 kDa 
present in stage V and VI oocytes that does not appear to be present on the membrane 
probed with pre-immune serum. This would be the expected result if at stages V and VI 
the maximum amount of Tal1 was being synthesised and was overloading the 
modification mechanism. However, previous Western blots carried out on whole 
embryo extract using pre-immune serum show that there are non-specific bands 
observed corresponding to proteins of around this size (figures 4.3, 4.6 and 4.15) so the 
possibility that this a non-specific protein cannot be excluded.  
 
In order to try and determine if Tal1 protein does become modified in oocytes, Tal1 
protein was over-expressed in Xenopus tropicalis oocytes. Either H2O as a control or 
150 pg or 375 pg of tal1 mRNA was injected into both immature (stage IV and V) and 
mature (stage VI) oocytes. The oocytes were then incubated at 25 oC for either 0.5 hours 
or 3 hours. Western blots were then performed using Tal1 anti-serum against whole 
oocyte extract (figure 7.3) to allow a comparison to be made between the amount of 
unknown 64 kDa protein in control and tal1 mRNA injected oocytes. An increase in 
band intensity of the observed 64 kDa band in injected oocytes would indicate that the 
protein is Tal1 and that it immediately becomes modified in oocytes. The results show 
that both immature and mature oocytes synthesised a very low amount of exogenous 
Tal1 protein (**) compared to the amount produced in embryos (figure 4.15), although 
the amount of mRNA injected into oocytes was less. There was no increase in band 
intensity of the unknown 64 kDa protein observed in immature oocytes (*) but there 
does appear to be an increase in intensity of the 64 kDa band in mature oocytes that had 
been injected with 150 pg of mRNA and incubated for 3 hours. This result does suggest 
the possibility that Tal1 becomes modified in oocytes, however since only one of the 
extracts shows an increase in the amount of 64 kDa protein, the experiment needs 





































Figure 7.2: Western blots using Pre-immune serum and Tal1 anti-serum on 
Xenopus tropicalis oocyte extract.   
Protein from whole oocytes (approximately four oocyte equivalents) was separated 
alongside SeeBlue® Plus2 Pre-Stained protein ladder (Invitrogen) using SDS-PAGE 
and transferred to a nitrocellulose membrane. The Roman numerals above each lane 
indicate the stage of oocyte development. The Western blots were probed with either 50 
µg/ml of caprylic acid purified Tal1 anti-serum or 50 µg/ml of caprylic acid purified 
pre-immune serum. Following removal of the primary antibody the blots were probed 
with a 1/5000 dilution of donkey anti-sheep secondary antibody conjugated to HRP. 
The blots were developed using ECL (GE Healthcare). The blots show that the 
unknown protein of just under 64 kDa (*) observed in embryo extract is also present in 
oocyte extract and it is not observed when probing with pre-immune serum. There is 
also a faint band observed in stage IV, V and VI oocyte extract corresponding to a 
protein of approximately 50 kDa (**) that is not present on the pre-immune membrane. 
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Figure 7.3: Western blot analysis of Tal1 protein over-expression in immature and 
mature Xenopus tropicalis oocytes.  
Immature and mature Xenopus tropicalis oocytes were injected with either 5 nL of H2O 
as a control, 2 nL (150 pg) or 5 nL (375 pg) of tal1 mRNA. Oocytes were incubated at 
25 oC for either 0.5 hours or 3 hours. Oocytes were then homogenised and freon-
extracted and the proteins were separated by SDS-PAGE alongside SeeBlue® Plus2 
Pre-Stained protein ladder (Invitrogen) then transferred to a nitrocellulose membrane. 
The Western blots were probed with 70 µg/mL of caprylic acid purified Tal1 anti-
serum. Following removal of the primary antibody the blots were probed with a 1/5000 
dilution of donkey anti-sheep secondary antibody conjugated to HRP. The blots were 
developed using ECL (GE Healthcare). (A) Immature oocytes produced a small amount 
of exogenous Tal1 protein (**), however no increase in the intensity of the unknown 64 
kDa band (*) is observed. (B) Mature oocytes also only produced a small amount of 
exogenous Tal1 protein (**). There does appear to be an increase in intensity of the 
unknown 64 kDa band (*) in oocytes that were injected with 2 nL and 5 nL of tal1 
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7.4 Tal1 expression in stage 40 Xenopus tropicalis embryos and in adult 
Xenopus tropicalis blood 
Since it is known that Tal1 is required for both the development (Robb et al., 1995 and 
Shivdasani et al, 1995) and maintenance of erythroid cells (Visvader et al., 1991) 
Western blots were carried using whole embryo extract from stage 40 Xenopus 
tropicalis embryos. By stage 40 primitive erythroid cells have left the VBI and have 
begun to circulate. Western blots were also carried out using the blood from adult 
Xenopus tropicalis, which would therefore contain the protein from fully differentiated 
adult erythroid cells. Performing these Western blots had two aims; firstly to find out if 
the unknown observed protein is present in stage 40 Xenopus tropicalis embryos and/or 
in adult Xenopus tropicalis blood and secondly to find out if a protein of the correct size 
to be Tal1 is present in stage 40 Xenopus tropicalis embryos and/or in adult Xenopus 
tropicalis blood.  
 
Results showed that the larger unknown protein is present in stage 40 Xenopus 
tropicalis embryos but no protein of the correct size to be Tal1 was observed (figure 
7.4). When probing Western blots containing the blood from an adult Xenopus 
tropicalis with either Tal1 anti-serum or pre-immune serum no difference was observed 
between the two. 
 
7.5 Tal1 immunohistochemistry 
Since it is known that Tal1 anti-serum is capable of detecting Xenopus tropicalis Tal1 
as shown by Western blot experiments using in vitro translated Xenopus tropicalis Tal1 
protein (figure 4.13), IHC was performed on MEMFA fixed stage 27 Xenopus tropicalis 
embryos using caprylic acid purified Tal1 anti-serum as described in section 2.8.12. The 
purpose of this experiment was to test whether any staining is observed in the regions 
where Tal1 protein expression is expected from in situ hybridisation results: the head, 
the VBI and the DLP. A positive result would be further evidence to suggest that the 
observed band during Western blotting is Tal1. Pre-immune IHCs were also performed 
as a control. No difference was observed between embryos probed with pre-immune 



































Figure 7.4: Western blots using Pre-immune serum and Tal1 anti-serum on stage 
40 Xenopus tropicalis whole embryo extract.  
Protein from whole embryos (approximately 4 embryo equivalents) was separated 
alongside SeeBlue® Plus2 Pre-Stained protein ladder (Invitrogen) using SDS-PAGE 
and transferred to a nitrocellulose membrane. The Western blots were probed with 
either 50 µg/mL of caprylic acid purified Tal1 anti-serum or 50 µg/mL of caprylic acid 
purified pre-immune serum. Following removal of the primary antibody the blots were 
probed with a 1/5000 dilution of donkey anti-sheep secondary antibody conjugated to 
HRP. The blots were developed using ECL (GE Healthcare). The blots show that the 
unknown protein of just under 64 kDa (*) observed in earlier embryo extract is still 
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7.6 Discussion 
The aim of the experiments described in this chapter was to try determine whether or 
not the observed 64 kDa protein detected by Tal1 anti-serum in Xenopus tropicalis 
embryos is Tal1 or if the anti-serum is cross reacting with another protein. However, no 
firm conclusions can be drawn from these results.  
 
Tal1 from human and mouse has been shown to migrate at a slower rate than expected 
during SDS-PAGE (Goldfarb et al., 1992 and Valge-Archer et al., 1994). The same 
authors also report that Tal1 is a phospho-protein, although it is not known whether 
phosphorylation accounts for the size difference between the expected and observed 
size of Tal1. Attempts to test whether the unknown protein observed in Xenopus 
tropicalis is phosphorylated were unsuccessful since phosphatase treatment of Xenopus 
tropicalis embryo extract degraded some of the proteins in the sample including the 
protein of interest. There are also reports of Tal1 ubiquitination and acetylation (Nie et 
al., 2007, Terme et al., 2009 and Huang et al., 2000). Evidence from other models 
therefore, support the possibility that the unknown 64 kDa protein observed in Xenopus 
tropicalis during Western blotting is a modified form of Tal1. Future experiments could 
include treating Xenopus tropicalis embryo extract to remove ubiquitin or acetylation 
modifications then compare the protein from untreated and treated embryos and see 
whether the 64 kDa observed band is replaced with a new band closer to the expected 
size of Tal1. 
 
Western blots were carried out using the protein from all six stages of Xenopus 
tropicalis oocyte development in order to see if at any point a protein of the correct size 
to be Tal1 could be detected. Results showed that the unknown 64 kDa protein is 
expressed during mid to late oogenesis. There was also a protein closer to the expected 
size of Tal1 detected that was not detected by pre-immune serum. It is possible that this 
is an unmodified form of Tal1 (figure 7.1). To test whether Tal1 does become modified 
in oocytes, tal1 mRNA was injected into immature and mature oocytes. Only a small 
amount of exogenous protein was synthesized by oocytes and all but one extract 
showed no increase in intensity of the unknown 64 kDa band. However, oocytes that 
had been injected with 150 pg of mRNA and incubated or 3 hours did have a larger 
amount of the 64 kDa present compared to control oocytes, suggesting that Tal1 does 
become modified in oocytes. It is possible that an increase in band intensity was not 
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observed in other injected oocyte extracts because of the small amount of exogenous 
Tal1 protein produced compared to the amount of the possibly modified Tal1 protein 
already present in oocytes. Therefore, future experiments would include repeating the 
Tal1 over-expression experiment in oocytes using a higher concentration of tal1 mRNA 
(500 pg-1000 pg injections as previously used for one-cell stage embryos rather than 
150 pg-375 pg which was used in oocyte injections). 
 
If the unknown protein were found to be Tal1 then this result would be consistent with 
findings about Hex and fli1 expression during oocyte development. Both HTFs are 
expressed during oogenesis and as previously mentioned another HTF, Gata2 is also 
expressed during oocyte development (Partington et al., 1997).  
 
Without being able to isolate the unknown 64 kDa observed protein it has not been 
possible to determine whether or not it is Tal1. Since IPs were unsuccessful (figure 
4.16) one possible way in which to isolate the unknown protein could be to synthesise 
an affinity column from the Tal1 anti-serum then pass Xenopus tropicalis embryo 
extract through the column. The unknown protein may bind to the column. Following 
elution of the protein from the column the protein could be precipitated using TCA, 
resuspended it in a smaller volume of SDS-loading dye to concentrate the protein then 
use SDS-PAGE to separate the protein sample. The band could then be excised from the 







Discussion and future work 
  
The aim of the research discussed in this thesis was to analyse the spatial and temporal 
protein expression patterns of HTFs during early Xenopus embryogenesis and to find 
out whether post transcriptional and/or post translational regulation of HTFs contributes 
to early haematopoietic development. In order to carry out this research it was necessary 
to raise and characterise antibodies against as many HTFs as possible. Seven HTFs 
were selected to raise antibodies against including: Gata1, Gata2, Lmo2, Spi1, Tal1, 
Hex and fli1 Antibodies were successfully raised against Xenopus laevis Hex and fli1 
and Xenopus tropicalis Tal1.  
 
The main findings from the work described in this thesis include: 1) Hex and fli1 
protein expression is observed throughout oogenesis and early Xenopus development, 
an unexpected result since previous work suggests that the mRNA transcripts encoding 
these proteins are not maternal; 2) at stage VI of oogenesis the majority of fli1 and all 
Hex protein was localised within the cytoplasm, suggesting an alternative second 
function for each protein; 3) an intensively sampled developmental time-course carried 
out for fli1 between stages 24 and 31 revealed striking post-transcriptional control over 
fli1 expression; 4) Hex and fli1 are eluted in the same fractions following SEC, 
suggesting the possibility that they may be in complex together; and 5) either Tal1 
protein is undetectable during early Xenopus embryogenesis, or is heavily modified. 
 
8.1 Hex and fli1 are maternal 
In order to establish at which stages of Xenopus early development Hex and fli1 
proteins are expressed, Western blots were carried out on a developmental stage series 
between the 2-cell stage and stage 40. These initial Western blots showed Hex and fli1 
to be expressed throughout early development (figures 5.2 and 6.4). Previous hex and 
fli1 mRNA data (Newman, et al., 1997; Jones, et al., 1999; Zorn et al., 1999; Meyer et 
al., 1993; Meyer et al., 1995) suggest that neither hex or fli1 transcripts are maternal so 
RT-PCR was carried out in order to check the current mRNA data. Results revealed that 
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hex mRNA transcripts were present in stage VI oocytes, unfertilised eggs, 2-cell stage 
and stages 5, 8, 10, 12.5, 18, 24 and 32 of Xenopus development (figure 5.5). This result 
was consistent with the finding that Hex expression could be knocked-down in stage 7 
and 17 embryos using AMO (figure 4.7). Fli1 mRNA transcripts were found to be 
present in stage VI oocytes and unfertilised eggs. The transcripts then become 
undetectable following fertilisation and reappear by stage 12.5 following activation of 
the zygotic genome (figure 6.8). This result suggests that fli1 protein is stable and this is 
consistent with the finding that it was not possible to knock-down fli1 expression in 
stage 7 and 17 embryos. Western blot results also revealed that both Hex and fli1 are 
expressed throughout oogenesis with expression levels increasing with advancing 
oocyte development. 
 
The finding that Hex and fli1 are maternal proteins leaves an important unanswered 
question ‘what do the maternal HTFs do?’ At stage VI of oogenesis all Hex protein and 
the majority of fli1 protein is localised within the cytoplasm. This could be a 
mechanism for regulating the transcriptional activity of both these proteins. This has 
been observed for other transcription factors including a maternal CCAAT factor and 
Xnf7, which are stored in the cytoplasm then migrate to the nucleus following the mid-
blastula transition (Brewer et al., 1995; Miller et al., 1991). Alternatively, the 
localisation of Hex and fli1 within the cytoplasm could indicate a second function. 
Since both proteins are present in embryos prior to the mid-blastula transition and no or 
very little transcription occurs prior to the mid-blastula transition (Yang, 2002) this 
strengthens the possibility that Hex and fli1 are carrying out functions other than acting 
as regulators of transcription.  
 
Hex is already known to have an alternative function in acting as an inhibitor of 
translation through physical interactions with eIF-4E (Topisirovic et al., 2003; 
Topisirovic et al., 2005); section 5.7.3 discuses this function in more detail. Alternative 
fli1 functions are unknown. Another HTF known to be maternal is gata2 (Zon et al., 
1991). Gata2 was shown to be nuclear in Xenopus oocytes but only a small proportion 
of Gata2 was found to be functional as a transcription factor, the majority of Gata2 was 
in nuclear complexes but not chromatin bound  (Partington et al., 1997). The authors 
suggest that this is a mechanism for regulating the amount of Gata2 available to regulate 
transcription of its target genes. Elefanty et al. (1996) report that Gata2 is complexed in 
discrete nuclear bodies in erythroleukemia cells and murine haematopoietic cells. The 
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authors report that the function of these nuclear bodies is unknown but they do not 
appear to be sites of transcription. Hex has also been shown to be found in discrete 
nuclear bodies (Soufi et al., 2006), perhaps these HTFs are carrying out alternative 
functions that require them to be in these nuclear structures. Although the maternal role 
of these proteins is unknown, they must perform a function otherwise their expression 
would surely be down regulated to conserve the oocytes/embryos energy and resources. 
 
Future experiments would include investigating exactly what function these maternal 
HTFs carry out during very early embryogenesis and what effect knocking-down their 
expression would have on development. This would be difficult to investigate for fli1 
since it would appear that by stage VI of oogenesis the oocyte has already produced the 
required amount of stable fli1 protein for development. However, one possible 
experiment could include injection of fli1 antibody into one-cell stage embryos. The 
antibody should bind to fli1 protein in the embryo and may inhibit its activity. The 
development of injected embryos would be analysed for any defects caused by the 
deactivated fli1 protein. For Hex it would be possible to carry out a maternal depletion 
experiment (Heasman et al., 1992). This involves the injection of antisense 
oligodeoxyribonucleotides (ODNs) specific for Hex into mature oocytes. Endogenous 
RNAse H activity in the oocyte cleaves any mRNA bound to an ODN, therefore 
blocking translation of that specific mRNA. Following replacement of the oocytes into 
a female Xenopus and subsequent fertilization of those eggs, development of the 
embryos can be analysed for any defects caused by a lack of maternal Hex protein. 
 
8.2 Post-transcriptional and post-translational control over Hex and 
fli1 
The most striking example of regulating HTF activity observed during this research was 
for fli1. An intensively sampled developmental time-course Western blot carried out for 
fli1 between stages 24 and 31 (figure 6.5) revealed both post-transcriptional control 
over fli1 expression and some form of protein degradation mechanism. An absence in 
fli1 expression protein expression was observed between 1.5 and 3 hours after stage 24, 
after which expression reappeared. In situ hybridisation carried out on the same set of 
embryos using a probe for fli1 show that the loss of fli1 protein expression is not due to 
loss of fli1 mRNA expression (figure 6.6). 
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If time was not limited, then future experiments to investigate the mechanism by which 
fli1 protein expression is lost would include the synthesis of two different fli1 mRNA 
constructs. Firstly, epitope-tagged fli1 mRNA flanked by the wild-type fli1 5′ and 3′ 
UTRs.  Secondly, epitope-tagged fli1 mRNA flanked by the 5′ and 3′ UTRs of Xenopus 
laevis β-globin, which confer stability and a high translation rate on the synthetic 
mRNA (Kreig and Melton, 1984). Each mRNA construct would then be injected into 
one cell stage Xenopus laevis embryos, following which the embryos would be allowed 
to develop up until the stages where endogenous fli1 protein expression is absent. 
Western blotting would then be used to compare the protein extract from control 
embryos, embryos injected with epitope-tagged fli1 mRNA with the wild-type fli1 5′ 
and 3′ UTRs and embryos injected with epitope-tagged fli1 mRNA flanked by the 5′ 
and 3′ UTRs of Xenopus laevis β-globin using both fli1 anti-serum and an antibody 
against the epitope tag. The fli1 anti-serum Western blot would confirm whether or not 
the correct stages had been selected to observe loss of endogenous fli1 expression. The 
epitope antibody Western blot would show whether the epitope-tagged fli1 protein had 
been expressed. If the epitope-tagged fli1 protein was present in the extract from 
embryos that had been injected with epitope-tagged fli1 mRNA flanked by the 5′ and 3′ 
UTRs of Xenopus laevis β-globin but absent in extract from embryos injected with 
epitope-tagged fli1 mRNA flanked by the wild-type fli1 5′ and 3′ UTRs then this would 
suggest that there is something in the wild-type fli1 UTRs negatively regulating fli1 
expression. 
 
MicroRNAs (miRNAs) are one way in which gene expression can be silenced. miRNAs 
work at the post-transcriptional level by hybridising to complementary sequences in the 
3′ UTRs (Bartel, 2004 and Bartel, 2009) and are thought to play a fundamental role in 
several biological functions including cellular proliferation, differentiation and 
apoptosis (Sachdeva and Mo, 2010). There is evidence for fli1 expression being 
regulated by miRNAs. Larson et al., (2009) used miRNA target software to identify fli1 
as a miR-145 target. The authors then used a reporter assay to show that cotransfection 
of a miR-145 mimic and reporter constructs containing either the 3′ UTR of mouse or 
human fli1 does significantly reduce reporter activity compared to transfection without 
miRNA or an unrelated miRNA. Furthermore, the authors show that miR-145 does have 
an affect on endogenous fli1 protein expression in mouse vascular aortic endothelial 
cells and used qRT-PCR to show that miR-145 was carrying out translational repression 
without target mRNA degradation. Zhang et al., (2010) produced results suggesting that 
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fli1 expression is down-regulated by miR-145 in colon cancer. The identification of 
miR-145 in humans (Michael et al., 2003) revealed a unique seed sequence that is 
conserved in Xenopus and mammals (Lakshmipathy et al., 2007). The seed sequence is 
essential for a miRNA to bind to its target mRNA and the base pairing between a 
miRNA and target transcript must be perfectly complementary in the seed region. 
Future work would include analysis of the fli1 3′ UTR for miRNA binding sites. 
 
The other issue to address concerning the loss of fli1 expression (figure 6.5) is not only 
how fli1 translation is repressed but also how the existing protein is degraded. The first 
step would be to investigate the stability of fli1 protein. This would firstly be carried out 
using stage 22 Xenopus laevis embryos. The embryos would either be treated with 
DMSO as a control or cycloheximide, which blocks translation of proteins. An 
appropriate number of embryos would be collected at the following time points from 
the onset of treatment (incubated at 23 oC); 0 minutes, 30 minutes, 60 minutes and 90 
minutes. Western blotting would then be carried out using the embryo extract from 
control and cycloheximide treated embryos at each time point. If fli1 expression is not 
lost following treatment with cycloheximide then this suggests that fli1 protein is stable 
at this stage since no new fli1 protein is being translated. However, if fli1 expression is 
lost, then this would suggest that fli1 is normally unstable but is being continuously 
translated. The experiment would then be repeated using stage 24 embryos (just before 
fli1 expression is repressed naturally in embryos). The Western blot performed using 
control embryos should show a loss of fli1 expression since this was observed in 
previous results. There are two possible outcomes for the treatment of embryos with 
cycloheximide at this stage. Firstly, fli1 expression is lost or if fli1 expression is not lost 
then this would suggest that whatever normally causes the degradation of fli1 is not 
being translated. 
 
The second step would be to investigate the mechanism by which fli1 gets degraded. 
Since the majority of nuclear and cytosolic proteins are degraded via the ubiquitin and 
proteasome proteolytic pathway the effect on fli1 stability following a loss of 
ubiqiutination would also be analysed. UbPred (predictor of protein ubiquitination sites) 
predicts that fli1 has six possible ubiquitin binding sites with medium confidence and 
three with high confidence so it does appear possible that ubiquitination of fli1 can 
occur. 
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From the results discussed in this thesis there is no evidence for negative control over 
translation of Hex protein but many of the Western blot images do suggest that post-
translational modifications of Hex and fli1 are occurring. Since the fli1 anti-serum is not 
purified it is difficult to differentiate between fli1 protein and non-specific bands by 
Western blotting, however Hex anti-serum is purified and a protein approximately10 
kDa larger than Hex is observed following SEC of stage 5 and stage 18 Xenopus extract 
(figures 5.14 and 5.15) which is likely to be a modified form of Hex. Furthermore, the 
Hex RT-PCR results shown in figure 5.5b suggest the possibility of a hex splice variant 
in stage 32 Xenopus embryos. The hex cDNA fragment appears to be approximately 26 
base pairs smaller than the expected size.  
 
8.3 Hex and fli1 complex analysis 
SEC was carried out using stage 5 and stage 18 Xenopus laevis extract followed by 
Western blotting of the different fractions eluted from the column using both Hex and 
fli1 anti-serum. Although the results showed no obvious difference between stage 5 and 
stage 18 Hex and fli1-containig complexes it was interesting to observe that Hex a4d 
fli1 were eluted from the column in the same fractions, C5-C10 (figures 5.13; 5.15; 
6.12; 6.13). Furthermore, both Hex and fli1 were absent from fractions C9 and C10 
when SEC was carried out using extract from the anterior-ventral region of stage 18 
embryos (figures 5.16; 5.17; 6.14; 6.15). Fractions C9 and C10 correspond to both Hex 
and fli1 being as present as monomers. These data therefore suggest the possibility that 
Hex and fli1 eluted in fractions C5/C6 and/or fractions C7/C8 are in complex together. 
 
To test this hypothesis further experiments would include the synthesis of an epitope-
tagged fli1 mRNA construct. Following injection of the fli1 mRNA construct into one-
cell stage Xenopus laevis embryos the embryos would be allowed to develop to an 
appropriate stage. A Co-IP would then be performed using extract prepared from 
injected embryos and an antibody against the epitope-tag. Western blotting against any 
bound protein to the epitope-tagged fli1 protein with the Hex antibody would then 
reveal if Hex and fli1 were in complex together. The reverse experiment using an 
epitope-tagged Hex mRNA construct would also be performed. 
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8.4 Tal1 expression during early Xenopus tropicalis development 
From the results described in this thesis it was not possible to draw any definite 
conclusions about the expression of Tal1 protein during early development. However, 
since it is known that the Tal1 antibody does detect Xenopus tropicalis Tal1 protein 
there are two possible conclusions. Either Tal1 protein is undetectable during early 
Xenopus embryogenesis, or it is heavily modified. If the observed 64 kDa protein is 
indeed a heavily modified form of Tal1, which initial oocyte over-expression 
experiments (figure 7.3) suggest is likely, then it is another example of a maternal HTF.  
Carrying out RT-PCR on a Xenopus tropicalis developmental stage series as was done 
for hex and fli1 would show whether it was possible for the observed 64 kDa protein to 
be Tal1. If tal1 mRNA was absent from oocytes and embryos prior to the mid-blastula 
transition then the protein cannot be Tal1. If tal1 mRNA was at least present in oocytes 
then this strengthens the possibility that the observed 64 kDa protein is Tal1. 
Furthermore, if the 64 kDa protein is Tal1 and if a similar result were observed as was 
seen for fli1 mRNA expression in that transcripts were present in stage VI oocytes and 
unfertilised eggs then degrade following fertilisation, then this would explain why it 
was not possible to knock-down expression of Tal1 using AMO and why it was not 
possible to over-express the 64 kDa protein in embryos, because the oocyte is producing 
a stable, heavily modified form of Tal1. 
 
Moreover, if the observed 64 kDa protein is Tal1 then this is another example of how 
post-translational modifications are involved with HTFs. Future experiments could 
include performing IPs with antibodies against various protein modifications then 
carrying out Western blots with the Tal1 anti-serum to analyse whether any Tal1 protein 
has also been precipitated.  
 
8.5 Final conclusions 
The initial aim of this research was to analyse the spatial and temporal protein 
expression patterns of HTFs during early Xenopus embryogenesis and to find out 
whether post-transcriptional and/or post-translational regulation of HTFs contributes to 
early haematopoietic development. The data were not able to show definitively whether 
Hex, fli1 and Tal1 are expressed in haematopoitic regions or that post-transcriptional 
and/or post-translational regulation contributes specifically to haematopoiesis. 
However, they did reveal that Hex and fli1 and possibly Tal1 are maternal proteins, 
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suggesting that these HTFs have multiple functions and play an unknown role during 
very early development. Furthermore, although its relevance is not yet understood, there 
is evidence of post-transcriptional control over fli1 expression and evidence of post-
translational control over the activity of Hex and fli1 and possibly Tal1, suggesting that 
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Appendix I: RT-PCR primers 
 






Primer name Sequence 
Tal1 forward GCTAGCATGATGGAGAGGTTGGGGAC 
Tal1 reverse CTCGAGTCAAATGCTCTGCAGCCTCAGCT 
Hex forward GCTAGCATGCAGTACCAGCACCCCAG 
Hex reverse CTCGAGTCATGAAAACCGCACTTGGCCGC 
Fli1 forward GCTAGCATGTCTCATCTCAACTACCTCAG 
Fli1 reverse CTCGAGTCAAGGAGGGCTTTTTGTGACAG 
Spi1 forward GCTAGCATGAGCACGGTGCCCTTTAAGGC 
Spi1 reverse CTCGAGTCACATGTAGGAGACCTGATGGC 
Lmo2 forward GCTAGCATGTTCGGCCAGGACGGACTGTG 
Lmo2 reverse CTCGAGTCACTGCTCGCACACAATGTCCG 
Gata2 forward GCTAGCATGGCCCATCACCACAACCCTTG 
Gata2 reverse CTCGAGTCACTTCATGCCCTCAGATAGGG 
Gata1 forward GCTAGCATGACTCTGACCACACAGGAGCC 
Gata1 reverse CTCGAGTCAGAACTCCTGTCCTCCTACTC 
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Primer name Sequence 
ODC forward  CAGCTAGCTGTGGTGTGG 
ODC reverse  CAACATGGAAACTCACACC 
Fli1 forward  AATGGATCCAGGGAGTCACC 
Fli1 reverse  CCATGGGAGGACTTTTTGTG 
Hex forward  CCCAACTCCCTTCTACATTG 
Hex reverse TGGGTTCTCCTGCTTGAGAC 
Primer name Sequence 
Tal1 forward (Xtr) TCTAGAAAGATGATGGAGAGGTTGGG 
Tal1 reverse (Xtr) CTCGAGTTAATCACCGCTGCCCACTG 
Fli1 forward (Xla) TCTAGACATGGACGGAACCATTAAGG 
Fli1 reverse (Xla) CTCGAGTCTAGTAAAAACCACCTAAG 
Hex forward (Xla) CAGCTGATGCAGTACCAGCACCCCAG 
Hex reverse (Xla) CAGCTGTTTGTTAATGTGCACAGTTG 
 228 
Appendix II: Sequences 
 
Xenopus laevis XLFli protein (xlfli), mRNA 













Xenopus laevis hematopoietically expressed homeobox (hhex), mRNA 























Xenopus (Silurana) tropicalis T-cell acute lymphoblastic leukemia 1 (tal1), mRNA 























































Appendix IV:  
Homology between Xenopus tropicalis and 
Xenopus laevis antigen sequences 
 
Analysis of the homology between selected regions of Xenopus tropicalis amino acid 
sequence for Tal1, Hex, fli1, Lmo2, gata2 and gata1 antigen synthesis compared to the 
equivalent region in Xenopus laevis (Xenopus laevis Spi1 sequence is not available). 
The blue letters show the amino acid sequence from the region in Xenopus tropicalis 
and the black letters show the equivalent region in Xenopus laevis. The red letters 




Tal1 antigen sequence 
 
 
    
     M  M  E  R  L  G  T  D  I  D  G  T  H  D  V  
     M  M  E  R  L  S  T  D  M  D  G  T  R  D  V   
      
     A  S  P  P  A  Q  Q  D  A  A  E  P  E  R  T  
     A  S  P  P  A  R  Q  D  A  A  E  P  E  R  T 
 
     V  E  L  S  G  V  K  E  G  A  A  P  N  S  P  
     V  E  L  S  G  V  K  E  G  A  A  P  N  S  P 
 
     P  R  A  V  P  V  I  E  L  H  R  R  G  E  G  
     P  R  A  V  P  V  I  E  L  L  R  R  G  E  G 
 
     S  G  N  I  K  A  R  E  Q  E  L  R  L  Q  S  
     L  G  N  I  K  A  R  E  Q  E  L  R  L  Q  N 
      
     I 
     I 




Hex antigen sequence 
 
 
      
     M  Q  Y  Q  H  P  S  S  S  A  L  G  L  S  V  
     M  Q  Y  Q  H  P  S  S  S  A  L  G  L  S  V 
 
     P  L  Y  A  P  T  P  L  Q  P  V  H  P  T  P  
     P  L  F  A  P  T  P  L  Q  H  P  H  P  T  P 
 
     F  Y  I  D  D  I  L  G  R  S  S  A  S  N  G  
     F  Y  I  D  D  I  L  G  R  N  S  A  S  N  G       
 
     T  P  A  L  P  T  P  T  L  P  S  P  N  S  S  
     T  P  A  L  P  T  P  T  L  P  S  P  N  S  S     
 
     F  T  S  L  V  A  T  Y  R  T  P  I  Y  E  P  
     F  T  S  L  V  A  T  Y  R  T  P  I  Y  E  P 
 
     T  P  I  H  P  A  F  T  H  P  G  A  A  L  A  
     T  P  I  H  P  A  F  T  H  P  G  A  A  L  A      
 
     A  S  Y  G  A  S  T  Y  A  N  P  L  Y  P  F  
     A  S  Y  G  A  S  T  Y  A  S  P  L  Y  P  F    
 
     S  R  P  V  S  E  Y  T  H  A  L  I  R  H  D  
     S  R  P  V  S  D  Y  T  H  A  L  I  R  H  D    
 
     T  L  G  K  P  L  L  W  S  P  F  I  Q  R  P  
     S  L  G  K  P  L  L  W  S  P  F  I  Q  R  P   
 
     L  H  K  R  K  G  G  Q  V  R  F  S 
     L  H  K  R  K  G  G  Q  V  R  F  S 
              
 
 
The sequence highlighted in yellow indicates the sequence which Hex antibodies were 







Fli1 antigen sequence 
 
 
      
     S  H  L  N  Y  L  R  D  S  S  S  S  L  G  Y 
     S  H  L  N  Y  L  R  D  S  S  S  S  L  G  Y 
      
     N  T  Q  A  H  T  D  Q  S  P  R  L  T  A  K 
     N  T  Q  A  H  T  D  Q  S  S  R  L  T  A  K      
 
     E  D  P  S  Y  E  A  V  R  R  S  G  W  G  N 
     E  D  P  S  Y  E  A  V  R  R  S  G  W  G  N    
 
     S  L  S  S  P  V  T  K  S  P  P 










     
     F  G  Q  D  G  L  C  A  S  C  D  K  R  I  R 
     F  G  Q  D  G  L  C  A  S  C  D  N  R  I  R      
 
     A  F  E  M  T  M  R  V  K  D  K  V  Y  H  L 
     A  Y  E  M  T  M  R  V  K  D  K  V  Y  H  L    
 
     E  C  F  K  C  A  A  C  Q  K  H  F  C  V  G 
     E  C  F  K  C  A  A  C  Q  K  H  F  C  V  G     
 
     D  R  Y  L  L  I  N  S  D  I  V  C  E  Q 








     A  H  H  H  N  P  W  T  V  S  P  F  A  K  T 
     A  H  H  H  N  P  W  T  V  S  P  F  G  K  A    
 
     P  L  H  P  A  A  A  G  G  S  L  Y  P  G  T 
     P  L  H  P  A  A  A  G  G  S  L  Y  P  G  T     
 
     G  S  S  G  G  P  S  S  H  T  S  P  H  -  L   
     G  S  S  A  C  P  S  S  S  H  S  S  P  H  L       
 
     F  G  F  P  P  T  P  P  K  D  V  S  P  D  P   
     F  G  F  P  P  T  P  P  K  D  V  S  P  D  P        
 
     G  T  A  A  S  P  P  S  S  S  R  L  E  D  K   
     G  T  A  A  S  P  P  S  S  S  R  L  E  D  K        
 
     D  S  I  K  Y  Q  V  S  L  S  E  G  M  K  M   
     D  S  I  K  Y  Q  M  S  L  S  E  G  M  K  M   
      
     E 














     T  L  T  T  Q  E  P  L  P  N  Y  T  E  S  A 
     T  L  T  T  Q  D  P  V  P  N  Y  T  E  S  G      
 
     L  A  S  T  S  E  D  S  E  F  L  Y  G  L  G 
     L  A  S  T  S  E  D  S  Q  F  L  Y  G  L  G      
 
     G  E  S  S  P  G  H  Y  G  G  T  V  S  S  R 
     G  E  S  S  P  G  H  Y  G  G  A  V  S  S  R      
 
     A  V  G  G  F  R  H  S  P  V  L  Q  T  F  P 
     A  V  G  G  F  R  H  S  P  V  F  Q  T  F  P      
 
     L  H  W  P  E  T  S  V  G  I  P  H  S  L  T 
     L  H  W  P  E  T  S  A  G  I  P  S  N  L  T      
 
     A  Y  G  R  S  P  G  T  V  P  L  Y  P  S  A 
     A  Y  G  R  S  T  G  T  L  S  F  Y  P  S  A      
 
     A  S  S  F  G  P  I  T  S  P  P  L  Y  N  A 
     A  S  A  L  G  P  I  T  S  P  P  L  Y  S  A     
 
     A  P  F  L  L  G  S  A  P  P  A  E  H  E  G 
     S  S  F  L  L  G  S  A  P  P  A  E  R  E  G      
 
     S  P  K  F  L  E  T  L  K  T  E  R  T  S  P 
     S  P  K  F  L  E  T  L  K  T  E  R  A  S  P      
 
     L  T  T  D  L  L  P  L  E  S  R  S  P  S  L 
     L  T  S  D  L  L  P  L  E  P  R  S  P  S  I      
 
     P  Q  V  G  Y  L  G  V  G  G  Q  E  F  
     L  Q  V  G  Y  I  G  G  G  G  Q  E  F              








Appendix V: ETS domain sequences 






























































































Hex pre-immune Purified Hex anti-serum 
fli1 pre-immune fli1 anti-serum 
Tal1 pre-immune Tal1 anti-serum 
Xla st.28 Xla st.28 
Xla st.30 Xla st.30 
Xtr st.27 Xtr st.27 
